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Summary 
Epilepsy is the most common serious chronic neurological disorder, affecting 65 
million people worldwide. Antiepileptic drugs (AEDs) constitute the main 
treatment for epilepsy. The introduction of 14 new AEDs over the last three 
decades has expanded treatment options and increased the expectations about 
efficacy and tolerability. However, little is known about the effectiveness of new 
AEDs in routine clinical practice. It is also unclear whether the treatment 
outcomes in epilepsy have improved in recent decades as a consequence of the 
availability of an increasing number of AEDs. The present work attempts to provide 
a comprehensive evaluation of efficacy, tolerability, and retention rate of AED 
treatments in everyday clinical setting. This thesis is divided into six chapters, 
three general chapters and three result chapters (Chapter 3, 4, and 5). 
Chapter 1 sorts out the background of epilepsy, pharmacological management, 
and adverse drug reactions. The new classification of seizures and epilepsies, AED 
therapy, and guidelines for initiation, selection and dosing of AEDs are described. 
Followed by discussion of clinically relevant adverse effects of AEDs. 
Chapter 2 describes the study population and definition of outcome measures. 
Data collection and statistical analysis were presented as well. The data of this 
study were extracted retrospectively by reviewing the patients’ medical records. 
The patients were first diagnosed with epilepsy and prescribed AED treatment at 
the Glasgow Epilepsy Unit between Jul 1982 and Oct 2012; then they were 
prospectively followed up until 30 Apr 2016 with at least one year follow-up after 
starting AEDs therapy. The study cohort included 1,528 patients aged 18 to 93 
years (median 37), 849 (56%) were men, and 1,290 (84%) had focal epilepsy. 
Chapter 3 evaluates efficacy of AEDs and the changes in treatment outcomes of 
epilepsy over the past 30 years. This was achieved by comparing the results of 
current analysis to the results of three analyses conducted in 1999, 2003, and 2008 
on same expanding cohort (n=470, 890, and 1,098 respectively) from the Epilepsy 
Unit in Glasgow. The overall efficacy rate of AEDs in this study was 62% 
(n=941/1,528); this was comparable to what was observed in the previous analysis 
of 17 years ago on the same expanding cohort in which 64% (n=301/470) of newly 
diagnosed epilepsy patients achieved seizure-free. Likewise, the efficacy rates of 
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different established and new AEDs were comparable. Therefore, this provides a 
strong evidence that treatment outcomes in epilepsy have not improved in recent 
decades despite the availability of increasing number of AEDs. However, the 
results indicated that the use of new AEDs has increased, 41% of patients 
continued to take the new AEDs as a monotherapy in the current study, compared 
to 26% in 1999. This most likely due to their advantages in terms of tolerability. 
This analysis also found that family history of epilepsy, more than ten pre-
treatment seizures, psychiatric conditions, alcohol and recreational drugs abuse, 
and failure to response to two or more AEDs were significantly associated with 
poor seizure outcomes.  
In Chapter 4, the rate and predictors of intolerable adverse effects of AEDs were 
assessed. This study showed that 28% (n=815/2,911) of total AEDs prescriptions 
were discontinued because of poor tolerability. In which the most frequent 
problem was tiredness (5.2%, n=152/2,911) followed by poor coordination and 
rash, with a 2.9% (n=86) incidence for each. Among 17 different AEDs, lamotrigine 
was associated with the best tolerability whether it was used as monotherapy 
(19%, n=109/575) or as part of polytherapy (9%, n=35/387). While topiramate was 
associated with the highest rate of adverse effects (39%, n=32/81) among 
monotherapies, and retigabine had the highest rate of adverse effects (42%, 
n=8/19) among AEDs used as part of polytherapy. Moreover, each AED 
demonstrated a distinct tolerability profile; the main intolerable adverse reaction 
associated with lamotrigine and carbamazepine was skin rash while valproate was 
poorly tolerated most frequently due to tremor and weight gain. Furthermore, 
levetiracetam was poorly tolerated commonly due to psychiatric and behavioural 
side effects whereas cognitive dysfunction was the most common reason for 
topiramate intolerability. Beside individual AED, poor tolerability was related to 
patient’s susceptibility and number of co-prescribed AEDs. Prior intolerable AEDs 
schedule was associated with high probability to experience intolerable adverse 
effects at subsequent AED schedule. Likewise, female, focal epilepsy, more than 
ten pre-treatment seizures, and psychiatric comorbidity were significantly 
associated with higher rates of adverse effects. However, older AEDs usage was 
not significantly associated with poorer tolerability. These may present novel 
findings from this study as very few studies have evaluated the predictors for poor 
tolerability particularly non-AEDs variables. 
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In Chapter 5, a survival analysis was performed to identify retention rates (time 
to discontinuation) of lamotrigine, valproate, carbamazepine, and levetiracetam 
monotherapies. Lamotrigine showed the highest retention rate, with median 
duration of therapy of 84 months. This was significantly higher than the retention 
times of valproate (42 months), carbamazepine (36 months), and levetiracetam 
(36 months); there was no significant difference in retention rates of other AEDs. 
However, within six months of therapy initiation, lamotrigine and carbamazepine 
demonstrated the highest discontinuation rates, most probably due to rash. Few 
observational studies have investigated the long-term retention rates of AEDs in 
the UK. Therefore, the current research may present novel findings in term of 
population as well. 
In Chapter 6, study strengths and limitations are presented. Clinical implications 
and the future directions of research in epilepsy are described as well. 
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Chapter 1. Introduction 
 
1.1 Epilepsy 
Epilepsy is the most common serious chronic disorder of the brain, affecting 65 
million people worldwide (Moshe et al., 2015). It entails a significant economic 
burden, which has been estimated to constitute more than €20 billion per year in 
Europe alone (International League Against Epilepsy/International Bureau for 
Epilepsy/World Health Organization Global Campaign Against Epilepsy, 2010). 
Furthermore, epilepsy is associated with increased mortality; in a 40-year 
population-based study, overall mortality rate in people with epilepsy who had 
been followed up since childhood was 24%, which was three times higher than the 
expected mortality rate in the general population, with more than half of the 
fatalities being epilepsy-related, including sudden, unexpected death, which 
constituted a third of all of the deaths (Sillanpää  and Shinnar 2010). Moreover, 
epilepsy has a substantial impact on a person’s life, affecting both their physical 
and psychosocial well-being. Depression, cognitive difficulties, the 
unpredictability of seizures, and social stigma and isolation due to factors such as 
unemployment, driving restrictions, and low rates of marriage, are major concerns 
for people with epilepsy. Together with the burden of the adverse effects of 
antiepileptic drug (AED) treatments, these concerns have a significant influence 
on the quality of life of people with epilepsy (Baker et al., 1997, Luoni et al., 
2011, Quintas et al., 2012). The goal of treatment, therefore, should be to 
maintain a normal life with complete seizure control, with no, or minimal, adverse 
drug effects. 
1.1.1 Prevalence 
Active epilepsy has a prevalence of approximately six per 1,000 of the population 
worldwide (Fiest et al., 2017). However, the prevalence of epilepsy is higher in 
low-income countries than in developed countries, which may be due to 
differences in epilepsy risk factors, such as infections and poor neonatal care 
(Moshe et al., 2015). One meta-analysis estimated that in high-income countries, 
the annual incidence of epilepsy is 45 per 100,000 of the population [interquartile 
range (IQR 30–67)], and 82 per 100,000 of the population (IQR 28–240) in low- and 
middle-income countries (Ngugi et al., 2011).  
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In Scotland, there are 54,000 individuals with active epilepsy, with new annual 
diagnoses of between 2,000 and 3,500 cases (Scottish Intercollegiate Guidelines 
Network, 2015). 
1.1.2 Definition and classification 
Epilepsy is a tendency of the brain to produce unprovoked seizures, which are 
transient signs and/or symptoms that occur due to abnormal excessive, or 
synchronous, neuronal brain activity (Fisher et al., 2005). In practice, epilepsy can 
be diagnosed if:  
1. At least two unprovoked (or reflex) seizures occur more than 24 hours apart;  
2. A single unprovoked (or reflex) seizure and a probability of a second seizure 
comparable to the recurrence risk after two unprovoked seizures; for 
instance, one unprovoked seizure after a brain insult such as a stroke or 
trauma; or  
3. Diagnosis of an epilepsy syndrome occurs (Fisher et al., 2014).  
Clearly, epilepsy is not a uniform disorder, and it involves various seizure types 
and syndromes. Several attempts have been made by the International League 
Against Epilepsy (ILAE) to classify the seizure types and of epilepsies (Commission 
of ILAE, 1981, Commission of ILAE, 1989). However, this section discusses the most 
recent classification guidelines (Fisher et al., 2017, Scheffer et al., 2017), in which 
the new classifications include three categories: seizure type, epilepsy type, and 
epilepsy syndrome. Aetiology should be considered at each stage, since it 
influences the treatments substantially. However, when a patient presents with 
seizures, the first step in making a diagnosis of epilepsy is to confirm that the 
event is an epileptic seizure based on clinical evaluation (history and seizure 
description from the patient and witnesses of seizures), and investigations 
[Electroencephalography (EEG), Magnetic Resonance Imaging (MRI)]. 
Seizures can be categorised as focal, generalised, or unknown onset, and each 
seizure type includes the subgroups of motor, and non-motor, while focal seizures 
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also include the subgroups of retained, or impaired awareness. Figure 1-1 
demonstrates detail about new classification of seizure types (Fisher et al., 2017). 
 
Figure 1-1. The new classification of seizures types proposed by International League 
Against Epilepsy (ILAE) (Fisher et al., 2017)  
 
The diagnosis of epilepsy depends on clinical characteristics supported by the 
results of an EEG. As demonstrated in Figure 1-2, generalised epilepsies with 
absence, myoclonic, atonic, tonic, and tonic-clonic seizures are usually 
characterised in the EEG by generalised spike-wave activity, together with 
supporting information including a family history of epilepsy or myoclonic jerks 
which are particularly important in the case of a normal EEG. Focal epilepsies with 
focal motor, or non-motor seizures; focal with retained, or impaired awareness; 
and focal to bilateral tonic-clonic seizures are typically characterised by focal 
epileptiform discharges in the EEG. In combined generalised and focal epilepsies, 
both types of seizures occur, and the EEG may show both generalised spike-wave 
and focal epileptiform discharges. Dravet syndrome and Lennox-Gastaut syndrome 
are common examples in which both generalised and focal seizures occur. If there 
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is insufficient information to determine the epilepsy type, it can be denoted as 
‘unknown’ (Scheffer et al., 2017). 
The third stage is the diagnosis of an epilepsy syndrome. Generally, epilepsy 
syndromes include a set of characteristic seizure types, and EEG and neuroimaging 
findings appear together. They are typically age-dependent, include seizure 
triggers, and coexist with particular comorbidities, such as intellectual 
disabilities. Common syndromes of idiopathic generalised epilepsies are childhood 
absence epilepsy, juvenile myoclonic epilepsy (JME), and generalised tonic-clonic 
seizures (GTCs) (Scheffer et al., 2017).  
A wide range of epilepsy aetiology exists, such as structural, genetic, and 
metabolic pathology, and it is important to determine the aetiology early, 
following the first seizures. Structural aetiology can be determined on the basis 
of neuroimaging investigations, such as MRI. Common structural abnormalities that 
may cause epilepsy are stroke, trauma, tumour, and genetic (such as cortical 
malformation), or infection. Known or presumed genetic defects can either 
directly cause epilepsy as a result of a rare single gene mutation, or indirectly as 
a result of the interaction of multiple genes, with or without environmental 
contributions in which gene defect has a significant effect in causing the epilepsy. 
The epilepsy can be classified as ‘unknown aetiology’ if the cause has not yet been 
determined. It can also be classified into more than one aetiological group if there 
are more than one causes of the epilepsy (Scheffer et al., 2017). 
The identification of seizure types and syndromes is essential for the prognosis 
and selection of treatment. AEDs constitute the main treatment for epilepsy, 
while other intervention options include surgical treatment, neurostimulation, 
and ketogenic diet. 
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Figure 1-2. The new classification of epilepsy proposed by International League Against 
Epilepsy (ILAE) (Scheffer et al., 2017) 
It includes three stages: seizure types, epilepsy types, and epilepsy syndromes. Aetiology should 
be considered at each stage as it substantially influences the treatments. The classification of 
seizure types by ILAE illustrated in Figure 1-1. However, there is no formal classification of epilepsy 
syndromes by ILAE; the illustrated are some examples of established syndromes. 
 
1.2 Pharmacological treatment  
Epilepsy in 60 to 70% of newly diagnosed patients is controlled with an appropriate 
AED treatment. Moreover, 50% of controlled patients response successfully to the 
initial monotherapy and usually on modest doses (Kwan and Brodie, 2000, 
Mohanraj and Brodie, 2005, Brodie et al., 2012). 
There are currently 22 AEDs licensed in the UK as monotherapy, or as an adjunct 
for adult epilepsy patients (Table 1-1). They can be divided into established (old), 
and new AEDs on a chronological basis. Old generation AEDs were introduced to 
clinical practice before 1989, and include phenobarbital (PB), phenytoin (PHT), 
primidone (PRM), ethosuximide (ESM), carbamazepine (CBZ), sodium valproate 
(VPA), clonazepam (CZP), and clobazam (CLB).  
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The remaining AEDs are generally regarded as new drugs. These include vigabatrin 
(VGB), lamotrigine (LTG), gabapentin (GBP), topiramate (TPM), tiagabine (TGB), 
oxcarbazepine (OXC), levetiracetam (LEV), pregabalin (PGB), zonisamide (ZNS), 
lacosamide (LCM), eslicarbazepine acetate (ESL), retigabine (RTG), perampanel 
(PER), and brivaracetam.  
In addition to stiripentol and rufinamide, the use of which is restricted to adjunct 
therapy for Dravet syndrome and Lennox-Gastaut syndrome in infants and 
children, respectively. Felbamate (FBM), which causes serious adverse reactions, 
and is therefore not licensed in the UK. 
Table 1-1. Established and new antiepileptic drugs licensed as monotherapy or 
adjunct therapy for epilepsy in adults in the United Kingdom  
Antiepileptic drugs  Year of introduction  
Established drugs 
Phenobarbital 1912 
Phenytoin 1938 
Primidone 1952 
Ethosuximide  1955 
Carbamazepine  1965 
Sodium valproate  1967 
Clonazepam* 1969 
Clobazam* 1974 
New drugs 
Vigabatrin*  1989  
Lamotrigine 1991  
Gabapentin 1993  
Topiramate 1995  
Tiagabine* 1998  
Oxcarbazepine  2000  
Levetiracetam 2000  
Pregabalin* 2005  
Zonisamide  2006  
Lacosamide  2008  
Eslicarbazepine acetate  2009  
Retigabine*†  2011  
Perampanel*  2012  
Brivaracetam*  2016  
*Approved only as adjunct therapy. † Withdrawn in June 2017. Data sourced from 
(Loscher and Schmidt, 2011, Baulac et al., 2017, Brodie, 2017a, Trinka et al., 2017). 
 
AEDs can also be classified based on their primary mechanism of action, as 
discussed in the following section. 
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1.2.1 Mechanisms of action 
There are four main mechanisms by which most AEDs act: blockade of voltage 
gated sodium channels, blockade of voltage gated calcium channels, potentiation 
of gamma aminobutyric acid (GABA) inhibitory effect, and inhibition of the 
glutamate excitatory mechanism. Other mechanisms include: potentiation of 
potassium channels, and modulation of synaptic vesicle proteins.  
Voltage gated sodium channels control the action potential by controlling the 
passage of sodium ions across the neuronal membrane. PHT, CBZ, LTG, and OXC 
act mainly through blocking the fast-inactivated state of the sodium channel, 
while LCM and ESL acetate block the slow-inactivated state of the sodium channel. 
Meanwhile, VPA, FBM, TPM, and ZNS have an effect on the sodium channels as 
part of their multiple mechanisms. Sodium channel blockers act during high 
frequency repetitive action potentials without affecting physiological neuronal 
activity, when they are administered at therapeutic concentration. They prevent 
repetitive action potentials in both the epileptic focus, and the spreading of 
seizure activity (Lason et al., 2011, Baulac et al., 2017). 
Voltage dependent calcium channels include two main subtypes: high voltage 
calcium channels, and low voltage calcium channels (T-type). High voltage 
calcium channels control the neurotransmitter release from the presynaptic nerve 
terminals by controlling calcium influx across the neuronal membrane. GBP and 
PGB act mainly by blocking the high voltage calcium channels by binding to their 
α2δ subunit. TPM has also an effect on these channels. The low-voltage calcium 
channel (T-type) plays an essential role in the mechanism of the thalamo-cortical 
oscillatory activity, and the generation of spike-wave discharges; it plays a 
pathological role in the absence seizure. ESM acts mainly through the blocking of 
this channel; VPA and ZNS also have an effect on this T-type calcium channel 
(Lason et al., 2011). 
The GABA is the most important inhibitory neurotransmitter in the brain, and 
there are three types of GABA receptors (A, B, and C). The GABA-A receptor is 
responsible for the generation of fast inhibitory postsynaptic potentials, and 
therefore for controlling seizure activity. They are ligand-gated chloride channels, 
and the stimulation of GABA-A receptors increases the entrance of chloride ions, 
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thus increasing the hyperpolarisation of the neuronal membrane. GABA-A receptor 
agonists often increase the seizure threshold in the epileptogenic brain, but not 
in the normal brain, and inhibit the spread of seizure activity. After GABA is 
released to the synapse, it is taken back into presynaptic neuronal cells and into 
glia cells, where it is metabolised to succinic semialdehyde by GABA 
aminotransferase. The antiepileptic activity of PB and BZD is mainly to activate 
the GABA-A receptors, while VGB and TGB potentiate GABA by inhibiting GABA 
aminotransferase, and GABA reuptake into the presynaptic membrane, 
respectively. VPA also enhances the inhibitory effect of GABA as part of its 
multiple mechanisms (Lason et al., 2011). 
Glutamate is the main excitatory neurotransmitter in the central nervous system 
(CNS). It stimulates several receptors, such as N-methyl- D-aspartate (NMDA), α-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), and kainate 
receptors. The complex of these receptors is comprised of an ion channel that 
controls the calcium and sodium ions influx, and potassium ions efflux, and 
therefore neuronal depolarisation. Several binding sites have been recognised on 
the NMDA receptor, such as the glycine site, where antagonism could demonstrate 
an anti-convulsive action. LCM and FBM show antagonistic activity towards the 
glycine-binding site on NMDA receptors. PER is a selective AMPA receptor 
antagonist, while TPM has an inhibitory effect on kainate receptors. PB also 
inhibits AMPA receptors, though this effect plays a minor role in its mechanisms 
of action. 
The muscarine sensitive Kv7 (KCNQ) type potassium channels are responsible for 
controlling neuronal excitability and repetitive firing. The neuronal depolarisation 
induced by excitatory stimuli activates Kv7 potassium channels as a compensatory 
action, leading to the repolarisation of the neuronal membrane, with subsequent 
firing suppression that limits seizure activity. RTG is a first-in-class potassium 
channel opener (Lason et al., 2011). 
The synaptic vesicle protein 2A is a commonly distributed CNS protein that 
modulates the exocytosis of neurotransmitters, particularly glutamate. LEV and 
brivaracetam bind selectively to the synaptic vesicle protein 2A (Gao and Li, 
2016). 
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Figure 1-3, the mechanisms of action of different AEDs. The availability of more 
than 20 AEDs for treating epilepsy have increased the treatment options, however, 
there are key decisions to be considered in treating epilepsy, including the time 
at which AED treatment should be commenced, and which drug should be selected 
for the first-line therapy. The following sections discuss the initiation and 
selection of AED treatment. 
 
Figure 1-3. Mechanisms of action of different antiepileptic drugs that act on excitatory and 
inhibitory neurotransmitter systems  
Key: AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid, GABA, γ-aminobutyric acid: 
GAT-1, sodium- and chloride-depended GABA transporter 1: SV2A: synaptic vesicle glycoprotein 
2A, NMDA: N-methyl-D-aspartate. Reproduced with permission from Dove Medical Press Ltd and 
(Shih et al., 2013). 
 
1.2.2 Commencing antiepileptic drug treatment 
The decision to initiate AED treatment is often based on the chance of seizure 
recurrence, the consequences of seizure recurrence on a patient’s life, and the 
benefits and adverse effects of AED treatment. The decision of whether or not to 
commence treatment should be taken by an epilepsy specialist following a full 
Levetiracetam
Brivaracetam
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discussion with the patient and their family concerning the risks and benefits of 
both courses of action. Generally, AED treatment is recommended after two or 
more unprovoked seizures occurring more than 24 hours apart. However, 
treatment can be indicated after a single seizure in patients at high risk of 
recurrence. For instance, in the presence of a brain insult (like stroke, head 
trauma, or brain tumour), an abnormal EEG, a strong family history of epilepsy, 
or in the case of the diagnosis of an epilepsy syndrome with a high chance of 
seizure recurrence, such as JME (Stephen and Brodie, 2009, Perucca and Tomson, 
2011, National Institute for Health and Care Excellence, 2012, Scottish 
Intercollegiate Guidelines Network, 2015).  
1.2.3 Initial drug selection 
A number of evidence-based guidelines for the selection of AED therapy are 
available, such as that produced by the National Institute for Health and Care 
Excellence in the UK (NICE, 2012), and the Scottish Intercollegiate Guidelines 
Network (SIGN, 2015). The selected AED should be effective for the given seizure 
type, or syndrome. Other characteristics, such as age, sex, and comorbidities, 
should also be taken into account, together with a consideration of other 
important aspects of AEDs, including safety; tolerability; pharmacokinetic 
properties and potential for drug interactions; dosing constraints, such as slow 
titration, frequency, and formulations; and cost (Perucca and Tomson, 2011, 
Moshe et al., 2015).  
As shown in Table 1-2, AEDs possess different efficacy spectrums in relation to 
different seizure types and syndromes. Many established and new AEDs are 
currently licensed as monotherapy for epilepsy in adults. However, to date, no 
robust efficacy evidence exists supporting the use of a particular AED in relation 
to a specific seizure type (Perucca and Tomson, 2011). In focal epilepsy, LTG was 
found to be more effective than CBZ, GBP, TPM, and OXC in SANAD (Standard And 
New Antiepileptic Drugs) trial (Marson et al., 2007a). However, LTG was found to 
be superior to CBZ in the preceding trial largely due to fewer patients experiencing 
adverse effects, open-label design may have contributed to this difference, added 
to the use of immediate-release (rather than controlled-release CBZ) in some 
patients. Moreover, there was no significant difference in efficacy between LTG 
and CBZ in the per-protocol analysis in that trial. Other trials assessing efficacy of 
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newer drugs LEV, ZNS, LCM, and ESL acetate versus sustained-release CBZ showed 
that most of adults with newly diagnosed epilepsy respond to a modest dose of 
any first-line AED (Brodie et al., 2007, Baulac et al., 2012, Baulac et al., 2017, 
Trinka et al., 2017). Furthermore, LTG demonstrated a superior efficacy over PGB 
in one trial (Kwan et al., 2011). Few trials conducted in patients with generalised 
and unclassified epilepsies; in SANAD trial, VPA was more effective than LTG and 
TPM (Marson et al., 2007b). Altogether, the findings of these trials demonstrated 
that none of the newer AEDs were more effective than standard drugs for patients 
with newly diagnosed epilepsy.  
Table 1-2. Efficacy spectrum of antiepileptic drugs against common seizure types in 
adults 
  Idiopathic generalised seizures 
 Focal-onset 
seizures 
Tonic-clonic Absence Myoclonic 
Phenobarbital + + 0 0 
Phenytoin +  + Aggravate Aggravate 
Ethosuximide 0 0 + ?+ 
Carbamazepine + + Aggravate Aggravate 
Valproate + + + + 
Benzodiazepines + + ?  + 
Vigabatrin + ?+ 0 Aggravate 
Lamotrigine + + + + * 
Gabapentin + ?+ 0 Aggravate 
Topiramate + + ?  ?+ 
Tiagabine + ?+ Aggravate Aggravate 
Oxcarbazepine + + Aggravate Aggravate 
Levetiracetam + + ?+ + 
Pregabalin + ?+ 0 Aggravate 
Zonisamide + ?  ?+ ?+ 
Lacosamide + ? ? ? 
Eslicarbazepine 
acetate 
+ ? Aggravate Aggravate 
Retigabine + ? ? ? 
Perampanel + ? ? ? 
Brivaracetam + ? ? ? 
Key: +; effective, 0; not effective, ?+; possible efficacy, ?; efficacy not documented. 
*occasionally can aggravate. Data obtained from (Stephen and Brodie, 2009, Perucca and 
Tomson, 2011, Moshe et al., 2015, Gao and Li, 2016). 
 
However, while randomised controlled trails (RCTs) can assess a drug’s efficacy, 
they do not typically capture the other important factors affecting the selection 
of AEDs. These additional factors include teratogenic effects, rare idiosyncratic 
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reactions, chronic adverse effects, and enzyme-induction effects and the 
potential for drug interactions. Indeed, all of the available guidelines highlight 
the need to consider individual patient characteristics, such as childbearing 
potential, old age, and comorbidities, when selecting an AED (Perucca and 
Tomson, 2011). For instance, VPA is a potent teratogen, and should therefore be 
avoided in adolescent and young women (Tomson et al., 2015), whereas LTG and 
LEV are reasonable alternatives (Perucca and Tomson, 2011). Furthermore, CBZ is 
associated with poor tolerability in the elderly, while LTG, GBP, LEV appear to be 
more suitable (Werhahn, 2009).  
Overall, the selection of the initial AED is largely based on its efficacy and 
tolerability, and on patient characteristics. While standard AEDs, such as CBZ and 
VPA, remain valuable first-line treatments, some new AEDs, such as LTG and LEV, 
are increasingly utilised as initial monotherapy, primarily because of their 
enhanced safety, tolerability, and drug interaction profiles. 
1.2.4 Dosing guidelines 
AED treatment is usually commenced with a low dose, and is up-titrated slowly in 
order to minimise neurotoxicity and the risk of cutaneous adverse reactions, 
unless there is an urgent need for anti-seizure effects. It is also generally 
recommended that the lowest effective dose should be maintained. The 
maintenance dosage should also consider the patient’s characteristics, for 
instance, the elderly may require lower dosages, together with the patient’s 
susceptibility to potential adverse effects, and the risk of seizure recurrence 
(Perucca and Tomson, 2011). The optimal starting dose, target maintenance dose, 
and dosing frequency vary with the type of AED as shown in Table 1-3. 
Controlled-release CBZ is preferable over immediate-release formulation, as the 
former possesses a better tolerability (i.e. lower CNS toxicity). However, for other 
AEDs, there is no evidence that modified-release formulations are superior 
(Perucca and Tomson, 2011).  
Generally, the dose adjustment of some AEDs is necessary if a potentially 
interacting drug is added or removed. The pharmacokinetics of AEDs, and 
potential drug interactions, are discussed in detail later in this chapter. 
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1.3 Tolerability 
1.3.1 Importance 
The poor tolerability of AEDs is a major reason for treatment failure, because it 
leads to the early discontinuation of AEDs in approximately 20% of patients (Kwan 
and Brodie, 2000), prevents the administration of a therapeutic dosage (Perucca 
and Gilliam, 2012), and has a negative impact on patient adherence to medication 
(Eatock and Baker, 2007, Faught, 2012). The concerns relating to adverse effects 
remain significant for patients when taking a medication, and the adverse drug 
reactions experienced by patients with epilepsy, whether actual or perceived, 
increases the probability of non-adherence. A study examining the reasons for 
non-adherence in 131 patients who missed taking their AEDs revealed that the 
fear of adverse drug reactions (27%) was the third most frequent reason for non-
Table 1-3. Dosing guidelines for antiepileptic drugs in adults 
 Starting 
dose  
Commonest 
dose 
Maintenance 
range  
Dosing 
frequency 
Phenobarbital 60 120 60-240 OD-BD 
Phenytoin 100-200 300 100-600 OD-BD 
Ethosuximide 500 1000 500-2000 OD-BD 
Carbamazepine 200 600 400-2000 BD-QDS 
Valproate 500 1000 500-3000 OD-BD 
Clonazepam 0.5-1 4 2-8 OD-BD 
Clobazam 10 20 10-60 OD-BD 
Vigabatrin 500-1000 3000 2000-4000 OD-BD 
Lamotrigine 25 200-400 100-800 OD-BD 
Gabapentin 300-400 1800 900-4800 TDS 
Topiramate 25-50 200-400 100-800 BD 
Tiagabine 4-10 40 20-60 BD-QDS 
Oxcarbazepine 150-600 900-1800 600-2400 BD 
Levetiracetam 500-1000 1000-2000 1000-4000 BD 
Pregabalin 75-150 300 150-600 BD-TDS 
Zonisamide 50-100 300 100-500 BD 
Lacosamide 100 200 100-600 BD 
Eslicarbazepine 
acetate 
400 800 800-1600 OD 
Retigabine 150-300 900 600-1200 TDS 
Perampanel 2 6-8 4-12 OD 
Brivaracetam 50 100 50-200 BD 
Doses in mg/day. Key: OD; once daily, BD; twice daily, TDS; three times daily, QDS; four times 
daily.  Data obtained from (Perucca and Tomson, 2011, Brodie, 2017b). 
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adherence, preceded only by forgetfulness (54%), and being seizure-free for a 
period of time (49%) (Tang et al., 2013). 
In addition, the adverse drug reactions of AEDs represent a significant burden on 
the cost of healthcare and society. The total cost of the frequent adverse effects 
of AEDs has been estimated at approximately €21,000 per patient per year 
[confidence interval (CI) 15,000-27,200], which includes the cost to healthcare, 
the patients and their family in terms of informal care, together with other costs 
such as productivity loss (De Kinderen et al., 2014). 
Moreover, adverse drug effect is considered as one of the strongest predictors of 
impaired health-related quality of life in people with epilepsy (Baker et al., 1997, 
Perucca et al., 2009, Kwon and Park, 2011, Luoni et al., 2011). In a study of 
controlled (1-year seizure-free) patients on monotherapy, depressive symptoms, 
and the adverse effects of AEDs were the strongest negative determinants of their 
quality of life (Kwon and Park, 2011). Moreover, an Italian multicentre study of 
933 individuals with pharmacoresistant epilepsy demonstrated that adverse 
effects were by far the most important predictor of quality of life, with or without 
the symptoms of depression. The study also revealed that epilepsy-related 
factors, such as seizure frequency, tonic–clonic seizures, age of epilepsy onset, 
and epilepsy duration, together with the number of AEDs prescribed, had no 
significant predictive value on the quality of life. The authors of this study 
concluded that when seizure freedom is not achievable, managing depression, and 
reducing adverse drug effects can be far more valuable than interventions 
intended to reduce the frequency of seizures (Luoni et al., 2011). 
1.3.2 Assessment and prevalence of adverse effects 
A number of standardised methods exist for screening the adverse effects of AEDs 
in adults and children. The adverse event profile (AEP) method (Table 1-4) is one 
example of a self-completed screening measure of a patient’s perception of the 
adverse effects of AEDs (Baker et al., 1994). The accurate usage of these validated 
screening approaches can allow better quantification, and the reduction of the 
burden of AEDs’ adverse effects, together with the identification of the 
populations at a high risk of the adverse effects of AEDs (Perucca and Gilliam, 
2012). 
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However, these screening measures, which include checklists and questionnaires, 
tend to overestimate the prevalence of side effects. In contrast, relying on the 
spontaneous reporting of adverse effects, and on unstructured interviews, results 
in an underestimation, since the patients may forget about problems that occurred 
between visits, are unable to describe problems, or employ inappropriate 
terminology, such as stating that they experienced dizziness when they were 
actually feeling lightheaded, or stating that they experienced speech problems 
when in fact they were mentally confused (Cramer, 2012, Perucca and Gilliam, 
2012). In a multicentre study of 809 patients with pharmacoresistant epilepsy, the 
rate of adverse effects was almost three times greater when identified by a 
questionnaire (AEP 93%) than that detected by an unstructured interview (35%) 
(Canevini et al., 2010). Overall, the prevalence of the adverse effects of AEDs has 
been reported as being between 10 and 40% if tolerability was assessed by 
spontaneous reporting, and between 59 and 96% when it was detected via 
systematic screening methods (Perucca et al., 2009, Kwon and Park, 2011, Luoni 
et al., 2011). 
The frequency of patient-perceived adverse effects (as AEP) correlates with 
seizure control; it is highest in patients with pharmacoresistant epilepsy (mean 
AEP score 42.7) (Luoni et al., 2011), intermediate in mixed populations (AEP 38.8) 
(Perucca et al., 2009), and lowest in well-controlled patients (AEP 27.3) (Kwon 
and Park, 2011). Other risk factors for AEPs are polytherapy, psychiatric 
comorbidity, being of the female gender, and being either a child, or elderly 
(Perucca and Gilliam, 2012). 
In short, every method of tolerability assessment possesses limitations, and the 
prevalence of adverse effects varies greatly among studies, lies between 10 to 
90% or higher, depending on the assessment method, seizure control, and other 
factors.  
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Table 1-4. 19-item Adverse Event Profile (AEP) screening method also known as Liverpool 
AEP 
During the last four weeks have you had any of the problems listed below? 
For each item, if has always or often been a problem ring ④. If has sometimes 
been a problem ring ③ and so on. Please be sure to answer every item.  
Always or 
often a 
problem 
Sometimes 
a problem 
Rarely a 
problem 
Never a 
problem 
1-unsteadiness 4 3 2 1 
2-tirdedness 4 3 2 1 
3-restlessness 4 3 2 1 
4-feelings of anger or 
aggression to others  
4 3 2 1 
5-nervousness and/or 
agitation 
4 3 2 1 
6-headache 4 3 2 1 
7-hair loss 4 3 2 1 
8-problems with skin (like 
acne, rash) 
4 3 2 1 
9-double or blurred vision 4 3 2 1 
10-upset stomach 4 3 2 1 
11-difficultiy in 
concentrating 
4 3 2 1 
12-trouble with mouth or 
gums 
4 3 2 1 
13-shaky hands 4 3 2 1 
14- weight gain 4 3 2 1 
15-dizziness 4 3 2 1 
16-sleepiness 4 3 2 1 
17-depression 4 3 2 1 
18-memory problems 4 3 2 1 
19-disturbed sleep 4 3 2 1 
This is a patient-completed questionnaire for assessing the frequency of the most frequent 
adverse effects of antiepileptic drugs during the last four weeks. Ratings can be added to obtain 
a total score of 19-76, higher scores indicating a greater burden of adverse effects. Obtained 
from (Baker et al., 1994). 
 
1.4 Definition and classification of adverse drug 
reactions of antiepileptic drugs 
World Health Organisation (WHO) defines an adverse drug reaction as “a response 
to a drug that is noxious and unintended and occurs at doses normally used in man 
for therapy, diagnosis, and prophylaxis” (WHO, 1972, pp. 9). While a more precise 
definition was proposed by Edwards and Aronson (2000, pp. 1255), as follows: “an 
appreciably harmful or unpleasant reaction, resulting from an intervention related 
to the use of a medicinal product, which predicts hazard from future 
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administration and warrants prevention or specific treatment, or alteration of the 
dosage regimen, or withdrawal of the product”. 
According to the European Pharmacovigilance Legislation, the definition of the 
term ‘adverse reaction’ should be amended in order to ensure that it covers 
noxious and unintended effects resulting not only from the authorised use of a 
medicinal product at normal doses, but also from medication errors and uses 
outside the terms of the marketing authorisation, including the misuse and abuse 
of the medicinal product (Legislation, 2010). 
The term ‘adverse effect’ appears to be more suitable than ‘toxic effect’, or ‘side 
effect’, since ‘toxic effect’ implies that it is limited to an event that appeared at 
a high dosage in the form of an exaggeration of the therapeutic effect desired. In 
contrast, the term ‘side effect’ may be dose-related or not, but includes both 
desirable and undesirable events occurring in the form of different mechanism 
from the pharmacological action for which the drug was being administered. 
Meanwhile, the term ‘adverse effect’ is precise, and implies all of the unwanted 
effects, regardless of their mechanism (Edwards and Aronson, 2000). 
The terms ‘adverse effect’ and ‘adverse reaction’ are interchangeable, however 
it is important to distinguish between ‘adverse effect’ and the term ‘adverse 
event’. An ‘adverse effect’ is an unpleasant effect that can be attributed to the 
medication, directly or indirectly, while an ‘adverse event’ is an undesirable 
experience appearing during treatment that is not necessarily caused by the 
medication (Perucca and Gilliam, 2012). 
Different classifications of adverse drug reactions exist, based on their severity, 
frequency, symptoms, pathophysiological mechanisms, and the body organ 
affected. The adverse drug reactions of AEDs are divided into five categories, 
according to the revised version of the WHO classification: Type A (related to 
pharmacological characteristics of drug), Type B (idiosyncratic), Type C (chronic), 
Type D (delayed), and Type E (resulting from drug interactions) (Perucca and 
Gilliam, 2012). Table 1-5 compares these five categories, and the following 
section discusses the clinically relevant adverse effects of each type. In addition, 
the rate of adverse effects, underlying mechanisms, risk factors, offender AEDs, 
and prevention and management are described
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Table 1-5. Classification of the adverse drug reactions of antiepileptic drugs 
 Features Examples Prevention Management 
Type A  Common (1 to 10%), or very 
common (>10%); 
 Related to a pharmacological 
action of the drug; 
 Dose-dependent; 
 Predictable; 
 Reversible; 
 Low mortality. 
 Tiredness; 
 Dizziness; 
 Cognitive impairment; 
 Depression; 
 Gastrointestinal side 
effects. 
 Select a suitable antiepileptic 
drug based on tolerability profile 
and patients’ characteristics; 
 Start at low dose and up-titrate 
slowly; 
 Maintain at the lowest effective 
dose. 
 Reduce dose or 
discontinue 
medication; 
 Modify dosing scheme 
or drug formulation; 
Type B  Rare (<0.1%)*; 
 Known as idiosyncratic; 
 Related to the patient’s 
susceptibility such as genetic; 
 Dose independent†; 
 Unpredictable; 
 Reversible; 
 High mortality. 
 Maculopapular rash; 
 Steven-Johnson 
syndrome; 
 Aplastic anaemia; 
 Hepatotoxic effects; 
 Pancreatitis. 
 Avoid (or use very cautiously) 
particular antiepileptic drugs in 
high-risk patients;  
 Start lamotrigine at low dose 
and up-titrate slowly. 
 Withdraw medication; 
 Avoid medication with 
a similar adverse 
effects profile in 
future. 
Type C  Common; 
 Related to cumulative dose;  
 Chronic; 
 Commonly reversible. 
 Weight gain; 
 Folate deficiency; 
 Visual field loss;  
 Gingival hypertrophy. 
 Select a suitable antiepileptic 
drug based on the tolerability 
profile and patients’ 
characteristics. 
 Replacement therapy 
(e.g. folic acid);  
 Withdraw medication. 
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Table 1-5. Classification of the adverse drug reactions of antiepileptic drugs 
 Features Examples Prevention Management 
Type D  Uncommon (0.1 to 1%); 
 Related to prenatal exposure to 
the medication (i.e. 
teratogenesis) or 
carcinogenesis; 
 Commonly dose-dependent; 
 Delayed; 
 Irreversible. 
 Birth defects; 
 Neurodevelopmental 
delay in the offspring; 
 Pseudolymphoma. 
 Avoid valproate, phenobarbital, 
and polytherapy in women of 
childbearing potential, if 
possible; 
 Use low-risk monotherapies at 
the lowest effective dose before 
pregnancy; 
 Avoid discontinuation during 
pregnancy. 
- 
Type E  Common; 
 Adverse drug interactions; 
 Predictable; 
 Reversible. 
 Increased risk of 
cutaneous reactions 
after adding 
lamotrigine to 
valproate; 
 Decreased efficacy of 
warfarin after adding 
carbamazepine. 
 Avoid polytherapy if possible; 
 Select concomitant drugs with 
low potential for adverse drug 
interactions. 
 Dose adjustment. 
*Except maculopapular rash that can affect 5-17% of patients started phenobarbital, phenytoin, carbamazepine, and lamotrigine. †Except LTG-induced cutaneous 
reactions that correlate to starting dose and titration rate. Data obtained from (Edwards and Aronson, 2000, Perucca and Gilliam, 2012). 
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1.4.1 Type A reactions 
Type A effects can be attributed to the drug’s main mechanism of action, and are 
often predictable, thus the patient can be counselled regarding possible 
symptoms. The effects are generally present on the introduction of the drug or 
dose escalating, and diminish over time or after dosage reduction (Perucca and 
Gilliam, 2012). 
CNS effects represent most of type A reactions of AEDs and can be further 
categorised into four groups; sedative effects, coordination disturbances, 
cognitive dysfunction, and psychiatric adverse effects. 
1.4.1.1 Sedative effects 
The sedative effects of AEDs range from mild tiredness or drowsiness to profound 
lethargy (Perucca and Gilliam, 2012). They are the most commonly reported 
adverse effects of AEDs and are shared by most, if not all, AEDs (Marson et al., 
2007b, Perucca and Gilliam, 2012). They are also the most common reason for the 
treatment failure of AEDs, except for LTG, in which a rash is the most frequent 
reason (Marson et al., 2007a). Sedative effects are more common and severe in 
the first-generation AEDs, PB, PRM, and benzodiazepines (BZD) (Kennedy and 
Lhatoo, 2008). All new AEDs also possess sedative properties, except for LTG which 
rarely causes sedation (Zaccara et al., 2008, Brodie, 2017b).  
1.4.1.2 Coordination disturbances 
Coordination difficulties include dizziness, imbalance, unsteadiness, ataxia, gait 
difficulties, vertigo, nystagmus, tremor, and diplopia (Perucca and Gilliam, 2012).  
All old AEDs, particularly CBZ, PHT, PRM, and BZD, are associated with a 
considerable risk of poor coordination (Kennedy and Lhatoo, 2008). However, 
these adverse effects also appear with new AEDs, although the risk appears to be 
lowest with LEV (Kennedy and Lhatoo, 2008, Zaccara et al., 2008, Brodie, 2017b).  
In a meta-analysis of placebo-controlled studies of eight AEDs (GBP, LTG, LEV, 
OXC, PGB, TGB, TPM, and ZNS), all new AEDs except LEV have adverse 
coordination effects (but no meta-analysis could be performed with OXC and TGB) 
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(Zaccara et al., 2008). In another meta-analysis of the aforementioned eight AEDs, 
the risk of poor coordination related to the treatment was three times higher, 
compared with a placebo. A particular high risk was recorded with OXC, LTG, TPM, 
and PGB, whereas the risk was not significant for LEV and GBP (Sirven et al., 2007). 
1.4.1.3 Cognitive dysfunction 
The adverse cognition effects of AEDs primarily include psychomotor dysfunction, 
concentrating difficulty, and memory problems (Perucca and Meador, 2005). The 
rate of negative cognitive effects in AEDs is estimated at approximately 13-15%, 
although it varies greatly among AEDs (Arif et al., 2009, Javed et al., 2015). Among 
the older AEDs, PB, PRM, and BDZ possess more negative effects on cognition than 
VPA and CBZ. However, neither VPA nor CBZ are completely free of adverse 
cognitive effects. New AEDs are generally less likely to have adverse effects on 
cognition, and the only new AEDs known to cause substantial cognitive dysfunction 
are TPM and ZNS, both of which have a negative impact on cognition, and a 
specific effect on verbal function, language, and memory. However, LTG, GBP, 
and LEV are less likely to interfere with the cognitive processes, even among 
patients on polypharmacy (Perucca and Meador, 2005, Arif et al., 2009, Perucca 
and Gilliam, 2012, Javed et al., 2015).  
The risk of cognitive dysfunction is increased in polytherapy, and higher AEDs 
doses (Perucca and Meador, 2005). Other non-AED factors can also contribute to 
a high rate of these effects, including epilepsy aetiology and duration; seizure 
type, frequency, and severity; postictal states; comorbidity; and psychosocial 
factors (Perucca and Gilliam, 2012). Patients with an intellectual disability are 
less likely to report cognitive adverse effects, while patients with depression are 
more likely to do so (Javed et al., 2015). 
1.4.1.4 Psychiatric effects 
Approximately 15 to 20% of epilepsy patients who take AEDs report adverse 
psychiatric effects. These effects include behavioural or personality changes, such 
as irritability, hyperactivity, agitation, and aggressiveness; mood disorders; and 
psychoses (Perucca and Gilliam, 2012). Behavioural problems are the most 
commonly reported psychiatric adverse effects of AEDs, while psychosis is a 
relatively rare (Schmitz, 2006). AEDs can induce psychiatric changes via two 
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mechanisms: GABAergic effects in depression, and forced normalisation, i.e. 
seizure control, in psychosis (Schmitz, 2006). 
Not all AEDs have the same psychiatric effects; of the established AEDs, a high 
risk of negative psychotropic effects is associated with PB, PRM, ESM, and BZD, 
while among the new AEDs, VGB, TPM, TGB, LEV, ZNS, FBM, and PER are associated 
with a high risk of negative psychiatric effects. In contrast, several AEDs have 
positive psychotropic properties, and are commonly utilised in psychiatric 
disorders, including CBZ, VPA, LTG, and GBP (Schmitz, 2006, Weintraub et al., 
2007, Brodie, 2017b). 
A history of psychiatric disorders is an important risk factor for experiencing 
adverse psychiatric effects with AEDs. The risk of negative psychiatric effects with 
AEDs seems to also be related to the severity of the epilepsy, polypharmacy, fast 
up titration, and high doses of medication (Mula et al., 2003a, Schmitz, 2006, 
Perucca and Gilliam, 2012). Moreover, psychiatric comorbidity has been shown to 
deteriorate common AED-related adverse effects (Kanner et al., 2012).  
In summary, the Type A reactions of AEDs are the most frequently reported 
adverse effects, and are associated with the use of all AEDs at different rates, 
being typically more common and severe with first-generation agents. Table 1-6 
is an attempt to summarise the CNS adverse effects of AEDs that represent the 
majority of type A reactions. 
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Table 1-6. Central nervous system effects of antiepileptic drugs 
 Sedative 
effects 
Coordination 
disturbances 
Cognitive 
dysfunction 
Psychiatric 
effects 
Phenobarbital ++ + ++ ++ 
Phenytoin + ++ ++ 0 
Ethosuximide + + 0 ++ 
Carbamazepine + ++ + Protective  
Valproate + + + Protective 
Clonazepam ++ ++ ++ ++ 
Clobazam + ++ + ++ 
Vigabatrin + + 0 ++ 
Lamotrigine 0 + 0 Protective 
Gabapentin + + 0 Protective  
Topiramate + + ++ ++ 
Tiagabine + ++ ++ ++ 
Oxcarbazepine + ++ + 0 
Levetiracetam + + 0 ++ 
Pregabalin + + 0 0 
Zonisamide + + ++ ++ 
Lacosamide + + 0 0 
Eslicarbazepine 
acetate 
+ + 0 0 
Retigabine + + 0 + 
Perampanel + + 0 ++ 
Brivaracetam + + 0 + 
Key: 0; no effect, +; mild effect, ++; marked effect. This table based on information obtained 
from (Sirven et al., 2007, Weintraub et al., 2007, Kennedy and Lhatoo, 2008, Zaccara et al., 
2008, Arif et al., 2009, Javed et al., 2015, Brodie, 2017b). 
 
1.4.2 Type B reactions 
Usually known as idiosyncratic, these reactions cannot be attributed to the main 
mechanism of action of the medication. Type B effects are often unpredictable, 
and are related to individual vulnerabilities, such as genetic, immunological, or 
other mechanisms. Most of these adverse drug reactions occur irrespective of the 
dosage, while others such as LTG-induced skin rash, are correlated with the 
starting dose and titration rate (Zaccara et al., 2007, Perucca and Gilliam, 2012). 
Type B reactions account for up to 10% of all adverse reactions of AEDs. Apart 
from maculopapular rash, idiosyncratic reactions are rare but include the most 
life-threatening effects of AEDs. They are reversible on discontinuation, but 
delayed identification and intervention can lead to a high morbidity, and even to 
mortality (Zaccara et al., 2007). 
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Idiosyncratic reactions often occur within the first few weeks or months of 
treatment, and are more frequent with the established AEDs (Brodie, 2017b). The 
mechanisms underlying these effects include immune-mediated hypersensitivity 
reactions, direct cellular damage by the drug or its active metabolites, and, less 
commonly, the off-target interaction of the drug or its active metabolites with 
atypical system (Zaccara et al., 2007). 
The most common Type B effects of AEDs include cutaneous, haematological, 
hepatic or pancreatic reactions, or other reactions. 
1.4.2.1 Cutaneous reactions 
Immune-mediated skin hypersensitivity reactions are the most common 
idiosyncratic reactions of AEDs. These reactions often consist of maculopapular 
rash that can affect 5 to 17% of patients who are started on CBZ, PHT, PB, and 
LTG. However, these AEDs are also associated with a risk of potentially life-
threatening Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), 
and drug-related rash with eosinophilia and systemic symptoms (DRESS), affecting 
1 to 10 per 10,000 new users (Zaccara et al., 2007, Perucca and Gilliam, 2012).  
Genetic predisposition plays an important role in AED-induced idiosyncratic skin 
reactions. A strong association has been found between the genetic marker HLA-
B*1502 and CBZ-induced SJS in Han Chinese patients (Chung et al., 2004), while 
the genetic marker HLA-A*3101 has been found to be associated with CBZ-induced 
skin reactions in European patients (McCormack et al., 2011). 
Other risk factors for these reactions are young or old age, a history of drug-
induced skin reactions, a high start dose and fast up titration, concomitant 
infectious disease or immune system disorders, and particular concurrent 
medications (Zaccara et al., 2007, Perucca and Gilliam, 2012).  
1.4.2.2 Haematological reactions 
The most serious blood dyscrasia is aplastic anaemia (in which bone marrow fails 
to produce enough blood cells of all three cell types), and the AED most strongly 
associated with this reaction is FBM. The incidence of FBM-induced aplastic 
anaemia is 127 cases in one million per year, compared with two cases in one 
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million per year in the general population (Zaccara et al., 2007). Other AEDs can 
also cause aplastic anaemia. In a case-control study, 9.2% of 173 patients with 
aplastic anaemia were taking AEDs, with most taking CBZ, VPA, or PHT, although 
FBM was excluded. While 0.8% of the 497 control patients were taking these 
medications, which means that AEDs exposure was associated with a nine-fold 
increase in the risk of aplastic anaemia (Handoko et al., 2006).  
AEDs can also cause agranulocytosis (lowered white blood cell particularly 
neutrophils), with CBZ associated with the highest risk. In a population-based 
study, CBZ was observed to be associated with an increased risk of developing this 
condition; the OR (odds ratio) was 10.96 (95% CI 1.17–102.64) (Ibanez et al., 2005). 
PHT was also associated with an increased risk, and rare cases have also been 
reported with other AEDs (Ibanez et al., 2005, Zaccara et al., 2007).  
1.4.2.3 Hepatic or pancreatic reactions 
The liver is the main organ responsible for drug metabolism, and is therefore prone 
to drug toxicity. Hepatotoxicity can be part of DRESS, especially with aromatic 
AEDs such as PB, PHT, CBZ, LTG or it can present separately. Isolated 
hepatotoxicity can be caused by immune-mediated mechanisms, or by direct 
cytotoxic damage, as in VPA-induced liver toxicity (Zaccara et al., 2007). 
In a population-based study in Untied State, AEDs were found to be the fourth 
most frequent medications to cause acute drug-iduced hepatotoxicity leading to 
liver transplantation, preceded only by paracetamol, isoniazid, and 
propylthiouracil (Russo et al., 2004). 
VPA and FBM are associated with the highest risk of acute hepatotoxicity. The risk 
of fatal liver damage with VPA is one in 10,000 to 49,000 for the general 
population, and one in 500 for the highest risk group (paediatric < 2 years old, 
inborn metabolic conditions, and polypharmacy) (Pellock et al., 2006). However, 
the rate of fatal hepatotoxicity induced by VPA seems to have declined recently, 
perhaps because a better awareness of the condition has engendered an avoidance 
of VPA in the patients with a high risk, and the immediate withdrawal of the drug 
when the initial symptoms present (Zaccara et al., 2007). The risk of fatal liver 
damage with FBM is one in 26,000 to 34,000, while occasional cases of 
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hepatotoxicity have been reported with CBZ, PHT, and LTG (Perucca and Gilliam, 
2012).  
Pancreatitis is another rare, but serious, effect of VPA, with an incidence rate of 
1:40,000 in adults. An age of < 20 years, polypharmacy, haemodialysis, and chronic 
encephalopathy appear to be risk factors for pancreatitis induced by VPA (Zaccara 
et al., 2007, Perucca and Gilliam, 2012). Rare cases of pancreatitis have also been 
reported with other AEDs (Zaccara et al., 2007). 
1.4.2.4 Other reactions 
There are a number of other idiosyncratic reactions related to AEDs, such as CNS 
reactions, systemic lupus erythematosus, and ocular reactions. 
Encephalopathy caused by VPA, which may range from confusion to lethargy and 
coma; PHT-induced dyskinesia (abnormal involuntary muscle movement); and 
non-epileptic myoclonus induced by PGB and GBP are examples of unusual 
idiosyncratic CNS effects of AEDs (Zaccara et al., 2007). 
Systemic lupus erythematosus has been reported with a number of AEDs, including 
CBZ, and with less incidence, VPA, PHT, ESM, and LTG (Zaccara et al., 2007). 
In rare cases, TPM can cause a number of ocular adverse reactions, such as acute 
angle-closure glaucoma, of which 81 cases were reported up to 2002. Blurry vision 
is the usual symptom of this condition, and such reactions are reversible on 
immediate discontinuation of TPM. The sulfonamide part of TPM appears to be 
responsible for this reaction (Fraunfelder et al., 2004).  
In summary, the Type B reactions of AEDs are arguably the most concerning 
adverse effects associated with AED use. Apart from mild skin rash, these 
idiosyncratic reactions are often rare, but life threatening, and are reported more 
often with the old AEDs. Table 1-7 demonstrates some serious idiosyncratic 
reactions associated with individual AED
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Table 1-7. A selection of serious idiosyncratic reactions associated with some antiepileptic drugs 
 SJS/TEN/ 
DRESS 
Aplastic 
anaemia 
Agranulocytosis Hepatotoxicity Pancreatitis SLE Other 
 
Phenobarbital ++ + + + 0 +  
Phenytoin ++ + + + 0 +  
Ethosuximide + + + + 0 +  
Carbamazepine ++ + ++ + 0 +  
Valproate + 0 0 ++ ++ + Thrombocytopenia, 
hyperammonemia 
Lamotrigine ++  + + 0 0 Aseptic meningitis 
Felbamate + ++ ++ ++ + +  
Topiramate + 0 0 0 0 0 Angle closure 
glaucoma, 
oligohidrosis, 
hyperthermia  
Tiagabine + 0 0 0 0 0 Stupor, non-
convulsive status 
epilepticus 
Oxcarbazepine + + + 0 0 0  
Levetiracetam 0 0 0 0 0 0 Thrombocytopenia  
Zonisamide + 0 + 0 0 0 Hyperthermia, 
oligohydrosis 
Eslicarbazepine  
acetate 
+ 0 0 0 0 0  
Key: 0: no reported cases, +: occasional reported cases, ++: high risk. SJS: Stevens–Johnson syndrome, TEN: toxic epidermal 
necrolysis, DRESS: drug-related rash with eosinophilia and systemic symptoms, SLE: systemic lupus erythematosus. This table based 
on data obtained from (Ibanez et al., 2005, Handoko et al., 2006, Pellock et al., 2006, Zaccara et al., 2007, Perucca and Gilliam, 2012, 
Brodie, 2017b) 
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1.4.3 Type C effects 
Type C reactions are chronic effects that result from cumulative drug use. These 
effects progress slowly and complete manifestation appears after a long-term 
exposure of between a few months and several years. Although most of these 
effects disappear following the discontinuation of AEDs, others can be irreversible 
(Perucca and Meador, 2005). 
The known long-term effects of the enzyme induction of some AEDs, particularly 
old generation AEDs, can cause a number of chronic reactions, such as osteoporosis 
and osteomalacia, sexual dysfunction, and increased cardiovascular risk (Brodie, 
2017b). But for other chronic effects, the underlying mechanisms are not fully 
understood, as in gingival hyperplasia, induced by PHT (Perucca and Meador, 
2005). 
Type C effects of AEDs include changes in bodyweight, abnormalities in bone 
health, reproductive disorders, visual field loss, cosmetic side effects, renal and 
electrolytes disturbances, and atherosclerosis and cardiovascular risks. 
1.4.3.1 Changes in bodyweight 
This is a classic Type C effect, which can increase morbidity, impair self-esteem, 
and lead to a poor adherence to AEDs, or to the discontinuation of treatment 
(Perucca and Gilliam, 2012). AEDs have different effects on bodyweight, some of 
which are associated with weight gain, and some with weight loss, while others 
have a neutral effect on bodyweight (Figure 1-4). 
 
Figure 1-4. The effect of some antiepileptic drugs on body weight 
 
Valproate
Carbamazepine
Gabapentin
Vigabatrin
Pregabaline
Weight gain
Phenytoin
Lamotrigine
Levetiracetam
Weight neutral
Topiramate
Felbamate
Zonisamide
Weight loss
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Weight gain is a common adverse cosmetic effect associated with a number of 
AEDs. The underlying mechanisms are poorly understood, and vary among 
different AEDs. Several mechanisms have been suggested: first, a competition 
between the binding of AEDs and long chain fatty acids increases the availability 
of fatty acids, which consequently stimulates insulin production. Hyperinsulinemia 
causes a decrease in blood glucose level, which consequently stimulates eating, 
and increases hunger through its effect on the hypothalamus. Another possible 
explanation is that AEDs enhance GABA-neurotransmitters that increase appetite 
and decrease energy expenditure. Furthermore, abnormal thirst associated with 
some AED therapy may increase the intake of energy-rich beverages, and 
therefore increase weight gain (Jallon and Picard, 2001).  
The AEDs associated with weigh gain are VPA, GBP, VGB, PGB, and to a lesser 
extent, CBZ (Ben-Menachem, 2007).  
An increase in body weight can disturb general health, with a possible increase in 
the risk of cardiovascular diseases, Type 2 diabetes mellitus, hyperlipidaemia, and 
some cancers (Ben-Menachem, 2007, Perucca and Gilliam, 2012). Of note is the 
fact that enzyme-inducing AEDs have been found to increase the risk of 
cardiovascular disease independently of weight gain (Perucca and Gilliam, 2012, 
Brodie, 2017b). In addition to weight gain, VPA can cause several endocrine 
dysfunctions in women, such as hyperandrogenism, polycystic ovary symptoms, 
and menstrual disorders. It has been proposed that obesity-induced insulin 
resistance, and hyperinsulinemia, underlie these endocrine disorders (Ben-
Menachem, 2007). 
The AEDs associated with weight loss are TPM, FBM, and ZNS (Ben-Menachem, 
2007). Although possibly helpful in obese or overweight patients, weight loss can 
be a problem for nutritionally susceptible individuals (Perucca and Gilliam, 2012), 
therefore it is important to monitor the bodyweight of patients at every visit. 
The AEDs that appear to be weight neutral are PHT, LTG, and LEV, based on 
clinical experience and clinical study (Ben-Menachem, 2007). 
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1.4.3.2 Abnormalities in bone health 
Epilepsy patients treated with AEDs are at increased risk of fracture and 
abnormalities in bone health (Pack, 2011). Consistent evidence has suggested that 
the enzyme-inducing AEDs, PHT, PB, and PRM, are highly associated with a 
lowered active vitamin D metabolite, and low bone mineral density, while studies 
have produced conflicting results for CBZ, VPA, and LTG. OXC is also an enzyme 
inducer at a high dose, and has been observed to reduce bone health in adults and 
children (Kim et al., 2007, Pack et al., 2008, Pack, 2011). It is therefore important 
to optimise calcium and vitamin D intake for all epilepsy patients treated with 
AEDs. 
1.4.3.3  Reproductive dysfunction 
There is a complex interaction between epilepsy, AEDs, and the reproductive 
system. Low fertility, and reproductive endocrine disorders in both men and 
women with epilepsy are more common than in the general population due to 
epilepsy per se, and to the use of AEDs (Isojarvi et al., 2005). 
The enzyme-inducing AEDs, PB, PHT, and CBZ, increase serum sex hormone-
binding globulin (SHBG) concentrations in both men and women with epilepsy. 
This increase gradually leads to decrease testosterone and oestradiol bioactivity, 
which consequently causes impotence in men, and menstrual disorders in women, 
and therefore decreased fertility (Isojarvi et al., 2005).  
As previously described, VPA is known to cause reproductive endocrine dysfunction 
in women, which is usually associated with weight gain. In men, VPA also increases 
serum androgen levels. However, the clinical significance of endocrine changes in 
men is unknown. In low doses, OXC has no effect on the level of reproductive 
hormones in men, but it may have an effect in high doses, and may increase SHBG 
levels (Rattya et al., 2001). 
LTG has demonstrated better outcomes than enzyme-inducing AEDs with regards 
to sexual function and reproductive hormone levels in men. The hormonal effects 
of other new AEDs have not been studied (Isojarvi et al., 2005).  
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1.4.3.4  Visual field loss with vigabatrin 
VGB was approved in 1989 in the UK as adjuvant therapy for adult patients with 
focal epilepsy. Nine years later, the first cases of VGB-induced irreversible 
bilateral concentric visual field defects were noted (Eke et al., 1997). 
This defect is a common chronic side effect. A systematic review of 32 studies 
revealed that 44% (n=738/1678) of patients experienced visual field loss following 
exposure to VGB therapy, with a relative risk of 4 (95% CI 2.9–5.5) (Maguire et al., 
2010). This study concluded that the prevalence of this defect was lower in 
children compared to adult (34% vs. 52%), suggesting that risk factors include older 
age and cumulative doses of VGB. 
Interestingly, many affected patients are unaware of this visual defect, as they 
simply adjust their head to compensate for any restriction in vision (Brodie, 
2017b). Nevertheless, this adverse effect has substantially limited the use of VGB, 
which should therefore be reserved as last option for refractory epilepsy patients, 
and regular visual field examinations may be required (Maguire et al., 2010). 
1.4.3.5 Cosmetic adverse effects 
AEDs can cause several cosmetically undesirable effects, such as bodyweight 
changes, hair problems, acne, oligohydrosis, blue skin discoloration, and gingival 
enlargement. These adverse effects are common, accounting for 42% of reported 
adverse effects of AEDs, and impose a negative impact on drug adherence and the 
economic burden, the estimated annual cost of which per patient is €2,800 (De 
Kinderen et al., 2014, Chen et al., 2015). Being of the female gender, and 
possessing a history of previous cosmetic adverse effect seem to be risk factors 
for this category of adverse effects (Chen et al., 2015). Changes in bodyweight 
was described previously, therefore this section focuses on hair- and skin-related 
cosmetic adverse effects. 
VPA can cause alopecia, or hair changes such as hair thinning or change of colour, 
in 8 to 12% of patients. VPA-induced alopecia is typically mild and transient, and 
hair regrowth can occur without ceasing the use of VPA, although the hair can 
grow back curly. The hair-related problems induced by VPA are reversible on drug 
discontinuation (Tisdale and Miller, 2010, Gaitatzis and Sander, 2013). The 
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underlying mechanisms of VPA-induced alopecia remain unclear, although lowered 
zinc levels in hair and blood, and reduced biotindase activity induced by VPA may 
lead to hair loss. Meanwhile, biotin supplements have been found to ameliorate 
VPA-induced alopecia (Chen et al., 2015). CBZ and LTG can also cause hair loss, 
typically 2 to 3 months after treatment initiation (Gaitatzis and Sander, 2013). 
Additionally, VPA can cause hirsutism and acne in women, as consequences of 
hyperandrogenism, whereas PHT can cause hypertrichosis and acne in both sexes. 
Abnormal extra hair growth usually appears on the trunk and face, and can 
continue for a year or more after ceasing use of the medication (Gaitatzis and 
Sander, 2013). Both hirsutism and hypertrichosis are conditions of abnormal excess 
hair growth, but hirsutism presents only in women, due to hyperandrogenism, with 
the extra hair usually growing on the face and body in a ‘male-like’ pattern. While 
hypertrichosis can occur in both sexes, unrelated to androgen, hair can grow on 
any part of the body in excess to the amount that normally appears in individuals 
of the same sex, age, and race (Tisdale and Miller, 2010). 
Oligohydrosis, or reduction in sweating, and hyperthermia can present in a small 
number of patients taking ZNS, and to a lesser extent TPM. This effect is reversible 
upon discontinuation of ZNS and TPM (Gaitatzis and Sander, 2013, Brodie, 2017b). 
Although the underlying mechanism of oligohyrosis is not fully understood, the 
effect of carbonic anhydrase inhibition induced by ZNS and TPM on sweat glands 
may be involved. Hyperthermia resulting from oligohydrosis occurs mainly in 
children in hot climates, and it is therefore important to ensure that the children 
remain cool and well hydrated during the summer months (Low et al., 2004). 
A blue discolouration of the skin, nails, lips, mucous membrane, and most 
importantly, the retina, can be produced by chronic use of RTG (Figure 1-5), the 
manufacturer of which consequently discontinued production in June 2017. This 
effect is dose- and time-related, and is probably reversible following the 
withdrawal of RTG. It may result from the accumulation of RTG’s dimers, and/or 
its N-acetyl metabolite, in the tissues (Brodie, 2017b).  
 
 
34 
Chapter 1. Introduction 
 
 
 
 
 
 
 
Figure 1-5. Blue discolouration adverse effect induced by retigabine (Food and Drug 
Adminstration, 2013) 
 
Gum hyperplasia is a commonly reported chronic side effect of PHT (Figure 1-6). 
Approximately 40 to 50% of patients taking PHT experience gingival as early as 3 
months after treatment introduction. The underlie mechanism is multifactorial, 
and is not fully understood. Low serum folate is substantially associated with the 
severity and early onset of PTH-induced gum hyperplasia. PHT may also stimulate 
inflammation in patients with chronic gingivitis, leading to an abnormal excess of 
fibroblast proliferation and collagen deposition in the gingiva. Genetic 
predisposition is likely to be involved, since the growth of fibroblast is sensitive 
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to PHT in these individuals. The severity of the gingival enlargement of PHT has 
been found to be dose-dependent, although the data concerning this correlation 
is contradictory. The rate of this effect appears to be greater in children, and is 
similar in both genders. Poor dental care is a risk factor for gum hyperplasia in 
patients taking PHT, therefore it is important to maintain good oral hygiene. 
Additionally, long-term use of PHT may result in facial coarsening due to 
generalised skull thickening; this chronic dysmorphic change related to PHT 
appears to persist after its withdrawal (Gaitatzis and Sander, 2013, Chen et al., 
2015).  
 
Figure 1-6. Gingival hyperplasia induced by phenytoin (A) 
Improvement after 3 months of phenytoin discontinuation (B). Reproduced with permission from 
(Sharma  and Dasroy 2000), Copyright Massachusetts Medical Society. 
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1.4.3.6 Renal and electrolytes disturbances  
Renal calculi can occur as a result of TPM and ZNS chronic therapy in 
approximately 1 to 2% of patients (Wroe, 2007, Gaitatzis and Sander, 2013), 
probably due to the drugs’ inhibitory effects on carbonic anhydrase, and their 
potential for mild metabolic acidosis (Gaitatzis and Sander, 2013, Brodie, 2017b). 
However, the evidence is insufficient to conclude whether the combination 
therapy of TPM with ZNS increases the risk of kidney stones. Personal or family 
history of renal stones appears to increase the risk of developing kidney calculi 
induced by ZNS, and adequate hydration can minimise the risk of stone formation 
(Wroe, 2007).  
Dose-dependent hyponatremia (sodium <135 mg/l) can occur with OXC, CBZ, and 
ESL acetate (Gaitatzis and Sander, 2013). This adverse effect is more common and 
severe with OXC than with CBZ (30% vs. 13.5% of patients, respectively) (Dong et 
al., 2005). Old age is a risk factor for hyponatremia (Dong et al., 2005), and 
concomitant diuretic and selective serotonin reuptake inhibitors can deteriorate 
AED-induced hyponatremia (Gaitatzis and Sander, 2013, Brodie, 2017b), since they 
have similar effects. The majority of patients with mild hyponatremia (sodium 
125-135 mg/l) remain asymptomatic, and often require no intervention, but the 
dose should be reduced when the serum sodium level falls below this level (Brodie, 
2017b).  
Some bladder symptoms, such as hesitation, dysuria, and less often, urinary 
retention, have been documented with RTG use (Brickel et al., 2012). 
1.4.3.7 Atherosclerosis and cardiovascular risks 
The chronic use of enzyme-inducing AEDs can cause metabolic changes, and 
increase the risk of atherosclerosis in epilepsy patients at any age. The underlying 
mechanisms include the stimulation of cytochrome P450, which plays a significant 
role in cholesterol synthesis, as well as an increase in homocysteine (Belcastro et 
al., 2010, Chuang et al., 2012, Gaitatzis and Sander, 2013). VPA can cause 
metabolic dysfunctions including hyperinsulinemia, dyslipidaemia, 
hyperhomocysteinemia, obesity, and hypertension (Chuang et al., 2012). The lipid 
abnormalities induced by AEDs are hypertriglyceridemia, low high-density 
lipoprotein-cholesterol, and occasionally high total cholesterol. Switching to LTG 
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or LEV treatments can reverse, or ameliorate, the metabolic dysfunctions induced 
by VPA and enzyme-inducing AEDs (Belcastro et al., 2010, Chuang et al., 2012). 
Hyperhomocysteinemia is a contributor to atherosclerosis, and can increase the 
risk of cardiovascular and cerebrovascular diseases, and even brain atrophy and 
dementia. Hyperhomocysteinemia is often associated with low folate levels, and 
has consistently been reported in the chronic use of VPA and enzyme inducer AEDs 
including OXC and TPM, which are considered weak enzyme inducers. The risk of 
atherosclerosis is associated with the duration of AED therapy. In contrast, the 
chronic use of LTG therapy is not associated with hyperhomocysteinemia, or an 
increased risk of atherosclerosis (Belcastro et al., 2010, Chuang et al., 2012).  
1.4.4 Type D effects 
This category includes carcinogenic and teratogenic effects, which are delayed 
and irreversible (Perucca and Gilliam, 2012). 
Adverse drug effects on the foetus can present as foetal loss, intrauterine growth 
retardation, congenital malformations, impaired postnatal development, and 
behavioural problems (Tomson and Battino, 2012). 
1.4.4.1 Carcinogenic effects 
PHT and PB have consistently demonstrated carcinogenic effects in animals, 
however, to date, there is no clear evidence of the carcinogenic effect of AEDs in 
humans (Gaitatzis and Sander, 2013).  
In rare cases, PHT can cause pseudolymphoma, a benign condition that mimics 
clinically and histologically malignant lymphoma, and which disappears on 
treatment discontinuation. Misdiagnosis is not uncommon, and can lead to 
unnecessary chemotherapy. Occasional cases of pseudolymphoma have also been 
documented with other AEDs (Perucca and Gilliam, 2012). 
1.4.4.2 Major congenital malformations 
Prenatal exposure to AEDs, particularly in the first trimester, is associated with a 
greater risk of major congenital malformations; the risk is approximately three 
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times that in the children of healthy women (Perucca and Gilliam, 2012, Tomson 
and Battino, 2012).  
However, the magnitude of the risk differs for each AED, Figure 1-7 shows the 
rates of major congenital malformations for different monotherapies from 
different American and European pregnancy registries. The rates are greatest for 
VPA, ranging from 4.7 to 9.7%, while PB is also associated with a high risk of birth 
defects of up to 7.4%. However, the risk is smaller for PHT (2.9 to 6.7%), and CBZ 
(2.6 to 5.6%). Among the newer AEDs, LTG is the only agent for which sufficient 
exposed cases have been enrolled in pregnancy registries in order to allow a firm 
conclusion, demonstrating that LTG is associated with a low risk of teratogenicity 
(1.9 to 3.4%). The number of pregnant women on LEV, OXC, and TPM, have been 
too low to permit reasonable conclusions, nevertheless the current evidence 
suggests that LEV and OXC are associated with a low risk of teratogenicity, but 
that TPM is a potential teratogen (up to 7.7%) (Hernandez-Diaz et al., 2012, 
Tomson and Battino, 2012, Tomson et al., 2015). 
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Figure 1-7. Major congenital malformation rates of different monotherapies from different 
European and American pregnancy registries (Tomson et al., 2015) 
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The specific malformations vary for each AED. VPA has been found to increase the 
risk of several birth defects, including neuronal tube defects, cardiac defects, oral 
clefts, hypospadias, which is the unusual location of the urinary opening in males, 
polydactyly, which is extra fingers or toes, and craniosynostosis, or abnormal skull 
growth. Meanwhile, PB is associated with cardiac defects and oral defects; PHT 
with digit hypoplasia, or underdevelopment of fingers and toes; TPM and LTG with 
oral clefts; and CBZ with neuronal tube defects (Hernandez-Diaz et al., 2012, 
Tomson and Battino, 2012). 
Certain factors appear to increase the AED-related risk of major congenital 
malformations. Polytherapy of AEDs is consistently associated with higher rates 
than monotherapy, however, the risk depends on the involvement of specific AEDs 
in combination, rather than only the number of AEDs taken, with rates often 
increasing in polytherapy that includes VPA (Tomson and Battino, 2012). Risk of 
birth defects is also consistently correlated with the dose of VPA; generally, a 
higher risk has been found at a daily dosage (>600-1500 mg). Likewise, the risk 
has been found to be dose related for CBZ (>400-1000 mg), and LTG (>200-400 mg) 
in some registries (Tomson et al., 2015). Furthermore, it has been found that 
malformation in a previous child is associated with a high risk of having further 
children with birth defects; this may support the hypothesis that genetic factors 
may influence the AED-related risk of teratogenicity (Campbell et al., 2013).  
With regard to the potential mechanism of malformations, enzyme-inducing AEDs 
decrease serum and red blood cell folic acid levels by increasing the folic acid 
metabolism. While VPA-induced teratogenicity is not fully understood, it perhaps 
interferes with angiogenesis in uterus. Additionally, VPA appears to interfere with 
the folate metabolism by inhibiting glutamate formyl transferase, and reducing 
folinic acid production. Folic acid is critical for the biosynthesis of DNA and RNA. 
In women with epilepsy, low serum and red blood cell folate levels are associated 
with an increased incidence of spontaneous abortion and malformation (Morrell, 
2002). Folate supplementation is often recommended in order to reduce the risk 
of birth defects, such as neural tube defects, however there is no evidence of a 
reduction in the teratogenicity risk associated with VPA exposure (Tomson et al., 
2015). 
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1.4.4.3 Neurodevelopmental delay in offspring 
Increasing evidence has suggested an association between prenatal exposure to 
AEDs and an increased risk of neurodevelopmental impairment in the child. The 
prospective “Neurodevelopmental Effects of Antiepileptic Drugs” (NEAD) study 
compared the cognitive outcomes at age six of children exposed to VPA, CBZ, LTG, 
and PHT monotherapy. It suggests that the intelligence quotient (IQ) was 8 to 11 
points lower in children exposed to VPA, compared with children exposed to other 
AEDs. These IQ reductions were sufficient to affect education and occupational 
outcomes in later life. Memory and verbal abilities were also lower in the VPA-
exposed group than in other AED exposure. The cognitive impairment was dose-
dependent for VPA (Meador et al., 2013); however, this study did not include an 
unexposed control group. 
Similarly, a recent Cochrane Review of 22 prospective cohort studies, and six 
registry-based studies, revealed a significant reduction of cognitive function in 
VPA-exposed children, compared with the children of mothers without epilepsy, 
the children of mothers with untreated epilepsy, and the children of mothers 
treated with other AEDs, such as CBZ, LTG, and PHT. Furthermore, dose 
dependence for VPA was reported in six studies included in the review, and an 
increased cognitive impairment was associated with children exposed to a dosage 
>800-1000mg/day. No convincing evidence of dose dependence exists for other 
AEDs (Bromley et al., 2014).  
Aforementioned review also concluded that insufficient data exist concerning the 
newer AEDs. For instance, there has been no systematic review regarding the 
effect of prenatal exposure to TPM on the cognitive development of exposed 
children (Bromley et al., 2014). The only study evaluating the effects of LEV 
concerned the development of exposed children at age three, and indicated that 
the LEV-exposed children did not differ from the unexposed control children, but 
achieved higher scores in language and motor development than the VPA-exposed 
children (Shallcross et al., 2014). However, there was a low and varied age at 
assessment in this study, and fewer children were exposed to VPA than to LEV (44 
vs. 131). 
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1.4.4.4 Adverse behavioural effects in offspring 
It has been suggested that the maternal use of AEDs during pregnancy affects the 
behaviour of the exposed child. The aforementioned prospective NEAD study also 
examined the effects of foetal exposure to the AEDs CBZ, LTG, PHT, and VPA on 
adaptive and emotional/behavioural functioning in 195 six-year-old children. The 
adjusted mean scores for the four AED groups were in the low average to, average 
range for the parent ratings of adaptive functioning, and for the parent and 
teacher ratings of emotional/behavioural functioning. The VPA-exposed children 
possessed significantly lower adaptive functioning than the LTG and PHT exposed 
groups. These effects were dose-dependent for VPA and PHT. Furthermore, the 
VPA-exposed children were also recorded by their parents as possessing 
significantly more atypical behaviours and inattention than those in the LTG and 
PHT groups. Based on the parent and teacher ratings of attention span and 
hyperactivity, the children of mothers who took VPA during their pregnancy were 
at a significantly greater risk of a diagnosis of attention-deficit/hyperactivity 
disorder (ADHD) (Cohen et al., 2013). 
It has been found that the maternal use of VPA during pregnancy is associated 
with a significantly increased risk of autism spectrum disorders, and childhood 
autism in exposed children. After adjusting for maternal epilepsy, the children 
who were exposed to VPA in utero were at a 1.7-fold risk of autism spectrum, and 
a 2.9-fold risk of childhood autism, compared with children not exposed to VPA 
(Christensen et al., 2013).  
VPA is associated with the greatest teratogenicity risk, including postnatal adverse 
cognitive and behavioural effects. Consequently, the Medicines and Healthcare 
Products Regulation Agency (2015) in the UK stated that “in girls and women of 
childbearing potential, VPA should be initiated and supervised by a specialist and 
only when other medications have not been tolerated or have been found to be 
ineffective”. A number of recommendations have been proposed for the use of 
VPA in female patients of childbearing age (Tomson et al., 2015): 
1. Avoid VPA in young women whenever possible; 
2. Share the decision to choose VPA with patients; 
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3. Risks and benefits of VPA and alternatives should be assessed by an epilepsy 
specialist;  
4. VPA should not be prescribed as a first-line therapy for focal epilepsy; 
5. VPA may be prescribed as a first-line therapy for some idiopathic generalised 
syndromes associated with tonic–clonic seizures;  
6. VPA may be considered in women with significant intellectual or physical 
disabilities, who are unlikely to become pregnant; and  
7. Girls and young women who are currently on VPA therapy require regular 
follow-up in order to review the treatment. 
Since these adverse effects are dose-dependent, the key recommendation is to 
use the lowest effective dose of VPA before pregnancy (Tomson et al., 2015). 
1.4.5 Type E effects 
Type E adverse drug interactions constitute a clinically important aspect of AEDs, 
since many AEDs have a narrow therapeutic range (minor alterations in 
pharmacokinetics causes toxicity or low efficacy), and some AEDs such as PHT, 
CBZ, and VPA exhibit non-linear pharmacokinetics. Furthermore, many AEDs 
induce or inhibit drug-metabolising enzyme activities, and most AEDs are 
metabolised by the same enzymes. Moreover, intractable epilepsy patients usually 
require two or more co-prescribed AEDs that may interact with one other. AEDs 
can also interact with other concomitant medications (Perucca and Gilliam, 2012).  
These involve pharmacokinetic or pharmacodynamic drug interactions. 
Pharmacokinetic interactions may change the absorption, distribution, or 
metabolism, while pharmacodynamic interactions can be synergistic or 
antagonistic therapeutic effects (Zaccara and Perucca, 2014). 
1.4.5.1 Pharmacokinetic drug interactions 
Pharmacokinetic interactions are more frequent with old AEDs, since they can 
affect the activity of drug-metabolising enzymes. CBZ, PHT, PB, and PRM are 
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strong enzyme inducers, and thus decrease the serum levels and efficacy of 
several drug classes, including oral contraceptives, calcium antagonists, oral 
anticoagulants, antibiotics, steroids, immunosuppressants, antineoplastic drugs, 
antidepressants, and other AEDs (Johannessen and Landmark, 2010, Perucca and 
Gilliam, 2012, Zaccara and Perucca, 2014).  
In contrast, enzyme inhibition decreases the metabolic elimination of the 
substrates, and thus increases serum levels that may lead to toxic effects. Enzyme 
inhibition results most commonly from the use of VPA. Two important interactions 
include the inhibition of PB and LTG by VPA. VPA can increase PB concentration 
by 57 to 81%. The serum concentrations of LTG are also increased two- to three 
fold by VPA, which has major clinical significance. LTG should be introduced at 
much smaller doses, and up-titrated slower in patients with concomitant VPA, in 
order to reduce the risk of skin rash. The maintenance dosage of LTG is smaller 
when it is combined with VPA. There is also an increased risk of the CNS adverse 
effects of LTG if VPA is added, and thus the LTG dosage should be reduced by 50% 
when the VPA dosage reaches 500mg/day; the LTG dose should be also adjusted 
when VPA is discontinued (Johannessen and Landmark, 2010, Perucca and Gilliam, 
2012, Zaccara and Perucca, 2014). 
Despite the improved pharmacokinetic profiles of new AEDs, they are not 
completely free from clinically relevant interactions. LTG, OXC, ESL acetate, TPM 
(at dose >200mg/day), and PER (at dose 12mg/day) can reduce the serum 
concentration of some oral contraceptives. OXC, which is a weak enzyme inducer, 
can also decrease the serum concentration of some calcium channel blockers, such 
as felodipine (Johannessen and Landmark, 2010, Plosker, 2012, Zaccara and 
Perucca, 2014).  
Because most AEDs are substrates of drug-metabolising enzymes, they are 
susceptible to enzyme induction and inhibition. For instance, the serum 
concentration of CBZ can be increased by some antibiotics, such as erythromycin, 
and the serum concentration of LTG can be reduced by contraceptives containing 
oestrogen (Zaccara and Perucca, 2014). 
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GBP and PGB have no clinically relevant drug interactions, as they neither affect 
nor are metabolised by the hepatic cytochrome P system (Johannessen and 
Landmark, 2010, Zaccara and Perucca, 2014). 
1.4.5.2 Pharmacodynamic drug interactions 
The combination of two or more AEDs may cause shared interactions on the site 
of action, which may consequently affect their efficacy and tolerability. However, 
some of these interactions can have potentially favourable effects, and the best 
established pharmacodynamic interaction is that occurring between VPA and LTG. 
Several studies have suggested a synergistic therapeutic effect of the combination 
of these two AEDs on the seizure control of different seizure types, since doses of 
VPA and LTG in combination are lower than their doses when they were used 
alone, or are combined with other AEDs (Stephen et al., 2012). However, as 
previously mentioned, this combination requires dosage adjustments due to the 
significant pharmacokinetic interactions between VPA and LTG. Other possibly 
beneficial pharmacodynamic interactions have been indicated between VPA and 
ESM on absence seizures, and between VPA and CBZ on focal seizures (Zaccara 
and Perucca, 2014). These observations may suggest that additive or synergistic 
efficacy is included in combinations of AEDs with different mechanisms of action. 
In contrast, adverse pharmacodynamic drug interactions may result from the co-
prescribing of AEDs possessing the same main mechanism of action. In 
experimental and clinical studies, the combinations of sodium channel blocking 
AEDs have been shown to potentiate their individual neurotoxic effects. Indeed, 
combinations of CBZ with different sodium channel blocking AEDs, such as OXC, 
ESL acetate, LTG, and LCM, are associated with increased neurotoxicity (Zaccara 
and Perucca, 2014). 
1.5 Safety profile of individual antiepileptic drugs  
The safety profiles of 21 AEDs are summarised in chronological order in Table 1-8, 
excluding PRM, stiripentol, rufinamide, and FBM. PRM is a prodrug of PB and has 
similar tolerability profiles; the use of stiripentol and rufinamide is limited to 
children with Dravet syndrome and Lennox-Gastaut syndrome, respectively; and 
FBM is not licensed in the UK. 
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Table 1-8. Safety profile of antiepileptic drugs  
 Type A Type B Type C Type D Type E 
Phenobarbital Sedation, dizziness, 
cognitive impairment, 
depression, irritability, 
aggression, distractibility. 
Skin rash, SJS, 
TEN, DRESS, 
hepatotoxicity, 
blood dyscrasias. 
Frozen 
shoulder, 
decreased 
bone mineral 
density, folate 
deficiency, 
decreased 
libido. 
Birth defects.  
 
Pharmacokinetic: It is an enzyme inducer 
and can reduce the serum levels of 
concurrent drugs. Its metabolism is 
susceptible to enzyme inhibition.  
Pharmacodynamic: Concomitant CNS 
depressing agents (e.g. alcohol) can 
potentiate adverse effects.  
Phenytoin Fatigue, nystagmus, ataxia, 
diplopia, dysarthria, 
drowsiness.  
 
Skin rash, SJS, 
hepatotoxicity, 
aplastic anaemia, 
SLE. 
Hirsutism, 
gingival 
hypertrophy, 
acne, facial 
coarsening, 
osteopenia, 
folate 
deficiency, 
peripheral 
neuropathy, 
cerebellar 
atrophy.  
Pseudo-
lymphoma, 
birth defects 
(low risk). 
 
Pharmacokinetic: It has non-linear 
pharmacokinetic and its use needs 
phenytoin assay. It is an enzyme inducer, 
and can reduce the serum levels of 
concurrent drugs. Its metabolism is 
susceptible to enzyme induction and 
inhibition.  
Pharmacodynamic: Concomitant CNS 
depressing agents (e.g. alcohol) can 
potentiate adverse effects. 
Ethosuximide Nausea, abdominal 
discomfort, vomiting, 
diarrhoea, drowsiness, 
dizziness, ataxia, headache, 
hiccoughs, psychosis, 
irritability, aggression, 
euphoria. 
Skin rash,  
SJS, aplastic 
anaemia, SLE, 
agranulocytosis, 
hepatotoxicity. 
- Unknown. Pharmacokinetic: Its metabolism is 
susceptible to enzyme induction and 
inhibition.  
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Table 1-8. Safety profile of antiepileptic drugs  
 Type A Type B Type C Type D Type E 
Carbamazepine Drowsiness, dizziness, 
unsteadiness, vertigo, 
ataxia, diplopia. 
Skin rash, SJS, 
TEN, 
agranulocytosis, 
aplastic anaemia, 
dyskinesia.  
Decreased 
bone mineral 
density, folate 
deficiency, 
weight gain,  
hyponatremia. 
Birth defects 
(low risk).  
 
Pharmacokinetic: It is an enzyme inducer, 
and can reduce the serum levels of 
concurrent drugs. Its metabolism is 
susceptible to enzyme induction and 
inhibition.  
Pharmacodynamic: Concomitant sodium-
channel blocking AEDs increase CNS 
toxicity.  
Valproate Tremor, drowsiness, 
tiredness, nausea, 
abdominal discomfort, 
vomiting. 
Hepatotoxicity, 
pancreatitis, 
thrombocytopenia, 
aplastic anaemia, 
hyperammonemia, 
encephalopathy. 
Weight gain, 
alopecia, 
polycystic 
ovary 
syndrome, 
decreased 
bone mineral 
density.  
Birth defects 
(high risk), 
neurodevelop
-menal delay 
and 
behavioural 
disorders in 
the offspring.  
 
Pharmacokinetic: It is an enzyme 
inhibitor, and can increase the toxicity of 
concomitant drugs. Its metabolism is 
susceptible to enzyme induction and 
inhibition. 
 
Benzodiazepines  
 
Fatigue, tiredness, 
drowsiness, lethargy, 
dizziness, ataxia, cognitive 
impairment, hyperactivity, 
irritability, aggression, 
depression. 
-  - Unknown. Pharmacokinetic: Their metabolism is 
susceptible to enzyme induction and 
inhibition.  
Pharmacodynamic: Concomitant CNS 
depressing agents (e.g. alcohol) can 
potentiate adverse effects. 
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Table 1-8. Safety profile of antiepileptic drugs  
 Type A Type B Type C Type D Type E 
Vigabatrin Drowsiness, fatigue, 
dizziness, ataxia, agitation, 
depression, psychosis, 
agitation, confusion. 
- Visual field 
loss, weight 
gain.  
Unknown. Pharmacokinetic: It can reduce the serum 
levels of phenytoin.  
 
Lamotrigine Dizziness, ataxia, tremor, 
diplopia, insomnia, 
headache, nausea, 
vomiting. 
Skin rash, SJS, 
TEN, aseptic 
meningitis, 
agranulocytosis, 
hepatotoxicity. 
Nothing major 
reported to 
date.  
Birth defects 
(low risk).  
Pharmacokinetic: It can decrease the 
serum levels of levonorgestrel. Its 
metabolism is susceptible to enzyme 
induction and inhibition. 
Pharmacodynamic: Concomitant 
valproate and sodium-channel blocking 
AEDs can increase CNS toxicity.  
Gabapentin Drowsiness, fatigue, 
dizziness, vertigo, ataxia, 
nystagmus, diplopia, 
nausea, hyperactivity, 
irritability, aggression.  
Nothing major 
reported to date  
Weight gain  Not a 
teratogen 
No important drug interactions.  
Topiramate Cognitive impairment, 
concentration/attention 
difficulties, speech 
problems, drowsiness, 
fatigue, dizziness, 
depression, aggression, 
psychosis, anorexia, 
paraesthesiae, headache, 
ataxia. 
Angle closure 
glaucoma, 
oligohidrosis, 
hypertermia.  
Weight loss, 
nephrolithiasis
, glaucoma. 
Birth defects  Pharmacokinetic: At doses >200 mg/day, 
it can decrease the serum levels of serum 
levels of ethynylestradiol. Its metabolism 
is susceptible to enzyme induction. 
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Table 1-8. Safety profile of antiepileptic drugs  
 Type A Type B Type C Type D Type E 
Tiagabine Dizziness, unsteadiness, 
nausea, asthenia, 
nervousness, light-
headedness, ataxia, tremor, 
somnolence, irritability, 
aggression, depression, 
psychosis. 
Stupor, non-
convulsive status 
epilepticus. 
Nothing 
major. 
Unknown 
(probably not 
a teratogen). 
Pharmacokinetic: Its metabolism is 
susceptible to enzyme induction. 
Oxcarbazepine Drowsiness, dizziness, 
unsteadiness, ataxia, 
blurred vision, diplopia, 
nausea, vomiting, 
headache. 
Skin rash, 
including severe 
mucocutaneous 
reactions (SJS, 
TEN), aplastic 
anaemia, 
granulocytosis.  
Hyponatremia. Birth defects 
(probably low 
risk; limited 
evidence).  
Pharmacokinetic: It can increase serum 
phenytoin levels. It is a weak enzyme 
inducer, and can decrease the serum 
levels of oral contraceptives and calcium 
antagonist (felodipine). Its metabolism is 
susceptible to enzyme induction. 
Pharmacodynamic: Concomitant sodium-
channel blocking AEDs can increase CNS 
toxicity.  
Levetiracetam Drowsiness, fatigue, 
dizziness, ataxia, 
irritability, aggression, 
depression, psychosis, 
headache, nausea, 
vomiting. 
Thrombocytopenia
.  
Nothing major 
reported to 
date.  
Not a 
teratogen 
(limited 
evidence).  
Enzyme-inducing AEDs can moderately 
decrease its serum concentrations. 
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Table 1-8. Safety profile of antiepileptic drugs  
 Type A Type B Type C Type D Type E 
Pregabalin Dizziness, vertigo, abnormal 
coordination, ataxia, 
blurred vision, diplopia, 
drowsiness, fatigue, 
oedema, headache, tremor, 
constipation. 
No major reaction.  Weight gain, 
gynaecomastia
, 
erectile 
dysfunction. 
Unknown 
(probably not 
a teratogen). 
No important drug interaction.  
Zonisamide Drowsiness, fatigue, 
dizziness, 
concentration/attention 
difficulties, irritability, 
agitation, depression, 
psychosis, anorexia, nausea, 
vomiting, anorexia. 
Oligohidrosis, 
hyperthermia, skin 
rash, including 
severe 
mucocutaneous 
reactions.  
Weight loss, 
nephrolithiasis
.  
Unknown (no 
evidence that 
it is a 
teratogen). 
Pharmacokinetic: Its metabolism is 
susceptible to enzyme induction. 
Lacosamide Dizziness, unsteadiness, 
vertigo, ataxia, blurred 
vision, diplopia, nausea, 
vomiting, headache, 
tremor. 
Skin rash. Unknown.  Unknown (no 
evidence that 
it is a 
teratogen). 
Pharmacokinetic: Its metabolism may be 
susceptible to enzyme induction.  
Pharmacodynamic: Concomitant sodium-
channel blocking AEDs can increase CNS 
toxicity. 
Eslicarbazepine 
acetate 
Dizziness, vertigo, abnormal 
coordination, blurred vision, 
diplopia, nausea, vomiting, 
headache, drowsiness, 
fatigue, tremor. 
Skin rash, DRESS. Hyponatremia. Unknown.  Pharmacokinetic: It is a weak enzyme 
inducer, and may reduce the serum levels 
of certain concurrent drugs. Its 
metabolism may be susceptible to 
enzyme induction. 
Pharmacodynamic: Concomitant sodium-
channel blocking AEDs may increase CNS 
toxicity. 
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Table 1-8. Safety profile of antiepileptic drugs  
 Type A Type B Type C Type D Type E 
Retigabine Drowsiness, fatigue, 
dizziness, vertigo, blurred 
vision, diplopia, confusion.  
Unknown.  Weight gain, 
blue 
discolouration 
in skin and 
retina, urinary 
hesitancy/ 
retention. 
Unknown.  No important drug interaction to date. 
Perampanel Dizziness, somnolence, 
fatigue, irritability, nausea, 
falls, anger, hostility, 
aggression. 
- Weight gain. Unknown. At dose 12mg/day, it can reduce the 
serum concentration of levonorgestrel. Its 
metabolism may be susceptible to 
enzyme induction. 
Brivaracetam Dizziness, fatigue, 
somnolence, nausea, 
vomiting, depression, 
insomnia, irritability, 
anxiety. 
- - Unknown. No important drug interaction to date. 
Key: SJS: Stevens–Johnson syndrome, TEN: toxic epidermal necrolysis, DRESS: drug-related rash with eosinophilia and systemic symptoms, SLE: systemic lupus 
erythematosus. This table is based on data obtained from the supplementary appendix of (Perucca and Gilliam, 2012), and from (Brodie, 2017b). Additional information was 
sourced from other references mentioned in section 1.4. Only important adverse effects listed above, not comprehensive safety profile, considered important by the 
preceding authors, based on their frequency or severity.  
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1.6 Summary of the literature review, and rationale for the 
present study 
Epilepsy is the most common chronic neurological disorder. Many established and 
new AEDs are available, however it is unclear whether the treatment outcomes in 
epilepsy have changed over the last three decades as a result of the introduction 
of the 14 new AEDs. Data concerning their safety and efficacy can be obtained 
primarily from RCTs, however these trials do not capture other important factors 
such as teratogenic effects, rare idiosyncratic reactions, chronic adverse effects, 
enzyme-induction effects, and the potential for drug interactions, therefore 
further data regarding their long-term effectiveness and tolerability in everyday 
clinical practice are required. There is also limited evidence concerning certain 
predictors of efficacy and tolerability. This thesis therefore seeks to fill the gaps 
in knowledge listed below. 
1.7 Aims of the thesis 
This thesis attempts to evaluate the long-term effectiveness of AEDs in routine 
clinical practice. The following are the three core aims of this thesis. 
1. Evaluate the efficacy of AEDs on basis of seizure control at last follow-up. 
Determinants of pharmacoresistant epilepsy and changes in pharmacological 
outcomes over the last few decades are also studied. 
2. Study the rate and predictors of intolerable adverse effects of AEDs. 
3. Compare the retention rates of LTG, VPA, CBZ, and LEV as monotherapy. 
1.7.1 Methodologies for answering abovementioned research 
questions  
 Retrospective observational study. This was the methodology of the current 
study. This method has several advantages such as low cost, relatively 
rapid, can include large number of patients, accurate, good to moderate 
validity, and allows for historical comparisons or trend analysis. The 
following are potential different methodologies that can be used to address 
these research questions. 
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 Prospective observational study using standardised tools for screening some 
outcomes. For instant, use adverse event profile (AEP) for measuring 
adverse effects, use Morisky questionnaire to evaluate drug adherence, and 
use neurological disorder depression inventory for epilepsy for psychiatric 
screening. The accurate usage of these validated screening approaches can 
allow better quantification of the outcomes and identification of the 
populations at a high risk. However, these screening measures, which 
include checklists and questionnaires, tend to overestimate the prevalence 
of measured outcome.  
 Randomised controlled trial (RCT). Randomisation and control group can 
overcome the selection bias and confounding issues of observational 
studies, respectively. Indeed, RCT is the gold standard for comparing drug 
effectiveness. However, RCTs have some limitations as discussed in the 
next section. 
While comparative RCTs provide evidence of drugs efficacy, observational studies 
provide insight into their effectiveness in real-life. Clinical trials include a 
selection of patients who are often young, more intractable, and without 
comorbidities or concomitant medications, therefore they do not adequately 
represent the population of epilepsy patients. Whereas real-world studies 
provided bridge from the results of RCTs to daily clinical practice by including 
special populations such as elderly, pregnancy, children, and patients with 
psychiatric comorbidity and intellectual disability, who are often excluded from 
RCTs (French, 2012, Perucca and Gilliam, 2012).   
RCTs are often include small sample size and short duration (often 12 weeks) while 
epilepsy is a chronic condition and requires a lifelong treatment. Therefore, RCTs 
not only provide little information about long-term efficacy, they cannot detect 
the rare and chronic adverse drug reactions (Mohanraj and Brodie, 2003). For 
instance, FBM-induced aplastic anaemia and VGB-induced visual-field defects 
were identified during post-marketing phase (Perucca and Gilliam, 2012), and RTG 
was recently withdrawn from the market because of blue discolouration chronic 
side effect (Brodie, 2017b). Furthermore, the risk of teratogenicity is generally 
identified from real-world studies (Perucca and Gilliam, 2012).  
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Observational studies better reflecting the daily clinical setting where the dose of 
drug is individualised for each patient based on drug tolerability and efficacy, 
whereas RCTs usually use fixed doses and rapid titration protocol. Does-related 
side effects such as tiredness and poor coordination can abate with dose 
reduction. However, in trials with a rigid dose schedule, does reduction may not 
be allowable and thus the patients may discontinue drug and not gain efficacy 
from the drug. These neurotoxic adverse effects along with systemic adverse 
effects, including gastrointestinal upsets, may also resolve with time. The 
development of tolerance to initial adverse effects may allow higher doses to be 
used later (Mohanraj and Brodie, 2003). 
Additionally, in observational studies, other non-AED variables influencing the 
treatment outcomes can be evaluated. For instance, the effect of gender, age, 
epilepsy type, number and duration of pre-treatment seizures, psychiatric 
comorbidity, alcohol and recreational drug abuse, and number of prior 
unsuccessful AEDs can be assessed. 
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In order to achieve the aim and objectives set out in the previous chapter, a large-
scale observational study was conducted utilising a paper-based database and pre-
specified statistical analysis plan, as explained in the following section. 
2.1 Study design 
This study was a retrospective single centre clinic-based observational cohort 
study of patients with new-onset epilepsy from a tertiary care hospital. 
2.2 Study population 
The presented research involved a cohort of 1,528 consecutive unselected adult 
patients, who had been first diagnosed with epilepsy and prescribed AED 
treatment at Glasgow Epilepsy Unit. The patients were referred between 1 July 
1982 and 31 Oct 2012. The patients were prospectively managed and followed up 
until 30 April 2016, or death, with at least a one-year follow-up after initiation of 
AED treatment. The study cohort included most of patients investigated in three 
previous analyses in 1999, 2003, and 2008 (Kwan and Brodie, 2000, Mohanraj and 
Brodie, 2005, Brodie et al., 2012). 
2.2.1 Glasgow Epilepsy Unit 
The Epilepsy Unit at the Western Infirmary and subsequently at the West Glasgow 
Ambulatory Care Hospital (WGACH) provides a specialist clinical service for 
patients with suspected and established seizure disorders, conducts research 
related to aetiology and pharmacological management of epilepsy, and trains a 
range of health professionals. 
Clinical services for people with epilepsy were set up in 1982. Subsequently data 
has been collected from every patient using a “pink folder” system including a 
standard data collection form and investigative protocol. All subsequent 
information has been collected prospectively. A dedicated telephone line was 
made available to patients, families, and their primary care physician to facilitate 
optimal management. Patient data were included in a computer database and in 
pink folders which were stored in metal cabinets. The appropriate pink folders 
accompanied the team to every clinic and were available when patients, relatives 
and general practitioners phoned the Epilepsy Unit. Over the next 34 years, each 
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new patient was registered in the database and a folder developed for storage. 
There are currently 8068 pink folders in the system (Brodie, 2017a).  
Once the decision was taken to focus the outcome programme on adolescents and 
adult patients with newly diagnosed epilepsy, a letter was sent to all general 
practitioners in the West of Scotland offering to review suitable patients reporting 
a first seizure or with likely untreated epilepsy within a few weeks of referral. A 
direct line to the Epilepsy Unit office was set up to expedite the review of urgent 
cases. Most of these patients were sent home with no investigations or follow up 
arranged. Hence, a direct referral arrangement was established with the Epilepsy 
Unit, which initially bypassed the patient’s general practitioner. Lastly, the 
epilepsy nurse specialists reviewed patients admitted to the emergency and 
general medical wards with untreated seizures or epilepsy. Appropriate 
investigations were arranged and rapid referral to Epilepsy clinic was organised as 
appropriate. All clinical information available from these patients was included in 
the database (Brodie, 2017a). 
More than 90% of patients are referred from general practitioners with the 
majority of the reminder being tertiary referrals from other hospital across the 
West of Scotland. Most of the patients live in Glasgow but 20% travel to the clinic 
from outside the city. These largely originated from Lanarkshire, Argyll & Clyde, 
and Ayrshire & Arran. 
The epilepsy service is manned by medical and nursing staff from the division of 
Cardiovascular and Medical Sciences at Western Infirmary and subsequently at 
WGACH. The director of the Epilepsy unit is Professor Martin Brodie. Dr John Paul 
Leach is a consultant neurologist and neurophysiologist. Dr Linda Stephen 
organises patient services and the epilepsy Unit. In addition to other medical and 
nursing staff. 
2.2.2 Inclusion and exclusion criteria 
Patient inclusion criteria: 
 Age 18 years or above at treatment initiation; 
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 Referred to the Seizure Clinics between 1 Jul 1982 and 31 Oct 2012; 
 New-onset of seizure; 
  Confirmed diagnosis of epilepsy based on clinical evaluation (history and 
seizure description from the patient and witnesses of seizures), and 
investigations (EEG and MRI); 
 Started first-ever AED at the Glasgow Epilepsy Unit between 1 Jul 1982 and 
31 Oct 2012; and 
 Followed-up for at least one year after treatment commencement. 
Patient exclusion criteria: 
 Patients younger than 18 years old at treatment commencement; 
 Started AED therapy before 1 Jul 1982 or after 31 Oct 2012; 
 Previously treated with AEDs;  
 Psychogenic non-epileptic seizures 
 Most of the seizure were secondary due to reactional drug or alcohol abuse; 
 Patients with less than one years’ follow-up after treatment initiation, 
including patients with immediate seizure control on treatment, who did 
not complete one year of follow-up at 30 Apr 2016, and deceased patients 
with a period of treatment less than one year; and 
 Persistent poor adherence to AED treatments unrelated to drug efficacy or 
tolerability. 
58 
Chapter 2. Methods 
 
2.2.3 Patient flow chart  
As shown in Figure 2-1, of the 3,356 patients screened, 1,528 were eligible to 
include in this study based on the inclusion and exclusion criteria described in the 
previous section. 
 
Figure 2-1. Flow chart for patients’ inclusion 
 
Patients newly referred with undiagnosed seizure 
(1 Jul 1982 - 31 Oct 2012) 
(n=3,356) 
Excluded 
Not start antiepileptic drug (n=972) 
Previously treated (n=78) 
 
Patients newly initiated antiepileptic drug 
(n=2,306) 
 
Study Cohort 
n=1,528 
Excluded 
Persistent poor adherence (n=315) 
Non-epileptic or secondary seizure 
(n=196) 
Age < 18 year (n=254) 
Follow-up < 1 year (n=13) 
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At the first clinical visit, general physical and neurological examinations were 
performed. Additionally, clinicians used a predesigned questionnaire (Appendix) 
to collect demographic and clinical information from the patient and witnesses. 
Several investigations were performed [EEG, and brain imaging i.e. computed 
tomography (CT) scan and MRI] that might support the diagnosis and classification 
of the epilepsy, and to screen for underlying structural abnormalities, which 
subsequently helped in selecting the appropriate AED. 
2.3 Seizure and epilepsy classification 
Seizure and epilepsy types were classified according to the guidelines of the ILAE 
published in 1981 and 1989 (Commission of ILAE, 1981, Commission of ILAE, 1989). 
The most recent guideline for epilepsy classification published in 2017 (Fisher et 
al., 2017, Scheffer et al., 2017) was explained in Chapter 1; however, it was not 
applied to the classification of the current cohort. 
In this study, epilepsy was classified as either generalised or focal based on the 
seizure types and the assumed cause. Several important factors were also 
considered including the results of the EEG, CT, and MRI investigations, the 
patient’s age, and any family history of epilepsy. 
Generalised epilepsy was assumed to have a genetic origin and included primary 
GTCs, myoclonic jerks, absence seizures, and syndromes such as juvenile absence 
epilepsy and juvenile myoclonic epilepsy. 
Focal epilepsy, with or without secondary generalisation, was further subdivided 
into symptomatic or cryptogenic epilepsy. Symptomatic epilepsy was identified by 
the presence of epileptogenic lesions in the brain (evident on a CT or MRI scan), 
such as trauma, tumour, infection, cerebrovascular disease, mesial temporal 
sclerosis, and cortical dysplasia. Cryptogenic epilepsy was identified when an 
underlying brain lesion was presumed but not confirmed through clinical 
information or investigations. 
Once an epilepsy diagnosis was confirmed, an appropriate AED was initiated. 
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2.4 Treatment approach 
Treatment selection was based on efficacy of AED for the given seizure type or 
syndrome, the patients’ characteristics (i.e. age, gender, comorbidities, and 
concomitant drugs), and on the AEDs’ pharmacokinetics and tolerability profiles 
(Stephen and Brodie, 2009, Perucca and Tomson, 2011). In practice, the AED was 
usually initiated after two or more unprovoked seizures had occurred more than 
24 hours apart; however, patients who had experienced one seizure with evidence 
of an epileptogenic lesion in the brain that increased the probability of further 
seizures could be offered an AED therapy (Brodie et al., 2012, Fisher et al., 2014). 
Patients were subsequently evaluated at the epilepsy clinic every four to six weeks 
for the first six months and at least every four months thereafter. If medical 
attention was necessary between scheduled appointments, the patients or their 
primary care physicians could call the epilepsy unit by using a dedicated telephone 
line. At each follow-up visit, clinical information and the response to 
antiepileptic-drug therapy were recorded (Appendix). Compliance was monitored 
at the clinic as well. Drug doses were adjusted as clinical circumstances dictated, 
with particular attention paid to efficacy and tolerability. 
Initial monotherapy was prescribed for all the patients included in the study. 
Then, where necessary, treatment regimens were modified based on response to 
treatment (i.e. efficacy and tolerability). Modification of treatment schedules 
included dose adjustment, replacement of ongoing AED, or the addition of a 
combined therapy. Generally, if the initial AED was poorly tolerated at a low dose, 
or failed to improve seizure control, it was replaced with an alternative. If the 
first AED was tolerated and significantly improved seizure control, but did not 
completely provide seizure freedom, combination therapies were usually 
recommended (Brodie et al., 2012). 
Adherence to the medication was evaluated by directly questioning the patient in 
each visit and measuring drug levels in the blood whenever possible. Patients with 
persistent poor adherence to AEDs were excluded from this study. While patients 
with intermittent poor adherence who missed the medication occasionally were 
included and the reasons for the poor concordance were reported. 
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This approach to data collection provides benefits like highly accuracy and good 
validity to detect and quantify diagnoses that medically confirmed by general 
physical and neurological examinations, and laboratory investigations. These 
included adverse effects like weight gain, coordination abnormality specially 
tremor, skin reactions, haematological and hepatic side effects, and eye field 
examination. On the other hand, some symptoms were mainly recoded based on 
patient reports including seizure and some adverse effects like psychiatric 
disorders. 
2.5 Definitions 
2.5.1 Outcome measures 
This research was carried out to assess the long-term efficacy, tolerability, and 
effectiveness of AEDs. The efficacy of the AED treatment was evaluated on the 
basis of achieving a seizure-free status. Studies have indicated that absolute 
seizure freedom, usually 12 months, is the only relevant outcome resulting in a 
significant improvement on quality of life compared to reduced seizure frequency 
and severity (Kwan et al., 2010). Therefore, seizure-free status in the current 
study was defined as a minimum of one-year without a seizure at last follow-up, 
or no seizure reported at last follow-up, and there was at least one year between 
the last follow-up date and the date on which data was extracted (data extraction 
was completed on 30 Apr 2016). In many countries, including the UK, one-year 
seizure freedom is required to reinstate a driving licence. Therefore, there was 
consensus that the seizure-free duration assigned should be at least one year 
(Kwan et al., 2010). Seizure-free status included freedom from all seizures, 
including auras. The Epilepsy Clinic usually discharges seizure-free patients to 
primary care, requiring re-referral in the case of relapse, poor tolerability, or for 
a pregnancy consultation, etc. General practitioners and all patients are aware of 
this arrangement, also they could call the Epilepsy Unit if necessary. Therefore, 
it was assumed that the patients remained seizure-free if they were not referred 
back to the Epilepsy Clinic.  
Withdrawal of a drug because of intolerable or life threatening adverse drug 
reactions is the most significant outcome measure for side effects (Mohanraj and 
Brodie, 2003). Therefore, modification of the AED schedule due to intolerable 
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adverse effects was the outcome measure for poor tolerability in this study. In 
this context, modifications in the AED regimen primarily involved withdrawal of 
the offending AED, or a reduction in the dose and requiring of an adjunct AED to 
control seizures in some cases. This is because an intolerable adverse effect could 
cause treatment failure, either alone or in combination with poor seizure control. 
In this retrospective analysis, only intolerable adverse effects that contributed to 
treatment failure were explored. Thus, the prevalence of adverse effects of 
continued AEDs was not measured. This was because of the study design and the 
limited availability of data.  
Efficacy and tolerability integrate to form effectiveness and thus cannot be 
reasonably separated. The most relevant outcome measure to evaluate both these 
factors is the survival analysis, which reports the retention of patients on a 
specific treatment programme over a period of time (Mohanraj and Brodie, 2003). 
In addition, this approach shows the time to discontinuation of treatment due to 
any cause; thus, enabling the investigation of different reasons for treatment 
failure (Cramer, 2012). Therefore, in the present study, the retention rates for 
the most common monotherapies (LTG, VPA, CBZ, and LEV) were compared to 
evaluate their long-term effectiveness in routine clinical practice. Retention time 
was calculated in months from the start date of each AED to either the 
discontinuance date for the treatment, or the final follow-up date for continued 
therapy.  
2.5.2 Predictors  
A number of potential factors that influence the treatment outcomes (efficacy, 
tolerability, and effectiveness) were evaluated including factors related to patient 
and drug. Patient-related factors were gender, age at treatment initiation, 
epilepsy type and aetiology, family history of epilepsy, febrile convulsion, birth 
trauma, head injury, cerebrovascular disease, number and duration of pre-
treatment seizures, learning disability, psychiatric comorbidity, and alcohol and 
recreational drug abuse. While pharmacological factors were individual AED, 
number of prior unsuccessful AEDs schedule, number of co-prescribed AEDs, AED 
generation, and dosage. However, the influence of EEG results (normal, abnormal, 
epileptiform, not available) on treatment outcome was not evaluated, this 
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variable probably correlates to other variables such as epilepsy type and aetiology, 
and family history of epilepsy. 
The following are descriptions of some factors. 
 Family history of epilepsy: Family history of epilepsy in a first-degree 
relative (i.e. parent, child, full-sibling). This also includes a family history 
of any seizures, regardless of cause. 
 Birth trauma: Including documented birth trauma or any other birth 
difficulty resulting in an abnormality identified on brain imaging.  
 Learning disability: Including mild, moderate, and severe cases. Patients 
with Down’s syndrome were considered to have a learning disability. In 
these cases, a history was taken from care providers or parents at the 
follow-up stage. 
 Head injury: Including a skull fracture, head trauma with abnormality 
identified on a CT/MRI scan, or any severe head trauma that led to loss of 
consciousness or required investigation/hospitalisation. Not including 
minor head injury. 
 Cerebrovascular disease: Including stroke, transient ischaemic attack, or 
small vessel ischaemic change, as identified on brain imaging. 
 Psychiatric comorbidity: Including depression, anxiety, panic 
attacks/agoraphobia, suicidal attempts/thoughts, 
psychoses/schizophrenia, behavioural disorders (personality 
problems/antisocial), or anorexia. In addition to ongoing or past 
prescription of antipsychiatry medications.  
 Pre-treatment seizure count: The numbers of GTCs and focal (with or 
without impaired awareness, and auras) seizures were counted. More than 
one seizure within 24 hours was considered as one seizure. For myoclonic 
jerks and absence seizures, the number of days with seizures was counted. 
64 
Chapter 2. Methods 
 
 Alcohol abuse: Including alcoholism syndrome, frequent excess intake of 
alcohol, or chronic alcohol problems that resulted in hepatic problems or 
required medical intervention. This does not include occasionally drinking 
to excess. 
 Recreational drug abuse: Including smoke, inhalation, ingestion, or 
injection of illicit drugs; e.g. benzodiazepines, cannabis, cocaine, opioids, 
and amphetamines.  
2.5.3 Drug regimen 
Each AED used was expressed as AED regimen. The first AED regimen was always 
monotherapy while the subsequent regimens could be an alternative monotherapy 
or polytherapy combined the previous AED(s) and the add-on AED. Polytherapy 
could be a combined of 2 to 5 AEDs. Number of prior unsuccessful AED regimens 
ranged from 0 to 13th schedules.  
2.5.4 Drug dosage 
Medication dosage was recorded as daily dosage in milligrams based on what dose 
the patient was administered at the last follow-up or at what dosage the patient 
discontinued treatment.  
To evaluate the dosage of different AEDs, drug doses were categorised into low, 
moderate, and high doses based on the interquartile range (IQR) of each drug used 
in the presented cohort. Low doses were smaller than the IQR, moderate doses 
were within the IQR, and high doses were greater than the IQR. Generally, the IQR 
describes the middle 50% of values when ordered from smallest to largest, and 
therefore represents the average (common) dose interval. 
In this analysis, only the dosage for the most commonly used monotherapies (LTG, 
VPA, LEV, and CBZ) were included. The common doses (IQRs) of these drugs in the 
current study were comparable to the commonest doses according to other 
references as shown in Table 2-1. 
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Table 2-1. Dosages that considered as “common dosages” in the present study and 
according to other references  
 Interquartile 
range in 
current 
study 
Commonest 
dose 
(Brodie, 
2017b) 
Usual 
Dose (BNF 
NICE, 
2016)  
Defined Daily Dose 
(WHO, 2015) 
Lamotrigine 150-350 200-400 100-200 300 
Valproate 1000-1700 1000 1000-2000 1500 
Carbamazepine 400-800 600 800-1200 1000 
Levetiracetam 1000-2000 1000-2000 Max 3000 1500 
Doses in mg/ day 
 
2.5.5 Generations of antiepileptic drugs 
In this study, AEDs were divided into first and new generation on a chronological 
basis. AEDs introduced into clinical practice before 1989 were considered first 
generation drugs. This group includes PB, PHT, ESM, CBZ, VPA, CZP, and CLB. The 
remaining AEDs were regarded as new drugs. 
2.6 Adverse effects assessment 
Only one adverse effect of one offender AED was assigned for each case of 
treatment failure due to intolerable side effect. 
 If more than one intolerable adverse effect caused the treatment 
failure, the severest and/or the adverse effect closest to the date of 
discontinuation/dose reduction was indicated as the reason for 
treatment discontinuation. 
 If a combination of two AEDs or more caused the adverse effect, the 
AED that was discontinued or reduced was indicated as the offender 
AED.  
Adverse effects were categorised into groups including tiredness, poor 
coordination, skin rash, gastrointestinal side effect, tremor, mood disorder, 
headache, weight gain, aggression, cognitive dysfunction, insomnia, irritability, 
paraesthesia, anorexia/weight loss, psychotic effect, sexual dysfunction, 
hyponatremia, and other. This categorisation based on the importance and 
66 
Chapter 2. Methods 
 
frequency of adverse effect, and on the classifications used in other clinical 
studies (Baker et al., 1994, Mohanraj and Brodie, 2005, Marson et al., 2007a, 
Marson et al., 2007b). Table 2-2 shows some details of categorisation of 
intolerable adverse effects. 
Several criteria were considered to establish a causality of adverse effects 
(Edwards and Aronson, 2000): 
 Reasonable time relation between the use of AED (introduction or does 
elevation) and the incidence of adverse effect; 
 Concomitant disease or drugs cannot explain the adverse effect; 
 The pattern of the adverse effect may fit the known pharmacology or 
allergy pattern of AEDs; 
 Reversibility of adverse effects after drug discontinuation or dose 
reduction; and   
 The background frequency of the event and how often it is associated with 
drugs were considered. For instance, headache is relatively common, so its 
association with a medicine may be by chance. In contrast, rash has a low 
background incidence and is often associated with particular AED, 
therefore it is more likely to be an adverse drug reaction. 
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Table 2-2. Categorisation of intolerable adverse effects 
Category Include 
Tiredness Drowsiness, sleepiness, sedation, lethargy, and fatigue 
Poor coordination Blurred/doulbe vision, diplopia, dizziness, unsteadiness, 
vertigo, imbalance, ataxia, gait difficulties, nystagmus, 
and staggering 
Skin rash  
Gastrointestinal 
side effect 
Nausea, vomiting, diarrhoea, constipation, stomach 
cramps, and heartburn. 
Tremor  
Mood disorder Depression, low mood, mood swings, emotional lability, 
and suicidal thoughts/attempts 
Headache  
Weight gain  
Aggression Impulsiveness, anger, agitation 
Cognitive 
dysfunction 
Word finding difficulties, poor concentration, and poor 
memory 
Insomnia Sleep difficulties and sleep disturbance 
Irritability  
Paraesthesia  
Anorexia/ weight 
loss 
 
Hair loss  
Psychosis effect Visual hallucination, delusion, paranoia, and confusion 
Sexual 
dysfunction 
 
hyponatremia  
Other  
This categorisation based on the importance and frequency of adverse effect, and on the 
classifications used in other clinical studies (Baker et al., 1994, Mohanraj and Brodie, 2005, 
Marson et al., 2007a, Marson et al., 2007b). 
 
2.7 Data extraction and management 
I was based at the Epilepsy Unit between 1 Jul 2015 and 30 Apr 2016 to extract 
data from patients’ paper-based medical records. Each clinical record was 
assigned a unique identification (ID) number (Epilepsy Research Unit number). 
During the data collection phase, the ID numbers were only known to the research 
team. Access to the data was restricted to the team and movement of the data 
out of the Research Unit was limited. Physical and IT security was also applied to 
maintain confidentiality. This included storing the paper folders in a locked filing 
cabinet and saving the electronic data on a password-protected computer.  
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During the study, I reviewed 1,528 eligible clinical records and created an 
electronic database, entering the extracted data into a pre-designed template. 
Microsoft Excel 2016 software was used to construct and store the electronic 
database. 
Several details were extracted for each eligible patient, including the patient’s 
demographic information, medical history, risk factors for epilepsy, seizure 
information, investigations, antiepileptic drug treatment details, and 
pharmacological outcomes. Table 2-3 shows more details of extracted data for 
each included patient. 
After the data collection, the dataset itself was unlinked anonymised (the IDs were 
removed) prior to conducting the analyses. The data collection and dataset 
contained no potential identifiers or personal information (only the patient’s year 
of birth).  
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Table 2-3. Extracted information for each eligible patients 
 
Demographic information 
o Gender 
o Year of birth 
Referral details 
o Date of referral 
o Source of referral 
o Date of the last follow-up 
Risk factors 
o Family history of epilepsy (first degree relative) 
o History of febrile convulsion 
o Birth trauma 
o Head injury 
o Smoke, alcohol, and drugs abuse 
Seizure details 
o First seizure’s date and type 
o Subsequent seizures’ date, type and frequency at each visit 
o Classification of seizure type, epilepsy, and aetiology 
o Investigations’ date and results (EEG, CT, and MRI) 
Medical history 
o Other medical conditions including surgical procedures and onset 
date 
o Other medications and commence date 
Antiepileptic drugs 
o Name and commence date 
o Daily dosage at last follow-up or at discontinuation 
o Plasma concentration of antiepileptic drugs and measurement date 
o Adherence to medication, reason for poor adherence 
o Adverse effects: 
 Symptoms 
 Onset or reported date 
 Dose at adverse effect and date of this dose 
 Intervention (antiepileptic drug discontinuation, dose 
reduction, or other) 
o Treatment outcomes 
 Continuation or discontinuation of antiepileptic drugs 
 Date of discontinuation 
 Reason for discontinuation (lack of efficacy, poor 
tolerability, or both lack of efficacy and poor tolerability) 
Seizure outcomes at last follow-up 
o Controlled or uncontrolled seizure 
o Date of last seizure 
o Continued antiepileptic drug (s) regimen and daily doses 
o Off medication patient, date and reason for discontinuation 
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2.9 Ethical considerations 
This study was carried out in accordance with the World Medical Association 
Declaration of Helsinki (1964) and its revisions (Tokyo [1975], Venice [1983], Hong 
Kong [1989], South Africa [1996], Edinburgh [2000], Seoul [2008], and Fortaleza 
[2013]). 
This study was approved by the Yorkshire and the Humber – Bradford Leeds 
Research Ethics Committee (REC reference: 16/YH/0513), and by the NHS Greater 
Glasgow & Clyde Health Board (Research and Development reference: 
GN16NE639). 
My right of access to conduct research in the NHS Greater Glasgow & Clyde region 
was obtained from the Research and Development Office, West Glasgow-ACH.  
2.10 Statistical analyses 
2.10.1 Statistical packages used 
Microsoft Excel 2016, Minitab 17 Statistical Software, IBM SPSS statistics 22.0, and 
Graphpad Prism 5 were used for data analyses. 
2.10.2 Summary of statistics 
Categorical data was summarised using counts and percentage. Whereas 
continuous data was summarised using median, IQR, and range.  
2.10.3 Comparison of categorical data  
A chi-square (X2) test and test for two proportions were carried out to assess the 
associations of the categorical data. The chi-square (X2) test for trend was 
performed to evaluate the linear relationship between the ordered variables and 
the treatment outcomes. When previous analyses included expected counts of less 
than five, the Fisher’s exact test was applied. To address the issue of multiple 
comparisons, and to avoid a type I error, the p-value for significance was modified 
based on the Bonferroni correction (0.05/number of comparisons). 
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2.10.4 Comparison of continuous data 
The Mann-Whitney test and Kruskal-Wallis test were applied for a comparison of 
the non-parametric continuous data. The normality of the continuous data was 
tested visually (Normal Q-Q plot and histogram) and statistically (Shapiro-Wilk 
test). An attempt was made to transform the non-normally distributed variables 
(p<0.05) into normal ones using a natural logarithm and log base 10. 
2.10.5 Regression 
Univariate and multivariate regression analyses were used to evaluate and adjust 
the effect of the potential factors on treatment outcomes. The dependent 
variable was binary in efficacy and tolerability studies and thus logistic regression 
was used. However, the dependent variable was continuous in retention rate study 
and, therefore, Cox regression was used. The independent variables were a mix 
of binary, categorical with more than two groups, and continuous variables. Each 
covariate was entered into a univariate analysis, covariate that predicted the 
outcome significantly (P<0.05) in univariate analysis were subsequently entered 
into a multivariate analysis. If two variables were significantly correlated to each 
other, one (the weakest) should be excluded from multiple model as these 
variables had independent association with outcome due to their relationships 
with each other. No correction was made for multiple testing in regression analysis 
(i.e. significant at P<0.05). 
2.10.6 Survival analysis 
A Kaplan-Meier survival analysis was performed to estimate the cumulative 
probability of retention on treatments. A Cox regression model was applied to 
evaluate the effect of covariates and to compare the retention rates of different 
treatments before and after adjustment for significant covariates. 
All statistical tests were 2-sided, p-value was significant at 0.05, and a 95% 
confidence interval was used, except in X2 pairwise comparisons, where 
corrections were applied. 
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2.10.7 Missing data 
There were very few missing values. Missing data was treated as a separate group 
for categorical variables (not available, NA), and kept as missing data for 
continuous variables. Analyses then were run as if all complete cases. 
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3.1 Introduction  
Approximately 50% of newly diagnosed epilepsy patients are controlled on an 
appropriate AED, either immediately or after one to two years of trying different 
treatment schedules, however around 25-30% of this population continue to be 
pharmacoresistant from outset. The remainder of population show a 
relapsing/remitting pattern with some of these eventually developing refractory 
epilepsy (Brodie et al., 2012). It remains unclear why and how some patients 
become refractory, while others with an apparently identical form of epilepsy 
achieve complete seizure control on AED therapy. A number of clinical and 
pharmacological factors have been demonstrated as being correlated or predictive 
of seizure outcomes (Mohanraj and Brodie, 2013). A lack of early response to AEDs 
is frequently regarded as a strong predictor of pharmacoresistant epilepsy (Kwan 
and Brodie, 2000, Brodie et al., 2013). However, limited or inconsistent evidence 
exists about other factors that may predict seizure outcomes (Mohanraj and 
Brodie, 2013). Some patients with intractable epilepsy may benefit from non-
pharmacological treatment, particularly epilepsy surgery. Studies have 
demonstrated that epilepsy surgery in certain types of refractory epilepsy, 
specifically temporal lobe epilepsy, provides significantly better outcomes than 
continued manipulation of AEDs therapy (Wiebe et al., 2001). Therefore, the early 
prediction of treatment outcomes is necessary for selecting the appropriate 
clinical management at appropriate stage such as considering more aggressive 
pharmacotherapy or early referral for surgery (Hitiris et al., 2007, Kwan et al., 
2010). 
Over the last three decades, the introduction of 14 new antiepileptic drugs (Figure 
3-1), some with novel mechanisms of action, has expanded treatment choices and 
increased expectations about efficacy and tolerability (Loscher and Schmidt, 
2011, Brodie, 2017a). However, it is unclear whether treatment outcomes have 
changed in recent decades as a consequence of the availability of an increasing 
number of AEDs as adjunct therapy, or as initial monotherapy. 
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Figure 3-1. Development of antiepileptic drugs since 1912 [modified from (Loscher and 
Schmidt, 2011)] 
Circled in grey are new generation drugs 
 
This chapter evaluates efficacy of AEDs based on seizure control at last follow-up. 
Clinical and pharmacological determinants for pharmacoresistant epilepsy was 
identified. As well as, the changes treatment outcomes of epilepsy over the past 
30 years was studied. This was achieved by comparing the results of current 
analysis to the results of three analyses conducted in 1999, 2003, and 2008 on 
same expanding cohort (n=525, 890, and 1098, respectively) (Kwan and Brodie, 
2000, Mohanraj and Brodie, 2005, Bamagous, 2010, Brodie et al., 2012) from the 
Epilepsy Unit in Glasgow. 
3.2 Methods 
The patients were divided into controlled and uncontrolled groups based on their 
seizure outcomes at their final clinic visit. The ‘controlled’ group was constituted 
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of patients who had been seizure-free for at least 12 months. These patients had 
attained a seizure-free state either immediately after AED initiation (i.e. they had 
experienced no seizure on treatment) or they had attained a delayed seizure-free 
state after experiencing seizures on AED therapy, prior to their ultimate seizure 
control. Delayed seizure control was commonly achieved following the 
commencement of a new AED regimen, a new dosage, improved adherence to 
AEDs, or an adjustment of seizure triggers, such as excessive alcohol intake, 
stress, and sleep deprivation.  
Meanwhile, the patients who had not achieved seizure control were categorised 
into drug resistant, relapsed, or undefined, based on their response to the trials 
of AED schedules. The consensus definition of drug resistant epilepsy by the ILAE 
was adopted (Kwan et al., 2010). The patients were regarded as being drug 
resistant if they failed to achieve 12-month seizure freedom on their most recent 
two appropriate, adequate, and tolerated AED schedules. Relapsed patients were 
considered to be those who had successfully attained initial seizure freedom for 
at least 12 months, on one of their most recent two appropriate, adequate, and 
tolerated AED regimens, but had subsequently relapsed prior to the end of the 
study. In this study, the category of ‘undefined drug responsiveness’ was applied 
to uncontrolled patients who could not be classified as being either drug resistant 
or relapsed. Uncontrolled patients included those who preferred to continue with 
their AED schedules unchanged, because they accepted the improvement of their 
seizures, especially if their GTCs had been abolished, and their focal seizures were 
reduced. 
Dosage of AEDs was reported as daily dose in milligrams based on what dose the 
patient was taken at the last follow-up. Drug doses were categorised into low, 
moderate, and high doses based on the interquartile range (IQR) of each drug used 
in the presented cohort. Low doses were smaller than the IQR, moderate doses 
were within the IQR, and high doses were greater than the IQR. Only the dosage 
for the most commonly used monotherapies (LTG, VPA, LEV, and CBZ) were 
included. IQR in mg/day for LTG=150-350, VPA=1000-1700, CBZ=400-800, and 
LEV=1000-2000. 
Univariate and multivariate logistic regression analysis were applied to assess 
seizure determinants. A chi-square (X2) test was used to compare the proportions 
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of controlled patients, while a Mann-Whitney was performed to compare the 
dosages of successful and unsuccessful AEDs regimens. 
3.3 Results 
3.3.1 Patient demographics 
Table 3-1 summarises the clinical characteristics of the 1,528 patients involved in 
the study. All the patients were adults, aged 18 to 93 years (median=37) at the 
initiation of their treatment, and there was a slight predominance of male patients 
(56%). The patients were referred to the seizure clinic between 1 July, 1982, and 
30 October, 2012, and were prospectively followed until 30 April, 2016, with an 
average 5-year follow-up duration (range= 1-28) following the commencement of 
AED therapy. As expected from epidemiological studies on adult populations, focal 
seizures were more frequently represented in the cohort of this study (84%). 
Furthermore, 28% of patients possessed a psychiatric comorbidity at the baseline, 
or during follow-up. The cohort of this study included 10% deceased patients.  
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Table 3-1. Demographic characteristics of 1,528 patients 
 n (%) 
Gender 
    Female 
Male 
 
679 (44) 
849 (56) 
Age at treatment initiation (Years), median 
(range) 
37 (18-93) 
Age at treatment initiation in years 
18-29 
30-39 
40-49 
50-59 
60-69 
70-93 
 
519 (34) 
299 (20) 
258(17) 
179 (12) 
134 (8) 
139 (9) 
Year of referral Jul-1982 - Oct-2012 
Duration of follow-up after treatment initiation 
(Years), median (range) 
5 (1-28) 
Epilepsy type 
Focal 
         Generalised 
 
1290 (84) 
238 (16) 
Seizure aetiology 
   Cryptogenic 
Idiopathic 
    Symptomatic 
 
776 (51) 
238 (16) 
514 (34) 
Family history of epilepsy 246 (16) 
Febrile convulsion  66 (4) 
Birth trauma  14 (1) 
Cerebral infection 18 (1) 
Head injury 230 (15) 
Cerebrovascular disease 192 (13) 
Number of the pre-treatment seizure 
1 
2 
   3-5 
     6-10 
      11-20 
    >20 
 
55   (4) 
300 (20) 
439 (29) 
219 (14) 
95   (6) 
420 (27) 
Duration of the pre-treatment seizure (Months) 
<2 
2-6 
 7-12 
  13-24 
    25- 60  
 >60  
 
182 (12) 
378 (25) 
216 (14) 
214 (14) 
279 (18) 
259 (17) 
Learning disability  57 (4) 
Psychiatric comorbidities 433 (28) 
Alcohol abuse 329 (22) 
Recreational drug abuse 175 (11) 
Deceased patients 151 (10) 
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3.3.2 Seizure outcomes at the final follow-up 
As demonstrated in Figure 3-2 by the final follow-up session, of the total 1,528 
patients, 62% (n=941) were controlled, had been seizure-free for one year, while 
the remainder were uncontrolled. The mean duration of the seizure freedom of 
the controlled patients was 10 years (standard deviation [SD] =6). 47% (n=440) of 
the controlled patients achieved seizure freedom immediately following the 
commencement of their first AED. The remainder experienced a delay in achieving 
seizure freedom after commencing the new AED schedule, with the introduction 
of a new dosage, an improved drug adherence, or a modification to their lifestyle, 
such as a reduction in their alcohol intake, improved stress management, or 
control of other seizure triggers. Of the uncontrolled group, 30% were drug 
resistant (n=175), and 16% were relapsed (n=95), while the remainder were 
classified as ‘undefined drug responsiveness’.  
Table 3-2 shows the clinical characteristics of the 1,528 patients according to their 
seizure status at the final follow-up session (controlled and uncontrolled). 
Baseline characteristics such as gender, age, and epilepsy type and aetiology, 
were comparable between the controlled and uncontrolled groups. However, 
potential risk factors, such as a family history of epilepsy and head injury, were 
generally more frequent in the uncontrolled group.  
At their final visit to the clinic, 55 patients (4%) withdrew their AEDs, preferring 
to remain off-medication. Their reasons behind this choice included the side 
effects and concern regarding side effects (33%, n=18), long-term seizure freedom 
(25%, n=14), treatment ineffectiveness (7%, n=4), concerns about teratogenicity 
(5%, n=3), and unknown reasons (30%, n=16). Another 30 patients changed to a 
different AED regimen at their final visit to the clinic, while the remainder 
continued with their current regimen (n=1443).  
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Figure 3-2. Seizure outcomes and drug responsiveness at last follow-up 
 
 
 
Definition adapted from (Kwan et al., 2010): 
 
Controlled: seizure-free for at least 1 year at last follow-up 
Uncontrolled: continued to have seizures at last follow-up 
Immediate: achieved 1-year seizure-free immediately after starting 
antiepileptic drugs 
Delayed: ultimately achieved 1-year seizure-free after experienced seizures 
on treatment 
Resistant: failed to achieve any 1-year seizure-free on the last two proper 
antiepileptic drugs schedules 
Relapsed: seizure reappeared and continued at last follow-up after initial 1-
year seizure-free on one of the last two proper treatment regimens 
Undefined: drug responsiveness neither classified as drug resistant nor 
relapsed 
 
1,528 patients
941 controlled 
(62%)
440 immediate 
(47%)
501 delayed
(53%)
587 uncontrolled 
(38%)
175 resistant 
(30%)
95 relapsed 
(16%)
317 undefined 
(54%)
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Table 3-2. Clinical characteristics of 1,528 patients according to their seizure status 
(controlled/uncontrolled) 
  Controlled 
(n=941)  
Uncontrolled 
(n=587)  
P-value (95% CI) 
Gender Female  
Male  
412 (44) 
529 (56) 
267 (45) 
320 (55) 
0.515 
(-0.068, 0.034) 
Age at 
treatment 
initiation 
(Years), median 
(IQR) 
 38 (25,57) 37 (26,49) 0.039 
(0,3) 
Diagnosis Focal 
Generalised  
787 (84) 
154 (16) 
503 (86) 
84 (14) 
0.275 
(-0.057, 0.016) 
Seizure 
aetiology 
Cryptogenic  
Idiopathic  
Symptomatic  
459 (49) 
154 (16) 
328 (35) 
317 (54) 
84 (14) 
186 (32) 
0.135 
Family history 
of epilepsy 
Yes  
No  
118 (13) 
823 (87) 
128 (22) 
459 (78) 
<0.000 
(-0.132,-0.053) 
Head injury Yes  
No  
112 (12) 
829 (88) 
118 (20) 
469 (80) 
<0.000 
(-0.12, -0.043) 
Number of pre-
treatment 
seizure 
1  
2  
3-5  
6-10  
11-20  
>20  
43 (5) 
220 (23) 
294 (31) 
132 (14) 
46 (5) 
206 (22) 
12 (2) 
80 (14) 
145 (25) 
87 (15) 
49 (8) 
214 (36) 
<0.000 
Duration of pre-
treatment 
seizure (Months) 
<2  
2-6  
7-12  
13-24 
25-60 
>60  
120 (13) 
238 (26) 
142 (15) 
127 (13) 
164 (17) 
150 (16) 
62 (11) 
140 (24) 
74 (12) 
87 (15) 
115 (19) 
109 (19) 
0.286 
Learning 
disability 
Yes 
No  
29 (3) 
912 (97) 
28 (5) 
559 (95) 
0.106 
Psychiatric 
comorbidity 
Yes 
No   
195 (20) 
746 (80) 
238 (40) 
349 (60) 
<0.000 
(-0.246,-0.15) 
Alcohol abuse Yes 
No 
149 (16) 
792 (84) 
180 (31) 
407 (69) 
<0.000 
(-0.192, -0.104) 
Recreational 
drugs abuse 
Yes 
No 
59 (6) 
882 (94) 
116 (20) 
471 (80) 
<0.000 
(-0.17, -0.099) 
Number of prior 
antiepileptic 
drugs 
0 
1 
2 
3-13 
665 (71) 
182 (19) 
54 (6) 
40 (4) 
220 (37) 
155 (26) 
82 (14) 
130 (23) 
<0.000 
Data are presented in patient number (%). Statistical tests used were 2-proportions, X2 and Mann 
Whitney tests. 
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3.3.3 Continued antiepileptic drugs 
Of the 1,443 patients who continued to take AEDs at the last follow-up, 78% 
(n=1130) were on a monotherapy, while the remainder were on a combined 
therapy of 2, 3, 4, or 5 AEDs. The new AEDs were continued as a monotherapy by 
44% (n=630) of patients.  
63% (n=914) of continued AED schedules were successful, i.e. seizures were 
successfully controlled, while the remainder were unsuccessful regimens (37%, 
n=529). Table 3-3 shows the features of the 1,443 patients who continued on AED 
regimens at their final visit to the clinic, according to their seizure status in terms 
of whether it was controlled or uncontrolled. 89% (n=811) of the successful 
regimens constituted monotherapy, while only 11% (n=103) constituted 
polytherapy. The new AEDs were successful in 57% (n=459) of patients and the 
figure was slightly lower in the unsuccessful regimens, in which 54% (n=171) were 
on new AEDs. 
Table 3-3. Features of continued antiepileptic drug regimens at last follow-up according 
to the seizure status (controlled/uncontrolled)   
  Controlled 
(n=914) 
Uncontrolled 
(n=529) 
P-value (95% 
CI) 
Number of 
taken 
antiepileptic 
drugs 
Monotherapy  
Dual therapy  
Triple therapy  
or more 
811 (89) 
88 (10) 
15 (1) 
319 (60) 
155 (30) 
55 (10) 
<0.000 
  Controlled 
(n=811) 
Uncontrolled 
(n=319) 
 
Drug 
generation of 
monotherapy 
First generation  
New generation  
352 (43) 
459 (57) 
148 (46) 
171 (54) 
0.363 
(-0.094, 0.034) 
Data are presented in patient number (%).2-proportions and X2 tests were used. 
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3.3.4 Efficacy rates of individual antiepileptic drugs 
As shown in Figure 3-3, efficacy rates of individual AEDs ranged from 55% with 
LCM, to 88% with GBP. However, few patients had continued to take these AEDs 
as a monotherapy by the final follow-up session (n=11, and 17, respectively). 
However, the efficacy rates of the most commonly used monotherapies (LTG, VPA, 
CBZ, and LEV) were more comparable (74, 70, 72, and 76%, respectively). Indeed, 
there was no significant difference in the efficacy rates of the different AEDs 
(p=0.256).  
Monotherapies
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Figure 3-3. Efficacy rates of antiepileptic drugs that continued as monotherapy at the last 
follow-up  
X2 P-value was 0.256. Key: LTG: lamotrigine, VPA: valproate, CBZ: carbamazepine, LEV: 
levetiracetam, OXC: oxcarbazepine, TPM: topiramate, GPB: gabapentin, PHT: phenytoin, LCM: 
lacosamide, TGB: tiagabine. 
 
In order to assess and overcome the potential effect of confounders on seizure 
outcome and efficacy rate of AEDs, several analyses were performed. First, a 
univariate regression analysis which shows that 9 determinants significantly 
influenced the seizure outcomes: patients’ age, family history of epilepsy, head 
injury, number and duration of pre-treatment seizures, psychiatric conditions, 
alcohol and recreational drugs abuse, and number of prior AEDs. Head injury and 
pre-treatment seizure duration were excluded from the multivariate model 
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because they possessed strong correlations with other variables (p<0.000 for each 
comparison). After accounting for the significant variables in the adjusted model 
(multivariate), there was found to be no significant evidence of an association 
between age and seizure outcome. In this adjusted model, the odds of having 
uncontrolled seizures for an individual with family history of epilepsy, more than 
ten seizures before treatment, psychiatric comorbidity, alcohol abuse, or 
recreational drugs abuse, and more than two prior AEDs, were 1.8, 1.9, 1.7, 1.7, 
2.4, and 4.5 times the odds for an individual without these risk factors, 
respectively. Table 3-4 shows the univariate and multivariate logistic regression 
analysis for risk factors of intractable seizure. These factors will be discussed 
further later in this chapter. 
Then, the aforementioned significant determinants were assessed for individual 
AEDs (LTG, VPA, CBZ, LEV, OXC, and TPM) to examine their effect on the reported 
efficacy rates. As shown in Table 3-5 , age, family history, more than 10 /1-year 
pre-treatment seizures, and psychiatric comorbidities were comparable among 
monotherapies users. However, there were significant differences in rates of head 
injury, alcohol abuse, recreational drugs abuse, and more than two prior AEDs 
between treatments groups; and these may partially explain the reported efficacy 
rates. Patient taking VPA and CBZ had higher rate of head injury and alcohol abuse 
while OXC was more frequently used after trial of more than two AEDs.  Table 3-6 
demonstrates more details about pairwise comparisons of these factors among 
different treatment groups.
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Table 3-4. Univariate and multivariate logistic regression analysis for predictors of uncontrolled seizure  
 Univariate  Multivariate  
 Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
Female gender 1.067 (0.867, 1.313) 0.538   
Age (Years) 0.99 (0.984, 0.996) 0.001 0.997 (0.99, 1.004) 0.368 
Focal epilepsy 1.172 (0.878, 1.564) 0.281   
Idiopathic seizure aetiology† 
Cryptogenic seizure† 
1.218 (0.968, 1.533) 
0.962 (0698, 1.326) 
0.093 
0.812 
  
Family history of epilepsy 1.945 (1.477, 2.561) <0.000 1.796 (1.323, 2.439) <0.000 
Febrile convulsion 1.115 (0.675, 1.842) 0.67   
Birth trauma 0.265 (0.059, 1.187) 0.083   
Head injury* 1.862 (1.404, 2.47) <0.000   
Cerebrovascular disease 0.932 (0.682, 1.275) 0.662   
More than 10 seizures before treatment 2.219 (1.786, 2.758) <0.000 1.876 (1.475, 2.385) <0.000 
Seizures for >1 year before treatment* 1.278 (1.039, 1.571) 0.02   
Learning disability 1.575 (0.927, 2.676) 0.093   
Psychiatric comorbidity 2.609 (2.077, 3.277) <0.000 1.753 (1.353, 2.263) <0.000 
Alcohol abuse 2.351 (1.835, 3.012) <0.000 1.752 (1.317, 2.331) <0.000 
Recreational drug use  3.682 (2.64, 5.135) <0.000 2.446 (1.667, 3.59) <0.000 
More than two prior antiepileptic drugs 5.094 (3.882, 6.684) <0.000 4.491 (3.369, 5.987) <0.000 
†Symptomatic seizure aetiology was the reference group. *Head injury and pre-treatment seizure duration were excluded from multivariate 
model as they had strong correlations with other variables (p<0.000 for each comparison). 
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Table 3-5. Clinical characteristics of patients who continued monotherapy at last follow-up 
 LTG VPA CBZ LEV OXC TPM P-value 
Age (Years), median (range) 44 (18-87) 42 (18-89) 42 (18-93) 39 (18-83) 43 (18-82) 45 (19-77) 0.416 
Family history of epilepsy 50 (14) 50 (16) 34 (19) 17 (12) 7 (13) 7 (18) 0.569 
Head injury  32 (9) 46 (15) 36 (20) 15(10) 7 (13) 2 (5) 0.005 
More than 10 pre-treatment seizure  109 (31) 99 (33) 55 (27) 37 (26) 19 (35) 16 (40) 0.530 
More than 1 year pre-treatment seizure 165 (47) 157 (52) 90 (49) 71 (50) 25 (46) 21 (52) 0.844 
Psychiatric comorbidity 81 (23) 85 (28) 41 (22) 38 (27) 12 (22) 12 (30) 0.568 
Alcohol abuse 41 (12) 93 (31) 43 (23) 18 (13) 9 (17) 6 (15) <0.000 
Recreational drugs abuse 17 (5) 60 (20) 17 (9) 6 (4) 3 (5) 2 (5) <0.000 
Failure of two or more previous 
antiepileptic drugs 
27 (8) 20 (7) 14 (8) 13 (9) 12 (22) 5 (12) 0.031 
Total 354 304 183 143 54 40  
Data are presented in patient number (%). Kruskal–Wallis test, X2/ Fisher’s exact test were used. Key: LTG: lamotrigine, VPA: valproate, CBZ: carbamazepine, 
LEV: levetiracetam, OXC: oxcarbazepine, TPM: topiramate. Because of small sample sizes, other antiepileptic drug were not included. 
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Table 3-6. Pairwise comparisons of clinical characteristics of monotherapy users  
 VPA 
N=304 
CBZ 
N=183 
LEV 
N=143 
OXC 
N=54 
TPM 
N=40 
Head injury 15% 20% 10% 13% 5% 
LTG (9%), n= 354 0.017 0.001 0.627 0.415 0.557 
VPA  0.205 0.158 0.665 0.092 
CBZ   0.019 0.217 0.034 
LEV    0.637 0.371 
OXC     0.293 
Alcohol abuse 31% 23% 13% 17% 15% 
LTG (12%), n= 354 <0.000 0.001 0.757 0.34 0.562 
VPA  0.084 <0.000 0.015 0.012 
CBZ   0.009 0.252 0.188 
LEV    0.48 0.701 
OXC     0.826 
Recreational drug abuse 20% 9% 4% 5% 5% 
LTG (5%) n=354 <0.000 0.065 0.765 0.738 1 
VPA  0.001 <0.000 0.011 0.026 
CBZ   0.061 0.578 0.538 
LEV    0.708 0.687 
OXC     1 
≥2 prior antiepileptics 7% 8% 9% 22% 12% 
LTG (8%) n=354 0.601 0.992 0.778 0.012 0.368 
VPA  0.659 0.368 0.007 0.275 
CBZ   0.643 0.015 0.385 
LEV    0.033 0.554 
OXC     0.207 
Data are p-values of X2/ Fisher’s exact test. Key: LTG: lamotrigine, VPA: valproate, CBZ: 
carbamazepine, LEV: levetiracetam, OXC: oxcarbazepine, TPM: topiramate. 
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3.3.5 Efficacy rates of combined antiepileptic drugs therapies  
Efficacy rates of AEDs polytherapies that continued at the last follow-up are shown 
in Table 3-7. Dual therapies of VPA/LTG, LTG/LEV, and LEV/LCM were the most 
frequently employed regimens (n=71, 25, and 15, respectively). Among these dual 
therapies (Figure 3-4), the efficacy was the highest with the LTG/LEV 
combination, in which 48% of patients achieved seizure-free status, and lowest 
with the VPA/LTG combination, in which 38% of patients achieved seizure-free 
status, however this difference was not significant (p=0.682). 
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Figure 3-4. Efficacy rates of the most commonly used dual therapies that continued at the 
last follow -up 
X2 P-value was 0.682. Key: VPA: valproate, LTG: lamotrigine, LEV: levetiracetam, LCM: 
lacosamide. 
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Table 3-7. Efficacy rates of ploytherapies that continued at the last follow-up  (n=313) 
 Controlled 
(n=103) 
Uncontrolled 
(n=210) 
Dual therapies   
VPA/LTG (n=71) 27 (38) 44 (62) 
LTG/LEV (n=25) 12 (48) 13 (52) 
LEV/LCM (n=15) 6 (40) 9 (60) 
VPA/LEV (n=9) 5 (56) 4 (44) 
CBZ/LEV (n=7) 3 (43) 4 (57) 
Others (n=116) 35 81 
Triple therapies   
VPA/LTG/LEV (n=8) 3 (38) 5 (63) 
VPA/LTG/TPM (n=4) 1 (25) 3 (74) 
VPA/LTG/ZNS (n=4) 1 (25) 3 (75) 
Others (n=41) 9 32 
Quadruple therapies   
VPA/LTG/LEV/TPM (n=1) 1 (100) 0 
Others (n=12) 0  11 (92) 
5 AEDs   
VPA/LTG/LEV/TPM/CLB (n=1) 0 1 (100) 
Data are presented in patient number (%). Key: VPA: valproate, LTG: lamotrigine, LEV: 
levetiracetam, LCM: lacosamide, CBZ: carbamazepine, TPM: topiramate, ZNS: zonisamide, 
CLB: clobazam.  
 
3.3.6 Drug dosage 
The median (IQR) dosage of controlled therapy in mg/day was 200 (150, 200) for 
LTG, 500 (400, 600) for CBZ, 1000 (1000, 1500) for VPA, and 1000 (1000, 1000) for 
LEV as a monotherapy. A comparison of the median doses between the controlled 
group and uncontrolled group for each AED is shown in Figure 3-5.  A Mann-Whitney 
test revealed that the median dosage in the uncontrolled group was significantly 
higher than that in the controlled group, for each of the AEDs. In addition, the IQR 
was wider in the uncontrolled group for each drug, compared to the controlled 
group. 
Table 3-8 shows daily dosages of dual therapy of VPA/LTG, LTG/LEV, and 
LEV/LCM. A similar general pattern of high medians and wider intervals in the 
uncontrolled group was also evident in the case of dual therapy. As expected, the 
median daily dosage of LTG was lower in the VPA combination than in the LEV 
combination (150 vs 400mg). Likewise, the dosage of LEV was lower in combination 
with LTG than its dosage in combination with LCM (1000 vs 2000mg). 
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Figure 3-5. Comparison between doses of controlled and uncontrolled groups  for each antiepileptic drug 
Mann Witney test was used. Key: **P≤0.01, ***P≤0.001 
91 
Chapter 3. Efficacy of antiepileptic drugs 
 
Table 3-8. Dosages (mg/day) of the most commonly used polytherapies 
Combination Controlled Uncontrolled 
Valproate 
Lamotrigine 
1000 (500,1500) 
150 (50, 200) 
1500 (1000, 1500) 
150 (100, 225) 
Lamotrigine 
Levetiracetam 
400 (300, 600) 
1000 (1000, 3000) 
400 (300, 600) 
2000 (1000, 3000) 
Levetiracetam 
Lacosamide 
2000 (1375, 2125) 
175 (50, 225) 
2000 (2000, 2500) 
500 (400, 550) 
Doses are presented in median (IQR). 
 
3.3.7 Clinical and pharmacological determinants of seizure 
outcomes 
In this section, the effect of the determinants of seizure outcomes will be 
examined and quantified in more detail. These include factors demonstrating a 
significant association in univariate regression analysis, i.e. patient’s age, family 
history of epilepsy, head injury, number and duration of pre-treatment seizures, 
psychiatric conditions, and alcohol and recreational drug abuse, in addition to 
pharmacological determinants including the number of prior AED regimens, the 
number of AEDs taken, and  drug generation..  
Overall, the patients’ age at treatment initiation demonstrated a positive linear 
association with the efficacy outcomes (p=0.001). However, an interesting pattern 
was observed with regard to age. The efficacy rate was 61% in patients aged 18 to 
29 years, and this was followed by a reduction in efficacy rate, reaching a 
minimum in patients aged 40 to 49 years (52%), after which the efficacy rate 
showed a gradual increase to a maximum rate in patients aged 70 to 93 years 
(81%). As shown in Table 3-9 and Figure 3-6 patients with a family history of 
epilepsy, head injury, psychiatric conditions, alcohol abuse, and recreational drug 
abuse demonstrated lower seizure control compared with patients without these 
risk factors. Furthermore, the rate of seizure control decreased as the number 
and duration of pre-treatment seizures increased.  
With regard to pharmacological factors, the number of prior and co-prescribed 
AEDs demonstrated a negative linear correlation with seizure control (both 
p<0.000). The rate of seizure control was highest in patients receiving their first 
AEDs schedules (75%), and then gradually decreased in subsequent schedules until 
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almost no patients achieved complete seizure control on their eighth regimen 
onwards. Similarly, more patients (72%) were controlled by monotherapy 
compared to dual therapy (36%), or by treatment with three or more AEDs (25%, 
8%, respectively). However, the seizure outcome was similar in patients treated 
with older AEDs (70%) compared to the patients treated with new AEDs (73%), 
p=0.363. Table 3-10 and Figure 3-7 demonstrate the effect of the pharmacological 
factors on seizure outcomes. 
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Table 3-9. Potential patient-related factors on seizure outcome 
  Controlled P-value (95% CI) 
Age group (Years) 18-29 (n=519) 
30-39 (n=299) 
40-49 (n=258) 
50-59 (n=179) 
60-69 (n=134) 
70-93 (n=139) 
318 (61) 
176 (59) 
134 (52) 
106 (59) 
95 (71) 
112 (81) 
 
0.001 
Family history of 
epilepsy 
Yes (n=246) 
No (n=1282) 
118 (48) 
823 (64) 
<0.000 
(-0.23, -0.094) 
Head injury  Yes (n=230) 
No (n=1298) 
112 (49) 
829 (64) 
<0.000 
(-0.221, -0.082) 
Number of pre-
treatment seizure 
1 (n=55) 
2 (n=300) 
3-5 (n=439) 
6-10 (n=219) 
11-20 (n=95) 
>20 (420) 
43 (78) 
220 (73) 
294 (67) 
132 (60) 
46 (48) 
206 (49) 
 
<0.000 
Duration of pre-
treatment seizure 
<2 (n=182) 
2-6 (n=378) 
7-12 (n=216) 
13-24 (n=214) 
25-60 (n=279) 
>60 (n=259) 
120 (66) 
238 (63) 
142 (66) 
127 (59) 
164 (59) 
150 (58) 
 
0.058 
Psychiatric 
comorbidity 
Yes (n=433) 
No (n=1095) 
195 (45) 
746 (68) 
<0.000 
(-0.285, -0.176) 
Alcohol abuse Yes (n=329) 
No (n=1199) 
149 (45) 
792 (66) 
<0.000 
(-0.268, -0.148) 
Recreational drugs 
abuse 
Yes (n=175) 
No (n=1353) 
59 (34) 
882 (65) 
<0.000 
(-0.389, -0.24) 
Data are presented in patient number (%). 2-proportions test and X2 for trends test were used. 
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Figure 3-6. Potential clinical determinants of seizure outcomes  
X2 and X2 for trends were used. Key: ***P≤0.001 
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Table 3-10. Potential pharmacological factors on seizure outcome 
  Controlled  P-value 
(95% CI) 
Number of prior 
antiepileptic drugs 
0 (n=885) 
1(n=337) 
2 (n=136) 
3 (n=68) 
4 (n=43) 
5 (n=20) 
6 (n=16) 
7 (n=4) 
8 (n=11) 
9 (n=2) 
10 (n=2) 
11 (n=1) 
12 (n=2) 
13 (n=1) 
665 (75) 
182 (54) 
54 (40) 
22 (32) 
7 (16) 
7 (35) 
3 (19) 
0  
1 (9) 
0 
0 
0 
0 
0 
 
<0.000 
Number of taken 
antiepileptic drugs 
Monotherapy (n=1130) 
Dual therapy (n=234) 
Triple therapy (n=57) 
Quadruple therapy (n=12) 
5 antiepileptics (n=1) 
811 (72) 
88 (36) 
14 (25) 
1 (8) 
0 
 
<0.000 
Drug generation of 
monotherapy  
First generation (n=500) 
New generation (n=630) 
352 (70) 
459 (73) 
0.363  
(-0.077, 0.028) 
Data are presented in patient number (%). Statistical tests included X2, 2-proportions, and X2 for 
trends.  
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Figure 3-7. Potential pharmacological determinants of seizure outcomes 
X2 and X2 for trends were used. 
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3.3.8 Comparison of treatment outcomes in the analyses of the 
Glasgow expanding cohort  
Table 3-11 summarises the baseline characteristics of the current and previous 
analyses on one expanding cohort. The previous three analyses were undertaken 
in 1999, 2003, and 2008 (n=525, 890, and 1098, respectively) (Kwan and Brodie, 
2000, Mohanraj and Brodie, 2006, Brodie et al., 2012) at Epilepsy Unit in Glasgow. 
The first analysis included few patients (10%) who had previously been treated 
with antiepileptic drugs, while the subsequent three analyses included only 
patients with new-onset seizures. The current analysis included only adult 
patients aged 18 to 93 years, while the other analyses included adults and 
adolescents, aged 9 to 93 years. As expected, the prescription of new agents as 
monotherapy increased from 26% in 1999, to 41% in 2016. Similarly, the use of 
combined therapy increased from 13% in 1999 and 17% in 2008 to 20% in 2016. 
Furthermore, the use of new agents as combined therapy in the form of a 
combination of new agents only, or together with standard drugs, increased from 
5 and 11.5% in 2008, to 6.5 and 13% in 2016, respectively. 
Table 3-12 and Figure 3-8 show the changes in pharmacological outcomes in newly 
diagnosed epilepsy over a period between 1999 and 2016. Seizure remission rates 
were similar in 1999 (64%) and 2016 (62%), although the rate changed between 
these dates, decreasing to 59% in 2003, and increasing to 68% in 2008. 
Furthermore, there was gradual increase in seizure control on polytherapy, with 
3% in 1999, 5% in 2003, 6% in 2008, and 7% in 2016. In contrast, fewer patients 
were controlled on standard monotherapy, with (23%) in 2016 compared to 31% in 
2008. Finally, more seizure control was achieved on a combination of new agents 
(2.5%) in 2016 compared to 1% in 2008. 
With regard to treatment tolerability, 21% of the initial AEDs were discontinued 
in 1999, due to their side effects. The figure was lower in 2003, 2008, and 2016, 
in which 11, 14, and 13% of patients respectively discontinued their first AEDs due 
to intolerable side effects. 
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Table 3-11. Comparison of baseline characteristics of the current and previous analyses of 
Glasgow expanding cohort 
Year of analysis 1999 2003 2008 2016 
Total number of patients 525* 780 1,098 1,528 
Year of referral 1982-
1997 
1982-
2001 
1982-
2005 
1982-2012 
Age in years as median 
(range) 
27 (9-93) 31 (9-93) 32 (9-93) 37 (18-93)  
Male n (%) 157 (47) 405 (52) 575 (52) 849 (56) 
Current treatment n (%) 
     No treatment 
     Monotherapy 
         Standard drugs 
                   Valproate 
                   Carbamazepine 
                   Phenytoin 
                   Ethosuximide 
                   Clobazam 
        New drugs 
                   Lamotrigine 
                   Levetiracetam 
                   Oxcarbazepine 
                   Topiramate 
                   Gabapentine 
                   Lacosamide 
                   Tiagabine 
                   Pregabalin 
                   Eslicarbazepine       
                   Vigabatrin 
                   Zonisamide 
    Polytherapy 
        Standard drugs 
        New drugs 
        Combination of 
standard and new drugs 
 
44 (8) 
423 (81) 
289 (55) 
125 (24) 
155 (29) 
8 (2) 
1 
0 
134 (26) 
99 (19) 
0 
7 (1) 
3 
15 (3) 
0 
9 (2) 
0 
0
1 
0 
70 (13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
913 (83) 
457 (42) 
 
 
 
 
 
456 (41) 
 
 
 
 
 
 
 
 
 
 
 
185 (17) 
4 (0.5) 
54 (5) 
127 
(11.5) 
 
55 (4)  
1130 (74) 
500 (33) 
304 (20) 
183 (12) 
12 (1)  
1 
0 
630 (41) 
354 (23) 
143 (9) 
54 (4) 
40 (2) 
15 
11 
4 
2 
2 
1 
1 
313 (20) 
7  (0.5) 
104 (6.5) 
202 (13) 
 
*470 newly diagnosed, 
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Table 3-12. Comparison of pharmacological outcomes of the current and previous 
analyses of newly diagnosed epilepsy cohort in Glasgow 
Year of analysis 1999 2003 2008 2016 
Total number of patients 470  780 1,098 1,528* 
Seizure control  301 (64) 462 (59) 750 (68) 941 (62) 
Successful monotherapy  
   Standard drugs 
              Valproate 
              Carbamazepine 
              Phenytoin 
    New drugs 
              Lamotrigine 
              Levetiracetam 
              Oxcarbazepine 
              Topiramate 
              Other 
 287 
(61) 
420 (54) 
 
680 (62) 
345 (31) 
 
 
 
335 (30) 
 
 
 
 
 
811 (53) 
352 (23) 
212 (14) 
131 (9) 
 
459 (30) 
262 (17) 
109 (7) 
32 (2) 
28 (2) 
28 (2) 
Successful polytherapy 
      Standard drugs 
      New drugs 
      Combination of 
standard and new drugs 
14 (3) 42 (5) 70 (6) 
1 
15 (1) 
54 (5) 
103 (7) 
1  
34 (2.5) 
68 (4.5) 
Pharmacoresistant†  276 (36) 272 (25) 175 (11) 
Withdrawal of initial 
monotherapy due to poor 
tolerability  
98 (21) 90 (11) 157 (14) 206 (13) 
Data are number of patients (%). *only 1443 continued to take antiepileptic drugs at last follow-up. 
†Pharmacoresistant was defined in 2003 and 2008 analyses for patients who never achieved 
seizure-free for any 12 months, and in 2016 as failure to achieve any 12-month seizure-free on 
the last two proper drug schedules. 
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Figure 3-8. Changes in pharmacological outcomes between 1999 1nd 2016 in the Glasgow 
cohort of newly diagnosed epilepsy 
 
3.4 Discussion 
This section compares the current pharmacological outcomes to those of 17, 13, 
and eight years ago in an expanding cohort of newly diagnosed epilepsy patients. 
The study concerned evaluated whether the outcomes in the treatment of 
epilepsy were enhanced as a result of the introduction of a number of modern 
AEDs with different modes of action, and also assessed the clinical and 
pharmacological factors involved in seizure outcomes. 
This observational study shows no evidence that treatment outcomes have 
improved in recent decades. Indeed, the seizure remission rate reported in this 
study (62%) was lower than that observed in the previous two analyses, with (64%) 
in 1999, and (68%) in 2008, despite an increase in the use of new AEDs as 
monotherapy, from 26% in 1999, to 41% in 2016, and as adjunct therapy, from 
11.5% in 2008, to 13% in 2016. Several factors may have contributed to this low 
rate of seizure remission. First, the longer period of follow-up of this study may 
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have increased the possibility of detecting fluctuations in seizure control, and 
occasional seizure recurrence, among patients who were regarded as being 
seizure-free in previous studies. Furthermore, children and adolescents younger 
than 18 years, in whom seizure control was observed to be relatively high 
(Bamagous, 2010), were excluded from this study.  
The findings of this study lend support to the concern that the efficacy of AEDs 
has not enhanced, despite the introduction of 14 new AEDs since the early 1990s, 
some of which include novel mechanisms of action (Loscher and Schmidt, 2011). 
The seizure remission rate in newly diagnosed epilepsy patients was estimated to 
be 70% in 1979 (Annegers et al., 1979). The figure was similar in the subsequent 
observational studies of newly diagnosed epilepsy in 2001 (Lindsten et al., 2001) 
and 2012 (Brodie et al., 2012), in which seizure-free rates were observed in 68% 
of patients in both studies. 
The reason for this failure of the new AEDs is most likely due to preclinical 
approaches in the discovery and development of AEDs. The typical animal models 
utilised in the development of almost all AEDs have not succeeded in discovering 
AEDs with better efficacy in pharmacoresistant patients. A further reason is that 
almost all available AEDs are anti-seizure, temporarily supressing symptoms of 
epilepsy, and are not anti-eplieptogenic, nor they possess disease-modifying 
effects (Bialer and White, 2010). The clinical development of new AEDs may also 
contribute to this failure, to a lesser extent, as follows: the first problem is the 
clinical testing of a new drug in refractory patients with continuously AED-
resistant seizures, who are unable to achieve seizure freedom to any significant 
degree, based on their treatment history. A further issue is the design of the 
current regulatory trials, in terms of them including intentionally fewer 
efficacious placebo controls and non-inferiority models, which do not determine 
whether the new drug is superior in efficacy to a standard treatment, prior to its 
approval (Loscher and Schmidt, 2011). In order to improve the discovery of AEDs, 
models for AED-resistant seizures are required, and anti-epileptogenic drugs 
should be developed that interrupt, or reverse, the underlying disease, instead of 
only symptomatically supressing seizures. In order to overcome the clinical 
problems, study populations should include patients with less resistant seizures, 
and the use of comparative effectiveness research of the new AEDs versus 
standard treatment, prior to approval (Loscher and Schmidt, 2011, Brodie, 2017a). 
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Although no enhancement was evident in the overall rate of seizure control in this 
study, several important changes in pharmacological treatments should be noted. 
The use of modern AEDs had increased: 41% of patients continued to take the new 
AEDs as a monotherapy in 2016, compared to 26% in 1999. A surveillance study 
conducted in 2011 showed that approximately 30% of epilepsy patients in Europe 
received the new AEDs (Cramer et al., 2011). This may imply that the prescription 
of modern AEDs has continually increased over the time, probably due to their 
favourable safety and tolerability, which makes them widely used AEDs. The use 
of combination therapy had also increased in this study. Due to the availability of 
many new AEDs as adjunct therapy alongside existing AEDs, the add-on strategy 
may have been preferred over alternative monotherapy approaches. Moreover, 
this analysis revealed that seizure remission achieved on polytherapy gradually 
increased as a result of the introduction of several new AEDs with different 
mechanisms of action. This increase in successful AED polytherapy may be due to 
a relapse of seizures in patients received monotherapy in the previous analyses, 
in whom combination therapy was required. 
The results of this study demonstrated that the efficacy rates of different AEDs as 
a monotherapy were comparable. It should be noted that the cohort involved in 
this study constituted a combination of generalised and focal epilepsies, and that 
the evaluation of drug efficacy relating to a particular seizure type, or epilepsy 
syndrome, is outside the scope of this analysis. Moreover, no important 
differences were demonstrated in the efficacy rates of established and new AEDs. 
This is consistent with the findings of earlier comparative monotherapy trials, in 
which none of the new AEDs were found to be superior in efficacy to standard 
AEDs (i.e. VPA and CBZ) in new-onset generalised and focal epilepsy (Brodie et 
al., 2007, Marson et al., 2007b, Marson et al., 2007a, Baulac et al., 2012, Baulac 
et al., 2017, Trinka et al., 2017). However, LTG was shown to be less efficacious 
than VPA in generalised epilepsy, and GBP was less efficacious than CBZ in focal 
epilepsy. Subsequent large-scale observational studies were unable to produce 
convincing evidence that any modern AEDs are more efficacious than standard 
AEDs for newly diagnosed epilepsies (Loscher and Schmidt, 2011). However, there 
is no doubt that some of modern AEDs possess advantages in terms of safety and 
tolerability, which makes them common first-line treatments. For example, LEV 
and GBP have a lower risk of hypersensitivity reactions, and potential drug 
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interactions mediated by enzyme induction, than CBZ and PHT (Perucca and 
Gilliam, 2012). Additionally, the potential risk of teratogenicity in the use of LTG 
and LEV is lower than in VPA, and similar to that in CBZ (Tomson and Battino, 
2012). Finally, LEV, GBP, and LTG appear to possess a better tolerability than CBZ 
in the elderly (Werhahn, 2009). Therefore, the tolerability aspect of AEDs is the 
single most important factor in drug selection, and this aspect will be discussed 
in later chapters. 
Likewise, no significant difference existed in the efficacy rates of the most 
common AED combined therapies in this analysis. In some studies, the VPA/LTG 
combination has been observed to produce the highest remission rate among 
polytherapies (Mohanraj and Brodie, 2005), however the results of this study did 
not confirm this observation. Indeed, the remission rate was lower in this 
particular combination than in other common dual therapies studied in this 
analysis. Stephen et al. (2012) found that VPA/LTG dual therapy was the most 
common successful combination therapy. Doses of both LTG and VPA as a 
combination were lower than their doses when they were combined with other 
AEDs, indicating a possible synergistic effect. However, it should be pointed out 
that VPA inhibits LTG metabolism, therefore dosage reduction of LTG is generally 
required in this combination (Zaccara and Perucca, 2014). Moreover, the finding 
that VPA/LTG dual therapy was the most common successful polytherapy perhaps 
because it was the highest prescribed combination, though, the remission rates of 
common combination therapies, and the unsuccessful combined therapies, were 
not evaluated in Stephen et al. (2012) study.  
The dosage involved in the uncontrolled group was higher than that in the 
controlled group in monotherapy and polytherapy. This may be because patients 
with intractable seizures require higher dosages. Moreover, consistent with other 
studies (Mohanraj and Brodie, 2005), the controlled patients commonly achieved 
seizure freedom on moderate doses (median LTG 200mg, CBZ 500mg, VPA and LEV 
1000mg). Furthermore, doses of AEDs in combination therapy were generally 
higher than their dosages in monotherapy, except for LTG and VPA where they 
recombine, due to the aforementioned pharmacokinetic interaction and pssible 
synergism, respectively. The general high dosages in combination possibly because 
those patients who required polytherapy were more refractory than those on 
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monotherapy, and consequently required larger doses, although the dosage of AED 
monotherapy is usually reduced before an extra AED is added. 
The univariate regression analysis demonstrates that poor seizure control was 
associated with the patients’ age, family history of epilepsy, head injury, number 
and duration of pre-treatment seizures, psychiatric conditions, alcohol and 
recreational drugs abuse, and number of prior AEDs. The factors not associated 
with uncontrolled seizures included the patients’ gender, epilepsy classification 
and aetiology, febrile convulsion, birth trauma, cerebrovascular disease, and 
learning disability. 
Increased age at treatment initiation showed a significant association with better 
seizure control in univariate analysis, however the effect was small (OD 0.99, 
p=0.001) and not significant in the adjusted analysis. Inconsistent evidence 
existed with regards to age as a prognostic factor; the studies included patients 
of all ages did not demonstrate a correlation of age at onset with seizure outcome 
(Hitiris et al., 2007, Shen et al., 2016, Jiang et al., 2017). However, studies of the 
elderly (age >65 years at epilepsy onset) have indicated better treatment 
outcomes than for young patients (Stephen et al., 2006, Werhahn, 2009). Seizure 
aetiology may explain the better outcome in this group of patients. The most 
common aetiologies of epilepsy in the elderly are stroke and neurodegenerative 
diseases (Werhahn, 2009). Moreover, genetic involvement and lesional 
epileptogenicity that negatively influence the epilepsy prognosis and treatment 
response are lower in the elderly (Stephen et al., 2006). The findings of this study 
support this hypothesis, as the oldest patients (over 60 years) possessed the 
highest rate of seizure control. 
A family history of epilepsy appeared to be a risk factor for poor seizure control 
in the adult cohort. Indeed, growing evidence exists for the contribution of genetic 
factors, and therefore of family history in the pathogenesis of epilepsy, and to a 
smaller degree in drug response (Reid et al., 2010). Similarly, a history of head 
injury was associated with uncontrolled seizure in this study, possibly due to brain 
damage (Mohanraj and Brodie, 2013). In line with other studies (Kwan and Brodie, 
2000, MacDonald et al., 2000, Schiller and Najjar, 2008, Shen et al., 2016, Jiang 
et al., 2017), an increased number of pre-treatment seizures and duration was 
associated with worse outcomes in this study. Those experiencing more than 10 
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seizures and/ or one year before commencing AED therapy were more likely to be 
uncontrolled. A high frequency and duration of seizures have been demonstrated 
to produce structural changes in the brain, and consequently drug resistance. 
However, this may only be the case for patients with specific seizure types, i.e. 
focal seizures with impaired awareness (MacDonald et al., 2000, Mohanraj and 
Brodie, 2013). 
Alcohol and recreational drugs abuse were associated with poor seizure control in 
this study. Ethanol can often provoke seizures as result of withdrawal 
phenomenon, since ethanol is a well-known sedative agent (Brust, 2008). Those 
admitting to the intermittent use of illegal recreational drugs in this study were 
two to three times more likely to be uncontrolled. Several reasons exist for the 
association between recreational drug abuse and intractable seizures. First, most 
illicit substances per se are psychostimulants, can reduce the seizure threshold, 
and have pharmacokinetics and pharmacodynamics potential interaction with 
AEDs. Furthermore, other seizure-provoking factors, such as alcohol abuse, head 
trauma, and other medical and psychiatric conditions, often coexist with illicit 
drug abuse. Finally, people exhibiting this behaviour are less likely to adhere to 
prescribed medications such as AEDs (Smith and McBride, 1999). Although 
particular illegal drugs, specifically cannabis, are beneficial to seizures, irregular 
and inappropriate use often results in uncontrolled seizures. The prevalence of 
this behaviour has been observed to be higher among epilepsy patients than in the 
general population (Smith and McBride, 1999). In this study, 11% of patients 
admitted to using illicit substances at some point during the follow-up period. 
However, there was no accurate tool to assess this activity, and it was possibly 
underestimated due to its dependency on self-reporting.  
Psychiatric disorders, particularly depression, are common in people with epilepsy 
(Boylan et al., 2004, Guo et al., 2015). The pathogenesis shared by epilepsy and 
depression includes abnormalities in brain structure, function, and 
neurotransmitters secretion, such as serotonin. Moreover, psychiatric problems 
are very common, and under-recognised, in patients with refractory epilepsy 
(Boylan et al., 2004, Guo et al., 2015). Boylan et al. (2004) examined 122 epilepsy 
patients with intractable seizures and found that 54% of patients had depression, 
with only 17% of them being managed with antidepressants, while 37% were 
undiagnosed. In this current study, patients with psychiatric comorbidity were 
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associated with poor seizure control. Several assumptions can be proposed as an 
explanation for poor seizure control among psychiatric patients. First, some 
antidepressants can decrease the seizure threshold (Mohanraj and Brodie, 2013). 
Furthermore, depression and anxiety have been demonstrated to reduce 
adherence to AEDs therapy (Guo et al., 2015). Finally, neurobiological abnormality 
involved in psychiatric disorders interacts with those producing seizure, and 
therefore increases brain abnormality and the probability of pharmacoresistant 
epilepsy. The latter fact explains both pharmacological and post-surgical poor 
outcomes in epilepsy patients with psychiatric comorbidities (Hitiris et al., 2007). 
However, it should be noted that data regarding psychiatric disorders was not 
collected systemically, using validated tools, in this study. 
The regression analysis of this study demonstrated that the failure of the first two 
AEDs schedules was the strongest covariate correlated with intractable seizures; 
patients with this covariate were four to five times more likely to be uncontrolled. 
Moreover, the majority (93%) of the controlled patients achieved seizure freedom 
on their first or second regimens. This finding lends further support to the ILAE 
definition of pharmacoresistant epilepsy, which recommends that patients who 
fail to attain a 12-month seizure remission on two tolerated and appropriate AED 
regimens should be reviewed by a specialist for a confirmation of their diagnosis, 
and for surgery consideration (Kwan et al., 2010). Indeed, early response to the 
AEDs has been regarded as the single most important predictor of the long-term 
prognosis (Kwan and Brodie, 2000, Schiller and Najjar, 2008, Brodie et al., 2013). 
In a prospective clinic-based study of 478 epilepsy patients, the seizure-free rates 
declined from 62% for the first AED, to 42% after one, 17% after two to five, and 
0% after six to seven previous AEDs that failed due to their ineffectiveness (Schiller 
and Najjar, 2008). 
However, other studies have appeared more optimistic, suggesting that 
pharmacological manipulation is still worthwhile in refractory patients. In a study 
of 155 refractory patients who tried 265 new drug introductions, 16% of drug 
additions resulted in a seizure remission of 12 months, and 28% of patients 
attained seizure remission by changing their medication (Luciano and Shorvon, 
2007). A further study of 246 adult patients who fulfilled the ILAE’s definition of 
drug-resistant epilepsy demonstrated that a high proportion of these patients 
(around 5% per year) achieved a seizure-free status of 12 months (Callaghan et 
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al., 2011). Although these studies apparently lend hope to refractory patients, the 
risk of subsequent relapse is high (71% at 5 years) (Schiller, 2009, Callaghan et al., 
2011, Brodie et al., 2012).  
Seizure relapse is not uncommon in patients who initially respond well to AEDs. In 
this study 16% (n=95) of uncontrolled patients initially entered a 12-month 
remission. Other studies have shown that 40% of patients had a seizure relapse 
five years after achieving seizure freedom; history of AED usage, and epilepsy 
duration were predictors for these seizure relapses (Schiller, 2009). This further 
evidence the fact that the available AEDs are anti-seizure, and not anti-
epileptogenic.  
Although seizure types and aetiology have been proposed as prognostic factors, 
this could not be confirmed by the results of this study. Several studies have 
observed better seizure outcomes in patients with idiopathic epilepsy than with 
symptomatic or cryptogenic epilepsy (Kwan and Brodie, 2000, Luciano and 
Shorvon, 2007). However, MacDonald et al. (2000) have concluded that the effect 
of the seizure type and aetiology is unimportant in determining long-term seizure 
remission, compared to other significant predictive factors, such as the number 
of early seizures. 
In summary, although the introduction of several new AEDs has expanded 
treatment options, the results of this study suggested that treatment outcomes 
have not improved. Future research should therefore focus on novel treatments, 
such as gene therapy, that are able to modify epilepsy, instead of merely 
supressing the seizures. Although this new generation of AEDs has failed to provide 
more efficacious treatment options, the findings of this study indicated that their 
use has increased, most likely due to their advantages in terms of safety and 
tolerability. Favourable pharmacokinetic profiles, improved tolerability, and 
lower risk of hypersensitivity reactions, drug interactions, and teratogenicity have 
made many new AEDs being widely medication, and some as a first-line therapy. 
Therefore, tolerability of AEDs is invaluable in assisting in the drug selection. The 
next two chapters will focus on tolerability of AEDs.  
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4.1 Introduction 
Adverse effects are a major reason for treatment failure, because they lead to 
early discontinuation of AEDs in 20% of patients (Kwan and Brodie, 2000), have a 
negative impact on patient adherence to medications (Eatock and Baker, 2007), 
and may prevent the administration of a therapeutic dosage (Perucca and Gilliam, 
2012). In addition, they have a significant influence on the costs of healthcare (De 
Kinderen et al., 2014), and have emerged as one of the strongest predictors of 
health-related impaired quality of life (Perucca et al., 2009, Kwon and Park, 2011, 
Luoni et al., 2011).  
Regulatory clinical trials and subsequent observational studies have focused on 
the efficacy of AED therapy rather than its safety and tolerability. However, if the 
patients cannot tolerate the treatment, efficacy becomes irrelevant (Brodie, 
2017b). Because efficacy rates do not demonstrate substantial differences across 
AEDs that are effective against a specific seizure type, whereas adverse effect 
profiles differ greatly from drug to drug, tolerability is often the single most 
important consideration affecting AED selection (Perucca and Meador, 2005). 
Adverse effects can be categorised as early and late appearing. Early appearing 
side effects are usually identified during regulatory clinical trials, while late 
appearing effects are generally detected during post-marketing surveillance. 
Thus, the adverse events reported in clinical trials are biased towards the 
inclusion of early problems, to which patients commonly develop tolerance. 
Further problem is the regulatory needs to evaluate AEDs as add-on to an existing 
schedule, versus placebo. Thus, adverse effect results are mixed-up by the 
concomitant AEDs (Cramer, 2012).  
Long-term observational studies better reflect clinical practice, but few existing 
studies have examined which variables other than AEDs influence adverse effect 
reporting (Perucca and Gilliam, 2012). Definition and quantification of adverse 
effects of AEDs, and identification of population at high risk can help in reducing 
burden of adverse effects by optimising treatment, and eventually resulting in 
enhanced quality of life.  
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4.2 Methods 
The primary endpoint for this analysis was the intolerable adverse effects of AEDs. 
In this context, an intolerable adverse effect was defined as that which caused 
drug withdrawal and an alternative AED was needed, or dose reduction and an 
add-on AED was required.  The intolerable adverse effect could cause treatment 
failure alone or in combination with poor seizure control.  
Adverse drug reactions were categorised into groups including tiredness, poor 
coordination, skin rash, gastrointestinal side effect, tremor, mood disorder, 
headache, weight gain, aggression, cognitive dysfunction, insomnia, irritability, 
paraesthesia, anorexia/weight loss, psychotic effect, sexual dysfunction, 
hyponatremia, and other. This categorisation based on the importance and 
frequency of adverse effect, and on the classifications used in other clinical 
studies (Baker et al., 1994, Mohanraj and Brodie, 2005, Marson et al., 2007a, 
Marson et al., 2007b). The details of these categories are explained in Chapter 2. 
To compare the rates of adverse drug reactions between AEDs, a series of Chi-
square (X2) analyses was performed. The rate of adverse drug reactions from one 
AED was compared with that of another AED in a two-by-two comparison. When 
X2 analyses included expected counts less than five, the Fisher’s exact test was 
applied. To address the issue of multiple comparisons and to avoid a type I error, 
the P-value for significance was modified based on the Bonferroni correction 
(0.05/number of comparisons). Univariate and multivariate logistic regression 
analyses were used to evaluate the effect of the potential factors on tolerability 
outcome. Chi-square and two proportional statistical tests were used to compare 
other categorical data, if one variable was ordered, a chi-square test for trend 
was performed. 
4.3 Results 
A total of 2,911 AED regimens were tried during the follow-up period (Figure 4-1). 
Of these 2,911 regimens, approximately 50% (n=1,443) were continued by the 
patients when they were assessed during their final visit, while the remaining 
regimens were discontinued at any given time during the follow-up period. The 
continued AED schedules and the seizure outcomes were discussed in the previous 
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section. For each discontinued drug, the reasons for discontinuation were 
recorded and categorised into four groups: poor seizure control, poor drug 
tolerability, both ineffective and intolerance, or other reasons. Other reasons for 
AED discontinuation (n=100) included a long-term seizure-free period (n=34), 
regulatory reasons (such as trial halted) (n=32), patient preference (such as fear 
of side effects) (n=23), or teratogenicity concerns (n=11). The preceding group 
was excluded from subsequent analyses. The poor seizure control resulted in 
treatment failure in 553 attempts, and details of the AED regimens are shown in 
Table 4-1. Treatment failure due to poor tolerability or both ineffective and 
intolerance will be discussed in the following section (Table 4-2). 
 
Figure 4-1. Response to each antiepileptic drug schedule tried during the follow-up 
Other reasons for antiepileptic drugs discontinuation (n=100) included a long-term seizure-free 
period (n=34), regulatory reasons (n=32), patient preference (n=23), or teratogenicity concerns 
(n=11). 
 
 
 
 
2,911 antiepileptic 
drug regimens
1,443 continued 
(50%)
Discussed in Chapter 3
1,468 discontinued
(50%) 
410 intolerance and 
ineffectiveness (14%)
405 poor drug 
tolerability (14%)
553 poor seizure 
control (19%)
100 other reasonse (3%)
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Table 4-1. Discontinued antiepileptic drug regimens due to poor seizure control (n=553) 
Monotherapy Dual therapy Triple therapy Quadruple therapy 
VPA 108  VPA/LTG 21 CBZ/LEV/TPM 4 VPA/TPM/PGB/CLB 1 
LTG 99  LTG/LEV 17 VPA/LTG/TPM 3 VPA/LTG/TPM/RTG 1 
CBZ 61 VPA/LEV 10 Other 39 Other 2 
LEV 41  CBZ/LTG 6     
OXC 14  LTG/PGB 5     
GBP 8  CBZ/GBP 5     
TPM 8 Other 58     
Other 19        
Total 360  143  46  4 
Data are presented in number of cases. Key: VPA: valproate, LTG: lamotrigine, CBZ: 
carbamazepine, LEV: levetiracetam, OXC: oxcarbazepine, GPB: gabapentin, TPM: topiramate, 
PGB: pregabaline, CLB: clobazam, RTG: retigabine. 
 
 
Table 4-2. Discontinued antiepileptic drug regimens due to intolerable adverse effects 
(n=815) 
Monotherapy Dual therapy Triple therapy Quadruple therapy 
VPA  143 VPA/LTG 47  VPA/LTG/LEV 4 VPA/LTG/LEV/TPM 3 
LTG  109  VPA/LEV 16  VPA/LEV/ESL 3 Other 6  
CBZ  106  LTG/LEV 13  Other 55    
LEV  61  LTG/TPM 12     
OXC  43  CBZ/LTG 9      
TPM  32  VPA/TPM 7      
GPB  10  Other 102      
LCM   8        
FBM   6        
TGB   6        
PHT   6        
other   8       
Total 538  206  62  9 
Data are presented in number of cases Key: Key: VPA: valproate, LTG: lamotrigine, CBZ: 
carbamazepine, LEV: levetiracetam, OXC: oxcarbazepine, TPM: topiramate, GPB: gabapentin, 
LCM: lacosamide, FBM: felbamate, TGB: tiagabine, PHT: phenytoin, ESL: eslicabazepine 
acetate. 
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4.3.1 Rate of adverse drug reactions 
Of the total 2,911 treatment schedules, 815 (28%) failed due to intolerable 
adverse effects, either alone (n=405) or in combination with the lack of efficacy 
(n=410). Among 1,528 initial monotherapies, 206 (13%) were stopped due to 
adverse drug reactions.  
Tiredness was the most frequent intolerable side effect of AED usage. The overall 
incidence of tiredness was 5.2% (n=152/2,911), which represented 19% 
(n=152/815) of treatment failure due to adverse drug reactions. Poor coordination 
and skin rash were the second most common adverse drug reactions, with a 2.9% 
(n=86) incidence for each. Poor coordination and rash each alone accounted for 
11% of the total intolerable adverse effects. Incidence of gastrointestinal side 
effects and tremor was 2.7% (n=80) and 2.2% (n=63), respectively. The incidence 
of psychiatric and behavioural side effects including mood changes, aggression 
and irritability was 3% (n=91), and accounted for 11% of overall AED intolerability. 
Table 4-3 shows the frequent intolerable adverse drug reactions associated with 
AEDs use. 
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Table 4-3. Intolerable adverse effects associated with antiepileptic drug use 
 Overall 
n 
(%), [incidence] 
Monotherapy Polytherapy 
Tiredness 152 
(19), [5.2] 
92 (17) 60 (22) 
Poor coordination 86 
(11), [2.9] 
50 (10) 36 (13) 
Skin rash 86 
(11), [2.9] 
80 (15) 6 (2) 
Gastrointestinal 
side effect 
80 
(10), [2.7] 
57 (11) 23 (8) 
Tremor 63 
(8), [2.2] 
43 (8) 20 (7) 
Mood change 44 
(5), [1.5] 
22 (4) 22 (8) 
Headache 43 
(5), [1.5] 
32 (6) 11 (4) 
Weight gain 38 
(5), [1.3] 
29 (5) 9 (3) 
Aggression 33 
(4), [1.1] 
18 (3) 15 (5) 
Cognitive 
dysfunction 
24 
(3), [0.8] 
10 (2) 14 (5) 
Insomnia 20 
(2), [0.7] 
16 (3) 4 (2) 
Irritability 14 
(2), [0.5] 
11 (2) 3 (1) 
Paraesthesia 12 
(1), [0.4] 
8 (1) 4 (2) 
Anorexia/ weight 
loss 
11 
(1), [0.4] 
7 (1) 4 (2) 
Hair loss 8 
(1), [0.3] 
5 (1) 3 (1) 
Psychosis effect 8 
(1), [0.3] 
5 (1) 3 (1) 
Sexual dysfunction 8 
(1), [0.3] 
8 (1) 0 
hyponatremia 7 
(1), [0.3] 
4 (1) 3 (1) 
Other 78 
(9), [28] 
41 (8) 37 (13) 
Total cases 815 538 277 
Data are presented in number of cases (% of total number of cases), [incidence=case 
number/total number of attempts*100]. Total number of attempts was 2,911. 
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4.3.2 Comparison of tolerability of antiepileptic drugs 
The tolerability rates of 17 different AEDs were compared when AEDs were used 
as monotherapy or as part of polytherapy.  As shown in pairwise comparisons in 
Table 4-4, Figure 4-2, Table 4-5, and Figure 4-3, LTG was associated with the 
lowest adverse effects rate whether it was used as monotherapy (19%, n=109/575) 
or as part of polytherapy (9%, n=35/387). However, TPM was associated with the 
highest rate of adverse effects (39%, n=32/81) among monotherapies, while RTG 
had the highest rate of adverse effects (42%, n=8/19) among AEDs used as part of 
polytherapies. 
In order to asses and overcome the potential effect of confounders on tolerability 
rate of AEDs, several analyses were performed. First, a univariate regression 
analysis which shows that six factors were significantly influenced the tolerability; 
gender, epilepsy type and aetiology, number of pre-treatment seizure, psychiatric 
comorbidity, and number of prior and concomitant AEDs. Seizure aetiology and 
number of prior AEDs were excluded from the multivariate model because they 
interacted with other variables. After accounting for the significant variables in 
the adjusted model (multivariate), there was found to be no significant evidence 
of an association between seizure type and tolerability. Table 4-6 shows univariate 
and multivariate logistic regression analysis for predictors of tolerability. These 
factors will be discussed further later in this chapter. 
Then, the aforementioned significant factors were assessed for individual AEDs 
(LTG, VPA, CBZ, LEV, OXC, and TPM) to examine their effect on the reported 
tolerability rates. As shown in Table 4-7, psychiatric comorbidity rate was 
comparable among monotherapies users. However, differences were observed in 
gender, epilepsy type, pre-treatment seizure number, and number of prior AEDs. 
VPA was the least AED tried by female patients (30%), while LTG (61%) and LEV 
(57%) were the most frequent AEDs used by those patients. Likewise, VPA was the 
least AED tried by patients with focal epilepsies (80%), the figure was the highest 
in CBZ and OXC groups (both 90%). Patients with more than 10 seizures before 
treatment tried LTG (33%) less frequently than other treatment groups.  Patients 
tried OXC (19%) after failure of two previous AEDs more frequently than patients 
tried other AEDs. Table 4-8 demonstrates more details about pairwise comparisons 
of these factors among different treatment groups. 
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Figure 4-2. Comparison of tolerability of antiepileptic drugs used as monotherapy 
Pairwise comparison shown in Table 4-4. 
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Table 4-4. Pairwise comparison of tolerability of antiepileptic drugs used as monotherapy 
 LTG 
(19%) 
n=575 
CBZ 
(29%) 
n=366 
LEV  
(25%) 
n=247 
OXC 
(36%) 
n=118 
TPM 
(39%) 
n=81 
GPB 
(27%) 
n=37 
PHT 
(24%) 
n=25 
LCM 
(33%) 
n=24 
TGB 
(31%) 
n=19 
VPA 
(25%) 
n=577 
0.017 0.157 0.979 0.009 0.005 0.76 0.929 0.344 0.59 
LTG  <0.000 0.062 <0.000 <0.000 0.229 0.602 0.11 0.231 
CBZ   0.24 0.126 0.063 0.804 0.595 0.648 0.807 
LEV    0.02 0.01 0.76 0.939 0.354 0.583 
OXC      0.661 0.292 0.234 0.772 0.682 
TPM       0.183 0.158 0.584 0.518 
GBP        0.789 0.599 0.722 
PHT         0.47 0.577 
LCM          0.903 
Data are P-value of X2/ Fisher’s exact test, Significance at p < 0.001 (Bonferroni correction=0.05/45). n=number of total 
attempts (% of intolerable adverse reactions). Key: VPA: valproate, LTG: lamotrigine, CBZ: carbamazepine, LEV: 
levetiracetam, OXC: oxcarbazepine, TPM: topiramate, GPB: gabapentin, PHT: phenytoin, LCM: lacosamide, TGB: tiagabine. 
Eslicabazepine acetate, pregabaline, zonisamide, vigabatrin, clobazam, retigabine, and perampanel were excluded from 
pairwise comparison because the results were inaccurate for small samples. 
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Figure 4-3. Comparison of tolerability of antiepileptic drugs used as part of polytherapy  
Pairwise comparison shown in Table 4-5. 
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Table 4-5. Pairwise comparison of tolerability of antiepileptic drugs used as polytherapy 
 VPA 
(10%) 
n=353 
LEV  
(14%) 
n=267 
TPM 
(24%) 
n=141 
CBZ 
(9%) 
n=130 
LCM 
(15%) 
n=108 
PGB 
(24%) 
n=77 
OXC 
(12%) 
n=67 
ZNS 
(31%) 
n=64 
CLB 
(18%) 
n=56 
GBP 
(27%) 
n=45 
ESL 
(20%) 
n=30 
VGB  
(24%) 
n=25 
RTG 
(42%) 
n=19 
LTG 
(9%) 
n=387 
0.691 <0.000 <0.000 0.91 0.066 <0.000 0.411 <0.000 0.034 0.001 0.055 0.025 <0.000 
VPA  0.001 <0.000 0.695 0.13 0.001 0.564 <0.000 0.065 0.001 0.11 0.037 <0.000 
LEV   0.236 0.006 0.326 0.409 0.169 0.033 0.829 0.242 0.906 0.598 0.034 
TPM    <0.000 0.066 0.903 0.041 0.287 0.334 0.731 0.624 0.99 0.103 
CBZ      0.125 0.003 0.44 <0.000 0.063 0.003 0.094 0.034 0.001 
LCM      0.141 0.588 0.01 0.616 0.092 0.094 0.034 0.01 
PGB       0.071 0.295 0.441 0.685 0.704 0.949 0.1 
OXC        0.007 0.355 0.048 0.353 0.193 0.006 
ZNS          0.088 0.604 0.256 0.499 0.38 
CLB          0.288 0.809 0.544 0.059 
GBP           0.508 0.807 0.23 
ESL            0.721 0.098 
VGB             0.202 
Data are P-value of X2/ Fisher’s exact test, Significance at p < 0.0005 (Bonferroni correction=0.05/91). n=number of total attempts (% of intolerable adverse 
reactions). Key: LTG: lamotrigine, VPA: valproate, LEV: levetiracetam, TPM: topiramate, CBZ: carbamazepine, LCM: lacosamide, PGB: pregabaline, OXC: 
oxcarbazepine, ZNS: zonisamide, CLB: clobazam, GPB: gabapentin, ESL: eslicabazepine acetate, VGB: vigabatrin, RTG: retigabine. Phenytoin, tiagabine, and 
perampanel were excluded from pairwise comparison because the results were inaccurate for small samples. 
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Table 4-6. Univariate and multivariate logistic regression analysis for predictors of adverse effects 
 Univariate Multivariate 
 Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
Female gender 1.528 (1.299, 1.798) <0.000 1.485 (1.259, 1.754) <0.000 
Age (Years) 1.004 (0.999, 1.009) 0.133   
Focal epilepsy 1.4 (1.093, 1.794) 0.008 1.265 (0.981, 1.631) 0.087 
Seizure aetiology*   0.017   
Family history of epilepsy 1.147 (0.933, 1.41) 0.192   
Febrile convulsion 1.064 (0.729, 1.552)  0.749   
Birth trauma 1.549 (0.675, 3.554) 0.302   
Head injury 0.911 (0.731, 1.137) 0.411   
Cerebrovascular disease 1.209 (0.951, 1.537) 0.121   
More than 10 seizures before treatment 1.608 (1.365, 1.893) <0.000 1.488 (1.259, 1.758) <0.000 
Seizures for >1 year before treatment 1.08 (0.918, 1.269) 0.353   
Learning disability 0.617 (0.361, 1.054) 0.077   
Psychiatric comorbidity 1.388 (1.174, 1.641) <0.000 1.215 (1.022, 1.444) 0.027 
Alcohol abuse 0.881 (0.727, 1.067) 0.194   
Recreational drug use  1.099 (0.87, 1.388) 0.429   
Number of prior antiepileptic drugs* 1.118 (1.1071, 1.168) <0.000   
Monotherapy 0.642 (0.539, 0.766) <0.000 0.686 (0.577, 0.827) <0.000 
*excluded from multivariate analysis because they interacted with other variables. 
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Table 4-7. Clinical characteristics of patients starting different antiepileptic drugs as monotherapy 
 VPA 
n=577 
LTG 
n=575 
CBZ 
n=366 
LEV 
n=247 
OXC 
n=118 
TPM 
n=81 
X2-P-
value 
Female gender 176 (30) 353 (61) 155 (42) 141 (57) 48 (41) 42 (52) <0.000 
Focal epilepsy 460 (80) 490 (85) 328 (90) 210 (85) 106 (90) 67 (83) 0.001 
Seizure aetiology 
Cryptogenic 
Idiopathic 
symptomatic 
 
299 (52) 
117 (20) 
161 (28) 
 
286 (50) 
85 (15) 
204 (35) 
 
187 (51) 
38 (10) 
141 (39) 
 
122 (49) 
37 (15) 
88 (64) 
 
62 (53) 
12 (10) 
44 (37) 
 
45 (56) 
14 (17) 
22 (27) 
 
More than 10 pre-treatment seizure 226 (39) 192 (33) 130 (35) 84 (34) 53 (45) 37 (46) 0.045 
Psychiatric comorbidity 188 (33) 167 (29) 101 (38) 82 (33) 36 (31) 26 32) 0.527 
Failure of two or more previous 
antiepileptic drugs 
44 (8) 50 (9) 39 (11) 21 (9) 23 (19) 10 (12) 0.003 
Data are presented in patients number (%). Key: VPA: valproate, LTG: lamotrigine, CBZ: carbamazepine, LEV: levetiracetam, OXC: 
oxcarbazepine, TPM: topiramate. Because of small sample sizes, other antiepileptic drugs were not included in this sub-analysis. 
 
 
122 
Chapter 4. Adverse drug effects 
 
Table 4-8. Pairwise comparisons of clinical characteristics of different treatment groups 
 VPA 
n=577 
CBZ 
n=366 
LEV 
n=247 
OXC 
n=118 
TPM 
n=81 
Female 30% 42% 57% 41% 52% 
LTG 61%, n=575 <0.000 <0.000 0.25 <0.000 0.107 
VPA  <0.000 <0.000 0.038 <0.000 
CBZ   <0.000 0.748 0.121 
LEV    0.003 0.412 
OXC     0.147 
Focal 80% 90% 85% 90% 83% 
LTG 85%, n=575 0.014 0.043 0.942 0.143 0.574 
VPA  <0.000 0.06 0.002 0.508 
CBZ   0.098 0.947 0.125 
LEV    0.18 0.629 
OXC     0.158 
>10 pre-treatment seizure 39% 35% 34% 45% 46% 
LTG 33%, n=575 0.041 0.504 0.864 0.021 0.036 
VPA  0.258 0.156 0.251 0.269 
CBZ   0.7 0.072 0.094 
LEV    0.047 0.064 
OXC     0.915 
Failure of two previous 
antiepileptic drugs 
8% 11% 9% 19% 12% 
LTG 9%, n=575 0.507 0.326 0.928 0.005 0.389 
VPA  0.121 0.675 0.002 0.248 
CBZ   0.369 0.027 0.672 
LEV    0.007 0.344 
OXC     0.166 
Data are p-values of X2 test. Key: VPA: valproate, LTG: lamotrigine, CBZ: carbamazepine, LEV: 
levetiracetam, OXC: oxcarbazepine, TPM: topiramate. Because of small sample sizes, other 
antiepileptic drugs were not included in this sub-analysis. 
 
4.3.3 Tolerability profiles of individual antiepileptic drugs 
Table 4-9 shows the adverse drug reactions reported for individual AEDs. The main 
adverse reaction associated with LTG was skin rash which caused 28% of poor 
tolerated cases, this was the case with CBZ (28%) and PHT (50%) as well. VPA 
poorly tolerated most frequently due to tremor and weight gain, which scored 27 
and 18% respectively. Whereas LEV poorly tolerated commonly due to psychiatric 
and behavioural side effects including mood disorder, aggression, and irritability, 
which accounted for 41% (n=46/112) of the overall intolerability of LEV. Cognitive 
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dysfunction was most commonly associated with TPM with 6.4% incidence. The 
incidence of hyponatremia was 2.7% with OXC therapy, and much lower for CBZ 
(0.4%). Headaches were frequently associated with LCM (2.3%), while CLB was the 
most common AED cause the tiredness in this cohort with 10.5% incidence. ESL 
acetate was the most AED associated with gastrointestinal adverse effects with 
8.1% (n=3) incidence, while PER was the drug most associated with poor 
coordination (15.4%, n=2); though, the cases number were few.   
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Table 4-9. Intolerable adverse effects of individual antiepileptic drugs used as monotherapy or 
as part of polytherapy  
n 
(%), [incidence] 
 
LTG 
n=962 
VPA 
n=930 
LEV 
n=514 
CBZ 
n=496 
TPM 
n=222 
OXC 
n=185 
Tiredness 
 
15 
(10), [1.6] 
28 
(16), [3] 
26 
(23), [5] 
31 
(26), [6] 
10 
(15), 
[4.5] 
15 
(29), [8.1] 
Poor 
coordination 
17 
(12), [1.8] 
8 
(5), [1] 
4 
(4), [1] 
20 
(17), [4] 
1 
(2) 
12 
(24), [6.5] 
Skin rash 40 
(28), [4.2] 
1 
(1) 
 
33 
(28), [6.6] 
 
6 
(12), [3.2] 
GI side effect 12 
(8), [1.2] 
24 
(14), [3] 
8 
(7), [2] 
8 
(7), [2] 
 
6 
(12), [3] 
Tremor 10 
(7), [1] 
48 
(27), [5.2] 
 
2 
(2) 
  
Mood disorder 1 
(1), [0.1] 
3 
(2) 
22 
(20), [4] 
1 
(1) 
7 
(11), [3] 
1 
(2), [1] 
Headache 15 
(10), [1.6] 
3 
(2) 
10 
(9), [1.9] 
8 
(7), [1.6] 
1 
(2) 
1 
(2), [1] 
Weight gain  32 
(18), [3.4] 
1 
(1) 
 
  
Aggression 3 
(2), [0.3] 
1 
(1) 
18 
(16), [4] 
1 
(1) 
4 
(6), [2] 
 
Cognitive 
dysfunction 
1 
(1), [0.1] 
1 
(1) 
 
1 
(1) 
14 
(21), 
[6.4] 
1 
(2), [1] 
Insomnia 8 
(6), [0.8] 
1 
(1) 
7 
(6), [1] 
 
 
1 
(2), [1] 
Irritability 3 
(2), [0.3] 
1 
(1) 
6 
(5), [1] 
 2 
(3), [1] 
 
Paraesthesia  
 
1 
(1) 
 10 
(15), 
[4.5] 
 
Anorexia/ 
weight loss 
    10 
(15), 
[4.5] 
 
Hair loss  7 
(4), [1] 
 
1 
(1) 
  
Psychosis 
effect 
4 
(3), [0.4] 
  
 
  
Sexual 
dysfunction 
 1 
(1) 
 
5 
(4), [1] 
 
1 
(2), [1] 
Hyponatremia  
  
2 
(2), [0.4] 
 
5 
(10), [2.7] 
Other 14 18 9 4 7 2 
Total cases 143 177 112 117 66 51 
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Table 4-9. Intolerable adverse effects of individual antiepileptic drugs used as monotherapy or 
as part of polytherapy  
n 
(%), [incidence] 
 LCM 
n=132 
GBP 
n=82 
PGB 
n=81 
ZNS 
n=68 
CLB 
n=57 
PHT 
n=38 
Tiredness 4 
(17), [3] 
4 
(18), [5] 
2 
(10), [2] 
6 
(29), [8.8] 
6 
(60), 
[10.5] 
 
Poor 
coordination 
4 
(17), [3] 
6 
(27), [7.3] 
3 
(15), [4] 
1 
(5), [1] 
  
Skin rash 1 
(4), [1] 
 1 
(5), [1] 
  3 
(50), [7.9] 
GI side effect 2 
(8), [2] 
6 
(27), [7.3] 
2 
(10), [2] 
1 
(5), [1] 
1 
(10), [2] 
2 
(33), [5.3] 
Tremor 1 
(4), [1] 
 2 
(10), [2] 
   
Mood disorder 2 
(8), [2] 
 1 
(5), [1] 
3 
(14), [4] 
  
Headache 3 
(13), [2.3] 
  1 
(5), [1] 
 1 
(17), [3] 
Weight gain  2 
(9), [2] 
2 
(10), [2] 
   
Aggression    1 
(5), [1] 
1 
(10), [2] 
 
Cognitive 
dysfunction 
1 
(4), [1] 
1 
(5), [1] 
1 
(5), [1] 
2 
(10), [3] 
  
Insomnia   1 
(5), [1] 
1 
(5), [1] 
  
Paraesthesia 1 
(4), [1] 
     
Anorexia/ 
weight loss 
   1 
(5), [1] 
  
Psychosis 
effect 
1 
(4), [1] 
 1 
(5), [1] 
1 
(5), [1] 
  
Sexual 
dysfunction 
 1 
(5), [1] 
    
Other 4 1  4 1 2  
Total cases 24 22 20 21 10 6 
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Table 4-9. Intolerable adverse effects of individual antiepileptic drugs used as monotherapy or 
as part of polytherapy  
n 
(%), [incidence] 
 ESL 
n=37 
TGB 
n=27 
VGB 
n=27 
RTG 
n=19 
PER 
n=13 
 
Tiredness 1 
(13), [3] 
 2 
(29), [7] 
1 
(13), [5] 
  
Poor 
coordination 
3 
(38), [8] 
3 
(38), [11] 
 1 
(13), [5] 
2 
(50), 
[15.4] 
 
Skin rash 1 
(13), 
[2.7] 
     
GI side effect 3 
(38), 
[8.1] 
  1 
(13), [5] 
1 
(25), [8] 
 
Mood disorder  1 
(13), [4] 
 1 
(13), [5] 
  
Weight gain   1 
(14), [4] 
   
Aggression  1 
(13), [4] 
2 
(29), [7] 
 1 
(25), [8] 
 
Cognitive 
dysfunction 
 1 
(13), [4] 
    
Paraesthesia    1 
(13), [5] 
  
Other  2 2 3   
Total cases 8 8 7 8 4  
Data are presented in number of cases (% of total number of cases), [incidence=case number/total 
number of attempts*100], n=number of total attempts. ). Key: LTG: lamotrigine, VPA: valproate, LEV: 
levetiracetam, CBZ: carbamazepine, TPM: topiramate, OXC: oxcarbazepine, LCM: lacosamide, GPB: 
gabapentin, PGB: pregabaline, ZNS: zonisamide, CLB: clobazam, PHT: phenytoin, ESL: 
eslicabazepine acetate, TGB: tiagabine, VGB: vigabatrin, RTG: retigabine, PER: perampanel, GI: 
gastrointestinal. 
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4.3.4 Adverse drug reactions with particular combination 
therapies 
The combination therapy of VPA with LTG was the most commonly used 
combination in this cohort (n=136). Followed by the combination of LTG with LEV 
(n=55), then VPA with LEV (n=37). The rate of adverse drug reactions was 35% 
(n=24/136) with VPA/LTG, 24% (n=13/55) with LTG/LEV, and 43% (16/37) with 
VPA/LEV (Figure 4-4). However, these differences did not reach a statistical 
significance (p=0.132). Tremor was the most common side effect reported for the 
VPA/LTG combination, which rated a 28% of poor tolerability. Tiredness was the 
most frequent reaction reported for both LTG/LEV and VPA/LEV. The details about 
other adverse drug reactions are shown in Table 4-10. 
 
Figure 4-4. Tolerability of the most commonly used combination therapies 
X2 p-value=0.132. Key: VPA: valproate, LTG: lamotrigine, LEV: levetiracetam. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 10 20 30 40 50
VPA/LTG
LTG/LEV
VPA/LEV
35%
24%
43%
n=136
n=55
n=37
Adverse drug reactions (%)
128 
Chapter 4. Adverse drug effects 
 
Table 4-10. Adverse effects of particular antiepileptic drug combinations  
VPA/LTG LTG/LEV VPA/LEV 
Tremor 13 (28)  2 (13) 
Poor coordination 6 (13)  
 
Tiredness 6 (13) 6 (46) 5 (31) 
Weight gain 4 (8)  1 (6) 
Skin rash 3 (6)  
 
Gastrointestinal side effect 2 (4) 2 (15) 2 (12) 
Headache  2 (4) 2 (15) 1 (6) 
Cognitive dysfunction 1 (2)  
 
Hair loss 1 (2)  
 
Psychosis effect 1 (2)  
 
Insomnia 1 (2)  1 (6) 
Aggression 
 
 1 (6) 
Mood disorder  2 (15) 3 (19) 
Other 7 (15) 1 (8)  
Total 47 13 16 
Data are presented in number of cases (%). Key: VPA: valproate, LTG: 
lamotrigine, LEV: levetiracetam. 
 
4.3.5 Potential predictors for adverse drug reactions  
The following section will more closely examine and quantify the effect of several 
potential predictors that demonstrated a significant correlation with poor 
tolerability in the univariate regression analysis (Table 4-6). These included 
patient-related factors (gender, epilepsy diagnosis, seizure aetiology, psychiatric 
comorbidity, and number of pre-treatment seizure) and pharmacological factors 
(number of prior AEDs, number of concomitant AEDs, and drug generation). 
Female sex was significantly associated with higher levels of poor tolerability 
(28%, n=189/679) than the male patients (21%, n=177/849). The adverse drug 
reactions rate was also significantly higher in patients with focal epilepsy (25%, 
n=322/1290) compared to patients with generalised epilepsy (18%, n=44/238). 
Likewise, cryptogenic (26%) and symptomatic (24%) seizure aetiology had higher 
instances of poor tolerability than idiopathic seizure (18%). Patients with 
psychiatric comorbidity presented higher levels of poor tolerability (29%, 
n=125/433) than patients with no psychiatric problems (22%, n=241/1095), 
p=0.005 (95% CI 0.139, 0.258). Finally, number of pre-treatment seizures had a 
linear positive correlation with poor tolerability (p=0.001). Table 4-11 and Figure 
4-5 summarise the influence of patient-related factors on tolerability of AEDs.  
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With regard to pharmacological factors, the number of the prior unsuccessful AED 
schedules and co-prescribed AEDs showed a linear positive relationship with poor 
tolerability (both p<0.000). However, the adverse drug reactions rate was not 
different in patients treated with older AEDs compared to the patients treated 
with new AEDs (p=0.377). Table 4-12 and Figure 4-6 present the effect of the 
pharmacological factors on drug tolerability. 
As shown in Figure 4-7, patient groups who had an intolerable adverse effect at 
one AEDs schedule were more likely to experience intolerable adverse effects at 
subsequent AED schedule. 
 
Table 4-11. Potential patient-related factors on tolerability of antiepileptic drug used as 
first attempt (n=1,528) 
  Intolerable 
adverse effects 
(n=366) 
P-value (95% 
CI)  
Gender 
 
Female (n=679) 
Male (n=849) 
189 (28) 
177 (21) 
0.001 
(0.026, 0.113) 
Epilepsy type  
 
Focal (n=1290) 
Generalised (n=238) 
322 (25) 
44 (18) 
0.032 
(0.01,0.119) 
Seizure aetiology 
 
Cryptogenic (n=776) 
Idiopathic (n=238) 
Symptomatic 
(n=514) 
199 (26) 
44 (18) 
123 (24) 
<0.000 
Number of pre-
treatment seizure 
1 (n=55) 
2 (n=300) 
3-5 (n=439) 
6-10 (n=219) 
11-20 (n=95) 
>20 (n=420) 
10 (18) 
62 (21) 
98 (22) 
44 (20) 
31 (33) 
121 (29) 
0.001 
Psychiatric 
comorbidity 
Yes (n=433) 
No (n=1095) 
125 (29) 
241 (22) 
0.005 
(0.139,0.258) 
Data are presented in number of cases (%). X2, 2-proportions test and X2 for trend were 
used. 
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Table 4-12. Potential pharmacological factors on tolerability of all antiepileptic drugs 
regimens tried during follow-up (n=2,911) 
  Intolerable 
adverse effects 
(n=815)  
P-value 
(95% CI)  
Number of prior 
antiepileptic 
drugs 
0 (n=1,528) 
1 (n=643) 
2 (n=306) 
3 (n=170) 
4 (n=102) 
5 (n=59) 
>5 (n=103) 
366 (24) 
192 (30) 
98 (32) 
62 (36) 
39 (38) 
20 (34) 
38 (37) 
<0.000 
Number of co-
prescribed 
antiepileptic 
drugs 
Monotherapy (n=2113) 
Dual therapy (n=605) 
Triple therapy (n=167) 
Quadruple therapy 
(n=25) 
5 antiepileptics (n=1) 
538 (25) 
206 (34) 
 62 (37) 
 9 (36) 
0 
<0.000 
  Intolerable 
adverse effects 
(n=538) 
 
Drug generation 
of monotherapies  
First generation (n=969) 
New generation 
(n=1144) 
255 (26) 
283 (25) 
0.377 
(-0.02,0.054) 
Data are presented in number of cases (%). 2-proportion and X2 for trend tests were used. 
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Figure 4-5. Potential patient-related factors on tolerability 
X2 and X2 for trend tests were used. Key: *P<0.05, **P<0.01, ***P<0.001, ns: not significant. 
132 
Chapter 4. Adverse drug effects 
 
0 1 2 3 4 5 >5
0
10
20
30
40
P=0.000
24% 34%38%36%32%30% 37%
n=1,528 n=59n=102n=170n=306n=643 n=103
Number of prior unsucessful antiepileptic drug schedules
A
d
v
e
rs
e
 d
ru
g
 r
e
a
c
ti
o
n
s
 (
%
)
Monotherapy Dual therapy Triple therapy or more
0
10
20
30
40
25% 34% 37%
n=2,113 n=605 n=193
P=0.000
A
d
v
e
rs
e
 d
ru
g
 r
e
a
c
ti
o
n
s
 (
%
)
First New 
0
10
20
30
n=969 n=1,144
26% 25%
p=0.377
Drug generation
A
d
v
e
rs
e
 d
ru
g
 r
e
a
c
ti
o
n
s
 (
%
)
 
Figure 4-6. Potential pharmacological factors on tolerability 
X2 and X2 for trend tests were used.
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Figure 4-7 Tolerability of the previous antiepileptic drug schedules as a predictor for tolerability of the subsequent schedules  
Patients who experienced adverse drug reactions on one AED schedule were significantly more likely to experience adverse drug reactions on the successive 
schedule, compared to those with no reported adverse drug reactions. 2-proportions test p-value (confidence interval) were <0.000 (0.156, 0.253) for (28 vs 8%), 
<0.000 (0.245, 0.389) for (37 vs 6%), <0.000 (0.137, 0.348) for (37 vs 12%), and 0.005 (0.06, 0.355) for (35 vs 16%). 
1st attempt 
n=1528 
 
No adverse 
drug 
reaction 
n=1162 
Adverse 
drug 
reaction 
n=366 
5th attempt 
n=62 
 
Adverse 
drug 
reaction 
n=39 
No adverse 
drug 
reaction 
n=23 
4th attempt 
n=170 
 
Adverse 
drug 
reaction 
n=62 
No adverse 
drug 
reaction 
n=108 
3rd attempt 
n=306 
 
Adverse 
drug 
reaction 
n=98 
No adverse 
drug 
reaction 
n=208 
2nd attempt 
n=643 
 
Adverse 
drug 
reaction 
n=192 
No adverse 
drug 
reaction 
n=451 
n=103 
(28%) 
n=89 
(8%) 
 
n=72 
(37%) 
n=26 
(6%) 
 
n=26 
(12%) 
 
n=36 
(37%) 
n=17 
(16%) 
 
n=22 
(35%) 
134 
Chapter 4. Adverse drug effects 
 
4.3.6 Adherence and adverse drug reactions 
14% of the patients (n=315/2306) were excluded from this study because of 
persistent poor adherence to their AED therapy. In the study cohort, the overall 
intermittent poor adherence rate was 13% of the total regimens tried 
(n=371/2911). 
The rate of this erratic poor adherence was 11% in the regimens discontinued due 
to poor tolerability (n=86/815), 17% (n=180/1081) in ineffective regimens, and 
10% (n=90/9014) in successful regimens (Figure 4-8). Poor adherence was 
significantly higher in ineffective regimens than successful regimens (p<0.000, 95% 
CI 0.026, 0.088) and regimens with poor tolerability (p<0.000, 95% CI 0.03, 0.092). 
However, there was no significant difference between the successful regimens 
and poorly tolerated regimens (p=0.588).  
Erratic poor concordance was higher for monotherapies (14%, n=293/2113) than 
polytherapies (10%, n=78/798). 
In 102 cases, patients admitted to occasionally missing an AED dose, and the 
reasons for this were recorded. The primary reason was forgetfulness (42%) 
followed by alcohol intake (24%) (as some patients believed that AEDs interact 
with alcohol), then side effects (21%) (including fear of side effects and discomfort 
after taking the medication). All reasons recorded from the patients are presented 
in Figure 4-9. Social problems including homelessness, prison, and stress while 
other reasons given were misunderstanding the dosage, seizure-free achievement, 
and inability to swallow the tablet. 
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Figure 4-8. Poor adherence effect on treatment outcomes 
Test for 2 proportions was used. Key: ***P<0.001 
 
 
Figure 4-9. The reasons for poor adherence in 102 epilepsy patients who admitted missed 
antiepileptic drugs (AEDs) doses 
Social problems including homelessness, prison, and stress while other reasons given were 
misunderstanding the dosage, seizure-free achievement, and inability to swallow the tablet. 
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4.4 Discussion  
Patient tolerability of AEDs is integral to successful treatment. There are currently 
24 AEDs available for treating epilepsy, many of which have similar efficacy but 
differ in their tolerability profiles (Perucca and Meador, 2005, Brodie, 2017b). 
Clinical studies are intended to focus more on the efficacy of the drug than its 
tolerability. Furthermore, they concentrate on early adverse events than late 
appearing reactions, although patients usually adjust to these early problems 
(Cramer, 2012). Understanding the long-term tolerability of AEDs, and the risk 
factors involved, will provide valuable knowledge for tailoring treatment choices 
to individual patient characteristics and enhancing treatment effectiveness. 
In this large study of newly diagnosed epilepsy patients, who began treatment 
with AEDs at Glasgow Epilepsy Unit and were followed up for up to 32 years, the 
primary objective was to evaluate the long-term adverse drug reactions profiles 
of different AEDs and to assess the effect of the other variables. 
One of the main findings of the research is that the rate of intolerable adverse 
effects of AEDs therapy was 28%. 13% of patients stopped their initial AED 
treatment as a result of adverse drug reactions. This result is comparable to a 
previous study conducted on a similar cohort in 2010, in which 14% of the patients 
discontinued their initial AED due to adverse drug reactions (Bamagous, 2010). 
However, the figure is different from the findings of two earlier studies of similar 
cohorts conducted in 2000 (Kwan and Brodie, 2000) and 2005 (Mohanraj and 
Brodie, 2005), in which 21 and 11% of the patients, respectively, stopped their 
first monotherapy because of intolerable adverse drug reactions. The results of 
these studies are shown in Table 4-13. The differences in the findings may reflect 
the differences in study time, study period, sample size, and AEDs used. Extra new 
agents were included in the current study, as several new AEDs have been 
approved since the previous research conducted in 2005, and some new agents 
have become more popular. The findings of the current study are also comparable 
to an unblended randomised controlled trial conducted in the UK, which evaluated 
the effectiveness of five AEDs (CBZ, GBP, LTG, OXC, and TPM) in 1712 patients. 
The results of the study indicated that 12.3% (n=212) of patients stopped the initial 
AEDs due to adverse drug reactions (Marson et al., 2007a). 
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Table 4-13. Initial treatment discontinuation due to drug intolerance in the current 
and previous analyses on Glasgow cohort 
 Patients (n) Rate of discontinuation 
(Kwan and Brodie, 2000) 470 21% (n=98) 
(Mohanraj and Brodie, 2005) 780 11% (n=90) 
(Bamagous, 2010) 1098 14% (n=157) 
Current analysis in 2016 1,528 13% (n=206) 
 
 
However, the outcomes of the current study differ greatly from studies conducted 
in other countries. This dissimilarity reflects the variations in the nature of study 
populations, healthcare systems, AEDs used, treatment approaches, and study 
period and design. In a 10-year study conducted in Italy, the medical records of 
747 patients (aged 11m-94y) were identified by general practitioners between 
2000 and 2008; only 2.7% (n=20) of patients stopped their first AED as a result of 
adverse events (Giussani et al., 2017). Moreover, the rate of adverse drug 
reactions varied from study-to-study. In a retrospective study conducted in China 
of 784 patients followed up for 7 years, the overall discontinuation rate as a result 
of the adverse effects of six AEDs (CBZ, VPA, TPM, OXC, LTG, and LEV) was 7.10% 
(n=56) (Zhu et al., 2015). While another Chinese study of 654 patients followed 
up for 3 years found that 19.3% (n=126) of patients discontinued their AED (CBZ, 
VPA, LTG, TPM, or OXC) due to the adverse effects encountered (Zeng et al., 
2015). Although there was little variation in the populations and other parameters 
of the two studies, they showed a large difference in the rate of adverse drug 
reactions. 
A novel finding from the present study was the examination of the adverse drug 
reactions in all regimens used during follow-up. This enabled evaluation of poor 
tolerability in initial AED monotherapies, as well as successive AED regimens. 
Therefore, the tolerability of newer agents used as adjunct therapy was well 
evaluated. This method also allowed evaluation of poor tolerability in 
polytherapies. Furthermore, the study assessed treatment failure due to drug 
intolerance alone and in combination with poor drug efficacy; the latter is a 
common occurrence in epilepsy patients. 
In the present retrospective analysis, only intolerable adverse effects that 
contributed to treatment failure were explored. Thus, the prevalence of adverse 
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drug reactions of continued AEDs was not measured. This is because of the study 
design and limited available data. The prevalence of adverse drug reactions of 
continued AEDs has greatly varied in many studies, depending on the assessment 
tools and study populations (Perucca and Gilliam, 2012). Overall, the rate of 
adverse effects has been reported as between 10 and 40% if tolerability was 
estimated by unstructured interviews or spontaneous reporting, and between 59 
and 96% when adverse effects were estimated by screening methods (Perucca et 
al., 2009, Kwon and Park, 2011, Luoni et al., 2011, Perucca and Gilliam, 2012). 
The prevalence of adverse drug reactions associated with seizure control was 
highest in those with pharmacoresistant epilepsy, intermediate in mixed 
populations, and lowest in seizure-free patients (Table 4-14). 
Table 4-14. Adverse Event Profile (AEP) scores among different seizure control populations  
[modified from (Perucca and Gilliam, 2012)] 
 Patients 
(n) 
Seizure 
outcome 
Antiepileptic 
regimen 
AEP score  Version 
of the 
AEP 
(Kwon and 
Park, 2011) 
150 All controlled 
(1-year seizure-
free) 
All on 
monotherapy 
27.3 (8.2) 19-item 
(Martins et 
al., 2011) 
100 38% controlled 
(1-year seizure-
free) 
29% on 
monotherapy 
37.6 (13.3) 19-item 
(Perucca et 
al., 2009) 
200 29% controlled 
(6m-seizure-
free) 
50% on 
monotherapy 
38.8 (11.8) 19-item 
(Luoni et 
al., 2011) 
809 All uncontrolled 22% on 
monotherapy 
42.7 (11.4) 21-item 
AEP: adverse event profile. AEP score in mean (SD). 
 
In the cohort for this study, a sedative effect was the most common adverse effect 
leading to treatment failure. It accounted for approximately 20% of the total 
intolerability of AEDs. Almost all AEDs were associated with tiredness but at 
different rates. The figure was the highest with CLB, followed by ZNS and OXC, 
and lowest with LTG. This is not an unprecedented result. In a SANAD study of 
CBZ, LTG, OXC, TPM, and GBP, sedative effects such as tiredness/ drowsiness/ 
fatigue/ lethargy were the most common reported adverse drug reactions, 
although they did not seem specific to any individual drug (Marson et al., 2007a). 
Moreover, in a meta-analysis of placebo-controlled studies of eight new AEDs 
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(GBP, LTG, LEV, OXC, PGB, TGB, TPM, and ZNS), all AEDs except LTG (although no 
meta-analysis could be performed with OXC and TGB) had sedative properties 
(Zaccara et al., 2008). As with other benzodiazepines, sedation appears to be the 
most common adverse effect of CLB (Kennedy and Lhatoo, 2008, Brodie, 2017b). 
However, CLB (1.5-Benzodiazepin) is less likely to cause sedation than clonazepam 
(1.4-Benzodiazepine) because of the difference in their chemical structures. 
Therefore, CLB was preferred over clonazepam in the Glasgow Epilepsy Unit. 
Poor coordination was the second most frequent adverse effect reported in this 
cohort, and was associated with the majority of AEDs. It presented highest with 
PER, followed by TGB, GBP, and OXC, and lowest with LEV and VPA. A community-
based population study of 346 patients in the Netherlands in which adverse effects 
were assessed by questionnaire showed that CNS-related complaints such as 
fatigue and dizziness yielded the highest prevalence of adverse effects (Carpay et 
al., 2005). Furthermore, in the aforementioned meta-analysis conducted by 
Zaccara et al. (2008), all AEDs except LEV were significantly associated with poor 
coordination side effects such as dizziness, ataxia, and diplopia. In randomised 
clinical trials, PER had a strong negative impact on patient balance, including 
dizziness and falls (Steinhoff et al., 2013), and the intolerable side effects of PER 
in a recent German study of 214 patients are predominantly reported as dizziness 
(Pensel et al., 2016). 
In this study, the overall rash rate was 2,9%, and it was the most frequent reaction 
that caused discontinuation of LTG, CBZ, and PHT treatments. The highest rash 
incidence occurred with PHT, followed by CBZ, LTG, OXC, and then ESL acetate. 
The incidence of rash reported in this cohort is in line with other studies. The 
incidence of skin reactions in 753 Polish patients who were exposed to 18 different 
AEDs was 7.2% (n=54). 92.5% of the reactions occurred with LTG (n=27), CBZ 
(n=20), or OXC (n=3) (Bosak et al., 2016). In a large Chinese study of 3793 patients, 
3.61% (n=137/3793) of patients experienced a skin reaction with one out of 11 
different AEDs, most notably with CBZ (3.8%), LTG (11.11%), and OXC (8.92%) 
(Wang et al., 2012). In another Chinese study, of six AEDs used as monotherapies 
for 789 patients, the most common adverse effect related to treatment 
withdrawal was the appearance of a rash with 3.7% (n=29) incidence and this 
accounted for 52% of treatment discontinuation due to adverse effects (n=29/56). 
Of all terminated cases, LTG demonstrated the highest rate (8.69%, n=10/115) of 
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discontinuation due to rash, followed by OXC (7.53%, n=7/93), and CBZ (4.14%) 
(Zhu et al., 2015). It has been observed that AEDs with aromatic ring structures 
associated with the highest rate of rash (Wang et al., 2012). Furthermore, 
Handoko et al. (2008) showed that cutaneous adverse reactions appeared twice 
as frequently with aromatic AEDs than with non-aromatic AEDs. The outcome of 
the current study supports this hypothesis, in which higher rash cases were 
observed in patients treated with aromatic AEDs (such as PHT, CBZ, LTG, and OXC) 
and lower rates with nonaromatic AEDs (such as VPA and LEV). 
In the present study, a pairwise comparison of the tolerability rates of 17 different 
AEDs revealed that LTG had the best tolerability whether it was used as 
monotherapy or as part of polytherapy, while TPM and RTG were associated with 
highest rate of adverse effects when they were used as monotherapy and as part 
of polytherapy, respectively. Indeed, LTG has consistently demonstrated a better 
tolerability profile than most other AEDs in several studies, and TPM has shown 
inferior tolerability (Marson et al., 2007a, Marson et al., 2007b, Bamagous, 2010, 
Zeng et al., 2015, Zhu et al., 2015). Another study evaluated the rate of 
discontinuation due to adverse effects in new agents, including LEV (n=196), LTG 
(n=251), OXC (n=97), TPM (n=156), and ZNS (n=128). LTG showed the best 
tolerability rate (19%, n=47), followed by OXC (24%, n=23), ZNS (30%, n=38), and 
then LEV (37%, n=72). While TPM demonstrated the poorest tolerability rate (40%, 
n=61) (Chung et al., 2007). Most studies that have compared the tolerability of 
AEDs have focused on drugs used as monotherapy. Thus, newer agents which are 
used as adjunct therapies, such as RTG, have not been studied extensively. In the 
present study, RTG was associated with the highest rate of reported adverse 
effects. Although no specific adverse effect contributed to the high rate of RTG 
discontinuation in the population of this study, concerns about the blue 
discolouration effect substantially limited its use. At the final follow-up (data 
extraction end date was April 2016), only two patients continued to use RTG. As 
a consequent of its chronic adverse effects, it was regarded as the last choice of 
drug for refractory seizures (Brodie, 2017b). Therefore, the patients with the most 
intractable epilepsy were used RTG, which may have contributed to the poor 
outcome in this analysis. It is important to note that the results from these 
multiple comparisons should be interpreted with caution because of the 
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unavoidable selection bias of this study as the case with all observational studies. 
This selection bias and the efforts made to address it are explained in Chapter 6. 
One of the main results of this research is that each AED had its own distinct 
tolerability profile which allow tailoring treatment selection efficiently. The 
adverse effects profiles of the most widely used AEDs (LTG, VPA, CBZ, and LEV) 
are discussed in Chapter 5 of this thesis. In this study, TPM was one of the most 
widely prescribe AEDs. Cognitive dysfunction was reported in 6.4% of the patients, 
which represented the most common reason (20%) for TPM intolerability. Cognitive 
dysfunction included word finding difficulties, poor concentration, and poor 
memory. In fact, there is consistent evidence of TPM’s negative effect on 
cognition and verbal function. In a recent, large retrospective study (n=2,860) that 
compared the cognitive side effects of 18 different AEDs, intolerable cognitive 
side effects most commonly occurred with TPM as adjunct therapy (22.8% of 281 
patients) and as monotherapy (18.5% of 54 patients). The most frequent specific 
cognitive side effect associated with TPM was psychomotor/cognitive slowing 
(13.7%) (Javed et al., 2015). Beside tiredness, parathesia, and anorexia/weight 
loss, TPM was also associated with psychiatric and behavioural disorders in 
approximately 5% of patients in the current study. In another prospective study, 
psychiatric comorbidity occurred in 103 (23.9%) patients with PTM; this included 
aggressive behaviour, irritability and/or anxiety (Mula et al., 2003b). 
It is worthy of note that in this study, hyponatremia incidence was higher in OXC 
therapy than CBZ and this is consistent with other studies. Dong et al. (2005) found 
that the frequency of hyponatremia (Na<134 mEq/L) was 29.9% among OXC-
treated patients and 13.5% among CBZ-treated patients (p <0.0001) (Dong et al., 
2005). 
As with individual AEDs, tiredness was the most common adverse effect of the 
combination therapies. However, tremor was the most common side effect of the 
VPA/LTG combination, and resulted in 38% intolerability. The well-known 
pharmacodynamic and pharmacokinetic interactions can be proposed as the 
explanation for the marked tremor seen in some patients taking VPA and LTG in 
combination. Most tolerability studies have evaluated the rate of adverse effects 
in monotherapy and compared it to the overall rate in polytherapy. However, very 
few studies evaluate the adverse effects with specific AED combinations. Kowski 
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et al. (2016) investigated the adverse effects of dual AED therapy and found that 
the most commonly reported specific adverse effects were sleepiness, difficulty 
concentrating, and memory problems. Furthermore, the AED combination 
LTG/LEV was commonly associated with blurred vision, while hair loss was 
commonly reported with LTG/VPA and LEV/VPA combination therapies (Kowski et 
al., 2016). 
One of the most important findings of this study is that among the many variables 
investigated, female sex, focal seizure, number of pre-treatment seizure, 
psychiatric comorbidities, number of prior AEDs, and polytherapy were by far the 
most important determinants of poor AED tolerability. This result is similar to 
those found in a Brazilian study of 100 patients, in which higher AEP (Adverse 
Events Profile) scores were significantly associated with the female gender 
(P<0.001) (Martins et al., 2011). Similarly, a case-control analysis of 418 patients 
pooled from two large prospective studies on newly diagnosed epilepsy found that 
female gender was associated with higher AEP scores (Perucca et al., 2011). This 
could be explained by the compelling evidence that pharmacokinetic and 
pharmacodynamic drug properties are influenced by gender, leading to a higher 
incidence of adverse effects in females than in males across a variety of drug 
classes, including AEDs (Schwartz, 2007). An additional explanation may be an 
interaction between female gender and mood dysfunction (Kimiskidis et al., 
2007), as more women in our study presented with psychiatric comorbidities than 
men (34 vs 24%, p<0.001). Moreover, another study found that female gender 
predicted adverse effect reporting independently of drug exposure or mood 
dysfunction (Perucca et al., 2011). However, the author concluded that additional 
research are needed to determine potential mechanisms and whether this 
association is limited to women with seizures. Furthermore, a large study 
(n=3,793) conducted on Chinese epileptic patients showed that females had a 
higher risk of skin reactions compared to males (Wang et al., 2012), although once 
again the author recommended a further study to discern the underlying 
mechanisms. 
In the participants of this study, focal epilepsy was associated with a higher rate 
of adverse effects than idiopathic generalised epilepsy. Prior studies have 
described similar figures, with higher rates of adverse effects occurring with 
symptomatic epilepsy compared to other epilepsy types (Perucca et al., 2011). 
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This could be because symptomatic focal epilepsy has been found to be less 
tractable epilepsy (Kwan and Brodie, 2000); therefore, patients with 
pharmacoresistant epilepsy require higher AED loads and polytherapy, which may 
increase the AED toxicity burden. However, in this analysis, there was no 
significant difference in seizure outcomes among different seizure types. An 
additional explanation is due to difference in AED selection for different epilepsy 
subtypes, as AEDs have different tolerability profiles that could contribute to 
different rates of adverse effects in different seizure types. Although another 
study found that overall AEP scores were similar in patients with symptomatic 
focal epilepsy and idiopathic generalised epilepsy and were not helpful in 
differentiating adverse effects in these two groups (Martins et al., 2011). 
However, the latter study assessed the adverse effects using an AEP instrument, 
which has potential limitations because of its subjectivity, lack of a physical 
evaluation to medically confirm some side effects such as weight changes, ataxia, 
nystagmus, speech and coordination abnormalities, and lack of objective 
examination of systemic involvement such as haematological and hepatic side 
effects. Furthermore, the AEP instrument could cause over-reporting because of 
the direct approach of the questionnaire. In fact, the author of the study 
acknowledged some limitations of their research, such as the tertiary care feature 
of their institute, as well as the large number of pharmacoresistant epilepsy 
patients in their sample. 
In the current study, adverse effect rates were significantly higher in patients with 
psychiatric comorbidities compared to patients without psychiatric disorders. This 
is not an unprecedented finding (Weintraub et al., 2007, Perucca et al., 2011). 
28% of patients in this study had psychiatric comorbidity at baseline or during 
follow-up. It is well-known that psychiatric disorders, particularly depression, are 
more common in the epilepsy population (Hitiris et al., 2007, Lin et al., 2012, 
Chowdhury and Brodie, 2016). Indeed, there is a complex interrelationship 
between adverse drug effects and psychiatric disorders. Firstly, psychiatric and 
behavioural symptoms are a common adverse effect of many AEDs (Weintraub et 
al., 2007, Lin et al., 2012). In this study, psychiatric side effects accounted for 
11% of overall AED intolerability. Furthermore, patients with psychiatric disorders 
(depression and/or anxiety) are more likely to report adverse effects of AEDs 
(Kwon and Park, 2011, Kanner et al., 2012). Finally, patients with psychiatric 
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comorbidities are less tractable (Hitiris et al., 2007); consequently, they may need 
aggressive treatments (i.e., polytherapy/high AED doses) that increase the 
adverse effect burden of AEDs. It should be noted that the data on psychiatric 
comorbidities in this study was not collected systemically using validated 
instruments. 
Number of pre-treatment seizure and number of prior AEDs appeared to be 
correlated positively with high rate of adverse drug reactions in this cohort. In 
fact, it has been showed that the rate of seizure-free decreases with high pre-
treatment seizure and high prior AEDs, and the probability of developing a 
refractory epilepsy increases (Kwan and Brodie, 2000, Brodie et al., 2013). The 
patients with pharmacoresistant epilepsy may require higher AED loads and 
polytherapy, and consequently, associate with higher adverse drug reactions rate. 
These two particular factors were discussed in previous chapter. 
The rate of adverse drug reactions related to the number of concomitant AEDs 
was lowest with monotherapy, intermediate with dual therapy, and highest with 
triple therapy or more in this analysis. The observation that polytherapy caused 
more side effects than monotherapy is consistent with the findings of several other 
studies (Carpay et al., 2005, Martins et al., 2011, Andrew et al., 2012). Andrew et 
al. (2012) found that patients undertaking polytherapy reported significantly 
higher adverse effect rates (AEP 46, n=325) than patients on monotherapy (AEP 
42, n=186), patients were on numerous combinations typically including at least 
one new AED (the most common AEDs were, CBZ/LTG/LEV/VPA). Similarly, 
Martins et al. (2011) showed that polytherapy with three or more AEDs was 
significantly associated with higher rates of side effects than monotherapy, the 
most common AEDs-induced adverse effects were CBZ, VPA, PB, LTG, TPM, PHT, 
CLB. In contrast, a cohort study of 809 refractory epilepsy patients failed to show 
any significant difference in adverse effects between monotherapy and 
polytherapy patients, leading the authors to conclude that, “adverse effects are 
determined more by individual susceptibility, type of AEDs used and physicians’ 
skills than number of co-prescribed AEDs” (Canevini et al., 2010, page.797). 
However, the latter study was a cross-sectional survey on pharmacoresistant 
epilepsy patients, thus the issues of high drug toxicity caused by overtreatment in 
refractory patients, along with the subjectivity/ overestimation of AEP instrument 
use, may limit the generalisation of the results to newly diagnosed epilepsy.  
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It is also worth noting that in this study the rate and nature of safety profiles 
varied among individual AEDs. However, the generation of individual AED did not 
appear to influence the rate of adverse drug reactions: new agents did not 
consistently present better tolerability than the established AEDs. For example, 
VPA, an old generation drug, demonstrated a lower adverse effect rate than the 
newer agents TPM or OXC. Thus, the findings of this study do not support the 
assumption of inferior tolerability of standard AEDs. This is inconsistent with the 
results of a study that extensively reviewed the prevalence of systemic and 
neurological reactions reported in clinical trials of AED monotherapy, which 
demonstrated unidirectional higher prevalence of selected adverse effects with 
standard AEDs compared with new agents (Cramer, 2012). However, this report 
was limited to data from clinical trials of monotherapies. Such trials are sufficient 
to evaluate the efficacy of a drug, but inadequate to assess the tolerability of the 
medication. It should be noted that VPA and CBZ are the most common first-line 
monotherapy, while most newer AEDs like TPM and OXC are used after failure to 
response to initial therapy. This may contribute to the poor outcomes found with 
new agents in the current study as severity of seizure may differ across patients 
groups taking standard and new agents.  
In addition to the main evaluation of AED tolerability, this analysis also studied 
the correlation with poor adherence. Overall, 14% of patients were persistently 
non-adherent to their AEDs and another 13% were intermittently poor adherent. 
Several studies have measured drug adherence in adult epilepsy patients and 
found the rates to be between 50-79% (Faught, 2012, Ferrari et al., 2013). It 
should be noted that the data on medication adherence used in the present 
research was not collected systemically using a validated instrument. Instead, the 
patients were asked directly and/or their blood drug levels were measured. This 
may have led to underestimation of poor adherence in the population. In this 
study, erratic poor adherence was associated more with treatment failure due to 
poor seizure control than due to side effects. However, side effects, including fear 
of side effect and discomfort after taking medication, was one of the most 
frequently reported reasons for poor adherence. It is well known that side effects 
cause drug poor adherence (Eatock and Baker, 2007). With regard to efficacy, 
results of this study demonstrated a negative correlation between seizure 
frequency and adherence. Of course, drugs do not work in patients who do not 
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take them; however, patients seem to adhere to the effective drugs (i.e. stop 
their seizures) (Faught, 2012). Indeed, with poor adherence it is unclear whether 
patients are not adherent to the drugs because they do not prevent their seizures, 
or drugs do not work because the patients do not take them correctly. Patients in 
this study reported different reasons for missing doses; forgetfulness was the 
primary factor, followed by alcohol intake, as some patients assumed that AEDs 
interact with alcohol. This is consistent with another study that evaluated the 
adherence in 131 patients in China using a self-report instrument, in which 4.6, 
70.2, and 25.2% of patients reported high, medium, and low adherence, 
respectively, and the frequent reasons given for non-adherence were 
forgetfulness (54.2%), being seizure-free for a long period (48.9%), and fear of 
adverse drug effects (27.5%) (Tang et al., 2013). The relationship between the 
number of daily drug doses and adherence has been extensively investigated; 
available evidence suggests that taking a drug less frequently is a substantial aid 
to adherence (Eatock and Baker, 2007, Faught, 2012). However, the findings of 
this study contradict this fact: poor adherence was associated more with 
monotherapy than polytherapy. Nevertheless, this should be interpreted with 
caution for several reasons. Firstly, the number of co-prescribed AEDs was 
assessed rather than dosing frequency, and the data on adherence was limited to 
the patients with intermittent poor adherence, as patients with persistent poor 
adherence were excluded. In addition, the use of suboptimal assessment tools, 
long-term follow-up, and the large number of patients may have contributed to 
weakening the accuracy of drug adherence assessment. Taken together, erratic 
poor adherence to AEDs was relatively infrequent in this study but influenced 
seizure control substantially and side effects of AEDs was one of the most 
frequently reported reasons for this behaviour. 
In summary, this analysis showed that the incidence of adverse effects with AEDs 
was 28%, of which tiredness was the most frequent problem. Each AED had its own 
distinct tolerability profile which provides the opportunity of tailoring drug choice 
more effectively. LTG was the best tolerated AED, while TPM was associated with 
the highest rate of adverse effect among monotherapies and RTG had the highest 
rate of adverse effects among AEDs used as polytherapy. Poor tolerability was 
higher in females and in patients with focal epilepsy, psychiatric comorbidities 
and those established on AED polytherapy. Additionally, number of pre-treatment 
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seizure and number of prior AEDs appeared to be correlated positively with high 
rate of adverse drug reactions. Prior intolerable AEDs schedule was also associated 
with high probability to experience intolerable adverse effects at subsequent AED 
schedule. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5. Comparative retention rates of the most 
commonly used antiepileptic drugs 
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5.1 Introduction 
In the previous two parts of this thesis, the efficacy and tolerability of AEDs were 
discussed separately. Despite the valuable knowledge each section has provided, 
the effectiveness of comprehensive long-term treatments has not yet assessed 
sufficiently. Determining retention rates is one approach to evaluating both the 
efficacy and tolerability of a drug (Mohanraj and Brodie, 2003). This survival 
analysis is often employed as an assessment of short-term and long-term 
effectiveness because it considers time to treatment modification for any reason 
(Cramer, 2012). 
Because epilepsy is a chronic neurological condition, its management commonly 
requires lifelong intervention. Apart from the small number of patients who 
undergo successful epilepsy surgery, the majority of patients rely on 
pharmacological management to control seizures. The pharmacological treatment 
of epilepsy often involves exposure to a number of AEDs and requires long-term 
adherence and commitment from patients (Kwan and Brodie, 2000, Chung et al., 
2007, Ferrari et al., 2013). Drug selection is based on seizure type, patient 
characteristics such as age, gender and comorbidities, and the tolerability profiles 
of the AEDs (French et al., 2004, Chung et al., 2007). Providing information about 
the long-term retention times of AEDs and the most common reasons for 
discontinuation can be invaluable in helping to choose the most appropriate drug 
for each individual patient and minimising the probability of exposure to 
ineffective and/or poorly tolerated AEDs. 
LTG, VPA, CBZ, and LEV are the most commonly prescribed AEDs for epilepsy 
patients, particularly as initial monotherapies (Gamble et al., 2006, Hu et al., 
2011, Glauser et al., 2013, Brodie, 2017b). Both the efficacy and tolerability of 
these drugs have been investigated (Brodie et al., 1995, Steinhoff et al., 2005, 
Brodie et al., 2007, Hu et al., 2011). However, their long-term retention times as 
monotherapies in a large sample of patients with new onset epilepsy have not 
been studied extensively. The cohort for this study was made up of patients with 
new onset seizure; thus, the majority of the drug exposures of these AEDs were 
tried as a first or second treatment attempt.  
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This section presents a comprehensive comparison between the retention rates of 
the most common monotherapies, LTG, VPA, CBZ, and LEV, in order to provide 
insight into how they differ in their efficacy, tolerability, treatment duration, and 
reasons for discontinuation in everyday clinical practice.  
5.2 Methods 
Retention of patients on a specific drug over a period of time is the best outcome 
measure that represents its effectiveness. The effectiveness of an AED is a 
function of its efficacy and tolerability, and thus cannot be sensibly separated 
(Mohanraj and Brodie, 2003). 
In this study, the retention time of an AED was defined as the time between 
starting monotherapy and withdrawal or addition of another agent. This was 
calculated in months from the start date of each specific AED administered as 
monotherapy to either the discontinuance date for the treatment or the last 
follow-up date for continued therapy. Continuity was defined as patients treated 
currently with the same AED monotherapy from treatment beginning until the final 
follow-up. Discontinuation was defined for patients who stopped their AED 
monotherapy (or required alternative monotherapy or add-on therapy) at any time 
during the follow-up period. The reason for treatment discontinuation was 
documented based on patients’ main complaint, whether this was drug 
intolerance, ineffectiveness, both, or other causes. 
Dosage of AEDs was reported as daily dose in milligrams based on what dose the 
patient was taken at the last follow-up or at what dosage the patient discontinued 
treatment. Drug doses were categorised into low, moderate, and high doses based 
on the interquartile range (IQR) of each drug used in the presented cohort. Low 
doses were smaller than the IQR, moderate doses were within the IQR, and high 
doses were greater than the IQR. IQR in mg/day for LTG=150-350, VPA=1000-1700, 
CBZ=400-800, and LEV=1000-2000. 
A chi-square test was used to compare the proportions of continued AEDs; the 
significance p-value was set at p<0.008 (based on Bonferroni correction=0.05/6). 
A Kaplan-Meier survival analysis was applied to estimate the cumulative 
probability of retention on treatments. While a Cox regression model was 
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implemented to evaluate and adjust for potential covariates. Finally, a two 
proportional statistical test was used to compare the other categorical data, and 
a Mann-Whitney test and a Kruskal-Wallis test were used to compare the non-
parametric continuous data. 
5.3 Results 
5.3.1 Treatment response and antiepileptic drug use 
Figure 5-1 summarises patient responses to the AEDs tried during the follow-up 
period. Of the total 1,765 data points, 56% (n=989) of the AED therapies were 
continued at the final clinic visit, while 41% (n=723) were discontinued during the 
follow-up period. Overall, the main reason for discontinuation of the AEDs was 
poor seizure control (18%, n=318), followed by poor drug tolerability (12%, n=211), 
and then both ineffectiveness and intolerance (11%, n=194). A small group of 
patients (3%, n=53) discontinued the treatment for other reasons, such as long-
term seizure-free periods, clinical trial regulations, patient preference, or 
concerns about teratogenicity. As the results from this group could be misleading 
(Mohanraj and Brodie, 2003), this cohort was excluded from subsequent analyses, 
and the remaining 1,712 AEDs regimens were studied.  
 
 
 
Figure 5-1. Treatment response during the follow-up period 
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The highest level of AED exposure was obtained from LTG, making up 33% (n=562) 
of the data, although VPA data followed closely at 32% (n=555). CBZ data 
represented 20% (n=350) and the least amount of data was collected from LEV 
exposures, at 15% (n=245). As mentioned previously, these four drugs are the most 
commonly medications prescribed as initial monotherapies for newly diagnosed 
epilepsy patients. Therefore, in this study, the majority of the AED exposures were 
tried as a first treatment (74%, n= 1,270). 
5.3.2 Potential effect of covariate on treatment outcomes 
A number of analyses were performed to evaluate and adjust the potential effect 
of covariates on treatment continuation and retention rates of AEDs. First, Cox 
regression analysis that shows that five covariates were significantly (P<0.05) 
influenced the treatment continuation in the univariate model: epilepsy type and 
aetiology, CVD, number of pre-treatment seizures, and psychiatric condition. 
However, gender factor appeared marginally significant (p=0.058). Seizure 
aetiology was excluded from the multivariate model because it significantly 
correlated to epilepsy type (p<0.000). After accounting for the significant 
variables in the adjusted model (multivariate), there was no significant evidence 
of an association between epilepsy type and treatment continuation. Table 5-1 
demonstrates the univariate and multivariate Cox regression analysis for 
predicators of treatment discontinuation.  
Then, the potential covariates were assessed for individual AEDs (LTG, VPA, CBZ, 
and LEV) to examine their effect on the reported retention rates. As shown in 
Table 5-2, CVD, number of pre-treatment seizure, psychiatric disorder and number 
of prior AEDS were comparable among treatment groups. However, female gender 
was significantly higher (p<0.000) in LTG group (62%) and LEV (57%) than CBZ (42%) 
and VPA (42%). Similarly, patients with focal epilepsies were significantly 
(p=0.031) higher in LTG treatment (85%) than VPA (80%), and marginal significant 
(p=0.05) in CBZ (89%) than LTG (85%).
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Table 5-1. Univariate and multivariate Cox regression analysis for predictors of treatment discontinuation 
 Univariate Multivariate 
 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Female gender 1.151 (0.995, 1.331) 0.058   
Age (Years) 1.003 (0.999, 1.007) 0.179   
Focal epilepsy 1.303 (1.057, 1.607) 0.013 1.184 (0.957, 1.464) 0.121 
Seizure aetiology*  0.047   
Family history of epilepsy 1.002 (0.832, 1.208) 0.982   
Febrile convulsion 1.059 (0.757, 1.48) 0.739   
Birth trauma 0.933 (0.848, 1.0.26) 0.15   
Head injury 1.150 (0.951, 1.39) 0.15   
Cerebrovascular disease 1.245 (1.006, 1.539) 0.044 1.241 (1.002, 1.536) 0.048 
More than 10 seizures before treatment 1.396 (1.205, 1.617) <0.000 1.348 (1.162, 1.564) <0.000 
Seizures for >1 year before treatment 1.041 (0.9, 1.204) 0.539   
Learning disability 1.143 (0.915, 1.428) 0.238   
Psychiatric comorbidity 1.311 (1.129, 1.523) <0.000 1.256 (1.079, 1.462) 0.003 
Alcohol abuse 1.152 (0.977, 1.359) 0.093   
Recreational drug use  1.103 (0.903, 1.347) 0.336   
Number of prior antiepileptic drugs* 1.066 (0.989, 1.151) 0.096   
*excluding form multivariate model as they interacted with other variables. 
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Table 5-2. Clinical characteristics of patients starting different antiepileptic drugs  
 LTG 
N=562 
VPA 
N=555 
CBZ 
N=350 
LEV 
N=245 
X2-P-
value 
Female gender 346 (62) 159 (29) 147 (42) 140 (57) 0.000* 
Focal epilepsy 478 (85) 445 (80) 313 (89) 208 (85) 0.002† 
Seizure aetiology 
Cryptogenic 
Idiopathic 
symptomatic 
 
277 (49) 
84 (15) 
201 (36) 
 
287 (52) 
110 (20) 
158 (28) 
 
175 (50) 
37 (11) 
138 (39) 
 
120 (49) 
37 (15) 
88 (36) 
 
Cerebrovascular disease 73 (13) 74(13) 40 (11) 42 (17) 0.255 
More than 10 pre-treatment 
seizure 
186 (33) 217 (39) 123 (35) 83 (34) 0.185 
Psychiatric comorbidity 164 (29) 181 (33) 96 (27) 82 (33) 0.24 
More than two prior 
unsuccessful antiepileptic 
drug schedules 
47 (8) 39 (7) 29 (8) 21 (9) 0.854 
Data are presented in patients number (%). Key: LTG: lamotrigine, VPA: valproate, CBZ: 
carbamazepine, LEV: levetiracetam. *p<0.000 for all comparisons except for LTG vs. LEV p=0.241. 
†only significant for LTG vs. VPA (p=0.031), but p=0.05 for LTG vs. CBZ and p=0.097 for VPA vs. 
CBZ.  
 
5.3.3 Retention on treatment 
The cohort of this study was followed up for up to 32 years. Based on treatment 
continuation at the last follow-up, LTG demonstrated the highest retention rate 
of 63% (n=354/562). This was significantly higher than the retention rates of VPA 
(55%, n=304/555) and CBZ (52%, n=183/350). However, there was no significant 
difference in the retention rates of the other AEDs. Figure 5-2 and Table 5-3  
present the details of the retention rates (in percentages) of the different AEDs 
and the pairwise comparisons using the Chi-square test and the significance p-
value was set at p<0.008 (based on Bonferroni correction). Because this analysis 
does not take into account the duration of therapy (it only compares the 
proportions of continued AEDs), survival analysis was performed. 
 
 
 
155 
Chapter 5. Retention rates  
 
LTG VPA CBZ LEV
0
20
40
60
80
100
Continued
Discontinued
63% 52%55% 58%
**
n=562 n=350n=555 n=245
***
R
e
te
n
ti
o
n
 r
a
te
 (
%
)
 
Figure 5-2. Overall retention rate of different antiepileptic drugs at last follow-up 
Key: **P≤0.01, ***P≤0.001, LTG: lamotrigine, VPA: valproate, CBZ: carbamazepine, LEV: 
levetiracetam. X2 test was used. 
 
Table 5-3. Multiple comparison of retention rate of different antiepileptic drugs 
LTG vs. CBZ 0.001 
LTG vs. VPA 0.005 
LTG vs. LEV 0.215 
CBZ vs. VPA 0.465 
CBZ vs. LEV 0.142 
VPA vs. LEV 0.345 
Data are p-value of X2 test. Significant at P<0.008 (Bonferroni correction). Key: 
LTG: lamotrigine, VPA: valproate, CBZ: carbamazepine, LEV: levetiracetam, vs.: 
versus. 
 
In the survival analyses, a Kaplan-Meier method was carried out to estimate the 
retention times of the different AEDs (Figure 5-3 and Table 5-4), and Cox 
regression model was employed to compare the retention rates of different AEDs 
before and after adjustment for potential covariates. As demonstrated in Table 
5-5, the adjusted and unadjusted retention rates were similar. Consistent with 
the previous analysis (Chi-square), LTG achieved the highest retention rate, with 
an average therapy duration of 84 months. This was significantly higher than the 
retention rates of VPA (42 months), CBZ (36 months), and LEV (36 months). There 
was no significant difference in retention rates of other AEDs. 
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Figure 5-3. Retention rate of different antiepileptic drugs estimated by Kaplan-Meier analysis 
Median retention time in months was 84 for LTG, 42 for VPA, and 36 for CBZ and LEV. Key: LTG: 
lamotrigine, VPA: valproate, CBZ: carbamazepine, LEV: levetiracetam. 
 
 
Table 5-4. Retention time of different antiepileptic drugs estimated by Kaplan-
Meier survival analysis  
Retention time (Months) Log Rank P-value 
Lamotrigine 84 (64.404, 103.595) 0.007 
Valproate 42 (34.231, 49.769) 
Carbamazepine 36 (25.861, 46.139) 
Levetiracetam 36 (19.508, 52.492) 
Data are presented in median (95% confidence interval). 
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Table 5-5. Comparative retention rate of different antiepileptic drugs estimated by 
Cox regression analysis before and after adjustment for covariates 
 Unadjusted Adjusted 
 Hazard ration (95% 
CI) 
P-
value 
Hazard ration (95% 
CI) 
P-
value 
LTG vs. LEV 0.763 (0.602, 0.968) 0.026 0.769 (0.606, 0.975) 0.03 
LTG vs. CBZ 0.754 (0.615, 1.213) 0.007 0.768 (0.626, 0.943) 0.012 
LTG vs VPA 0.756 (0.629, 0.909) 0.003 0.772 (0.642, 0.929) 0.006 
CBZ vs. LEV 1.013 (0.791, 1.297) 0.921 1 (0.780, 1.283) 0.998 
VPA vs. LEV 1.01 (0.802, 1.271) 0.936 0.995 (0.79, 1.255) 0.969 
CBZ vs VPA 1.003 (0.824, 1.22) 0.976 1.005 (0.824, 1.225) 0.961 
Key: LTG: lamotrigine, VPA: valproate, CBZ: carbamazepine, LEV: levetiracetam. The 
hazard of treatment discontinuation on LEV, CBZ, and VPA was approximately 24% higher 
than the hazard on LTG before and after adjustment for covariates. The covariates included 
in the model were gender, cerebrovascular diseases, psychiatric comorbidity, focal epilepsy 
and more than 10 seizures before treatment.  
 
Because length of exposure to treatment was different for different subject, the 
person-months statistic was applied (Table 5-6). 
Table 5-6. Person-months of follow-up / drug exposure 
Lamotrigine Valproate Carbamazepine Levetiracetam 
7 cases per 1000 
person-months  
10 cases per 1000 
person-months 
10 cases per 1000 
person-months 
11 cases per 1000 
person-months 
Data are number of incident cases (discontinued) divided by the amount of person-months at 
risk. 
 
Results showed a rapid discontinuation rate during the first two years of 
treatment, as expected. Thus, the data was further stratified at every two months 
during the initial two years of therapy. As presented in Figure 5-4 , CBZ showed 
the highest discontinuation rate at most assessment points, while there was an 
overlap between the discontinuation of VPA and LEV at several assessment points. 
At six months of treatment initiation onwards, LTG demonstrated the lowest 
discontinuation rate. However, before six months (i.e. at two and four months), 
LTG had a higher discontinuation rate than VPA and LEV. 
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Figure 5-4. Short-term discontinuation rate of different antiepileptics over the first two years 
of treatment 
Key: LTG: lamotrigine, VPA: valproate, CBZ: carbamazepine, LEV: levetiracetam. 
 
5.3.4 Reasons for antiepileptic drug discontinuation 
As shown in Figure 5-5, poor seizure control was the primary reason for the 
discontinuation of LTG, VPA, and LEV. Rates ranged from 40% for LEV to 47% for 
LTG. In the case of CBZ, poor drug tolerability was the main cause of 
discontinuation and accounted for 43% of discontinued cases. 
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Figure 5-5. Reason for discontinuation with individual medication 
Key: LTG: lamotrigine, VPA: valproate, CBZ: carbamazepine, LEV: levetiracetam. 
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Table 5-7 summarises the intolerable adverse effects of LTG, VPA, CBZ, and LEV 
as administered as monotherapies. Tiredness was the most common intolerable 
adverse effect reported and did not appear to be specific to any individual AED. 
Skin rash was the most frequent reaction that caused discontinuation of LTG and 
CBZ that accounted for 32 and 31% of total adverse drug reactions, respectively. 
Tremor and weight gain were the most intolerable effects reported for VPA 
therapy, accounting for 25 and 20% of VPA’s poor tolerability, respectively. 
Psychiatric and behavioural disorders were the most common reported side effects 
with the LEV monotherapy, and represented 44% of LEV’s poor tolerability. A total 
of 27 (11%) patients developed these psychiatric adverse effects with LEV 
including: 12 reported mood changes (5%), 11 reported aggression (4.5%), and 4 
demonstrated irritability (1.5%). Gastrointestinal adverse effects were also 
common, particularly with VPA, accounting for 15% of its poor tolerability. Poor 
coordination was common with the Na-channel blocker AEDs (i.e. LTG and CBZ), 
and made up 12% of the intolerable effects for LTG and CBZ separately. While 
headaches represented 10% of the intolerable effects for each LTG and LEV, and 
insomnia was 6 and 10% of the intolerable effects in the same drugs, respectively. 
Table 5-7. Intolerable adverse effects with the most commonly used antiepileptic 
drugs  
LTG VPA CBZ LEV Total  
Tiredness 11 (10) 24 (17) 30 (28) 10 (17) 75 (18) 
Skin rash 35 (32)  1 (1) 33 (31) 1 (2) 70 (17) 
Tremor 5 (5)  36 (25) 2 (2) 0  43 (11) 
Gastrointestinal side 
effect 
8 (7) 22 (15) 8 (8) 4 (6) 42 (10) 
Poor coordination 13 (12) 4 (3)  13 (12) 3 (5) 33 (8) 
Weight gain 0 29 (20)  0 0 29 (7) 
Headache 11 (10) 3 (2) 7 (7)  6 (10) 27 (6) 
Aggression 3 (3) 1 (1) 1 (1) 11 (18) 16 (4) 
Mood change 1 (1) 2 (1) 1 (1) 12 (20)  16 (4) 
Insomnia 7 (6) 1 (1)  0 6 (10)  14 (3)  
Irritability 3 (3) 1 (1) 0 4 (6) 8 (2) 
Hair loss 0 5 (3) 0 0   5 (1) 
Other 12 (11)  14 (10) 11 (10) 4 (6)  36 (9) 
total 109 143 106 61 419 
Data are presented in number of cases (%). Key: LTG: lamotrigine, VPA: valproate, CBZ: 
carbamazepine, LEV: levetiracetam. 
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5.3.5 Duration of therapy among different reasons for 
discontinuation 
Kaplan-Meier and Cox regression analyses were performed to estimate and 
compare the cumulative probability of retention for AEDs stratified by the 
different reasons for discontinuation (Figure 5-6, and Table 5-8). Poor drug 
tolerability resulted in the lowest retention rates with average therapy duration 
of two months. This was significantly lower than time to discontinuation due to 
poor seizure control with or without adverse effects, which were nine and 
eighteen months respectively. 
 
Figure 5-6. Retention rate among different reasons for discontinuation estimated by Kaplan-
Meier analysis 
Median retention time in months for poor tolerability, poor seizure control, and for ineffective and 
intolerance was 2, 9, and 18, respectively. 
 
Table 5-8. Retention time for different reasons for discontinuation estimated by 
Kaplan-Meier survival analysis  
Retention time (Months) Log Rank P-value 
Ineffective and 
intolerance 
9 (6.772, 11.228) <0.000 
Poor control 18 (15.282, 20.718) 
Poor tolerability 2 (1.434, 2.566) 
Data are presented in median (95% confidence interval). 
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Figure 5-7 demonstrates the cumulative discontinuation rate at every two months 
for the first two years of treatment, and the different causes of discontinuation. 
The majority (70%) of AEDs discontinued due to poor tolerability appeared within 
six months of treatment initiation. The figure was far lower for AEDs discontinued 
due to poor seizure control with (35%) or without (17%) intolerance. 
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Figure 5-7. Discontinuation rate among different reasons for discontinuation 
 
5.3.6 Dosage evaluation 
The median (IQR) dose of continued therapy in mg/day was 200 (150, 300) for 
LTG, 600 (400, 700) for CBZ, and 1000 (1000, 1500) for VPA and LEV. A comparison 
of the median doses between the continued group and discontinued group for each 
AED is demonstrated in Table 5-9 and Figure 5-8. For LTG, VPA, and LEV, a Mann-
Whitney test of the dosages showed significant differences between the continued 
and discontinued groups. For these AEDs, the median daily doses were higher in 
the discontinued group. However, the median dosage of the CBZ groups did not 
reveal a significant difference between them. 
The dosage of the discontinued group for each treatment was further stratified by 
the cause of discontinuation (Table 5-10 and Figure 5-9). For each of the four AEDs 
there were significant differences (p<0.000, Kruskal Wallis test) between the 
three different groups that discontinued treatments for different reasons (poor 
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tolerability, poor seizure control, and ineffective and intolerance). The median 
dosage of the poor tolerability group was the lowest for each therapy, while the 
dosage of poor seizure control was the highest. Thus, the group that discontinued 
the therapy due to both ineffectiveness and intolerance had median dose in 
between the other two groups. 
 
Table 5-9. Average dosage (mg/day) of continued and discontinued groups for each 
medication  
LTG VPA CBZ LEV 
Continued  200 (150-300) 1000 (1000-
1500) 
600 (400-700) 1000 (1000-
1500) 
Discontinued 300 (100-400) 1500 (1000-
2000) 
600 (400-800) 2000 (1000-
2500) 
Mann Whitney 
test p-value 
(95% CI) 
0.022  
(-99.98, -0.01) 
<0.000 
(-500,0.0) 
0.9633  
(-0.0, 0.0) 
<0.000  
(-1000,0.0) 
Doses are presented in median (IQR). Key: LTG: lamotrigine, VPA: valproate, CBZ: 
carbamazepine, LEV: levetiracetam. 
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Figure 5-8. Comparison between the doses of continued and discontinued groups for individual medication 
Key: *P<0.05, ***P≤0.001. Mann-Whitney test was used.
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Table 5-10. Average dosage (mg/day) of discontinued group for each medication stratified 
by the discontinuation reasons  
  LTG VPA CBZ LEV 
Ineffective and 
intolerance 
200 (150-
350) 
1500 (1000-
2000) 
800 (400-
1000) 
1000 (1000-
2500) 
Poor control 
400 (300-
500) 
2000 (1500-
2000) 
800 (600-
1000) 
2500 (2000-
3000) 
Poor tolerability 50 (25-150) 
1000 (1000-
1500) 
400 (200-
400) 
1000 (875-
1000) 
Kruskal-Wallis test p-
value  
<0.000 <0.000 <0.000 <0.000 
Doses are presented in median (IQR). Key: LTG: lamotrigine, VPA: valproate, CBZ: 
carbamazepine, LEV: levetiracetam. 
 
 
Figure 5-9. Comparison between doses of different reasons for discontinuation of 
discontinued group for individual medication  
Kruskal-Wallis test was used. 
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5.3.7 Dose-response tolerability versus drug toxicity 
The dosages of each discontinued AED were categorised into three levels (low, 
moderate, and high dose) based on the median and IQR doses for the individual 
medications. At low dose, the majority (69%) of discontinued drugs were stopped 
due to poor tolerability alone, and one quarter (25%) were discontinued due to 
poor tolerability with poor seizure control. At moderate dose, around one-third of 
treatments were discontinued due to intolerable adverse effects alone (31%), and 
another third were discontinued due to intolerable adverse effects with poor 
efficacy (33%). At high dose, one quarter of the therapies were discontinued due 
to drug poor tolerability with (23%) or without (3%) ineffectiveness. More details 
of the dosage levels and reasons for discontinuation are shown in Figure 5-10. 
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Figure 5-10. Dose-response tolerability and drug toxicity 
Low, moderate and high doses were <, =, and > than Interquartile range (IQR), respectively. IQR in 
mg/day for lamotrigine=150-350, valproate=1000-1700, carbamazepine=400-800, and 
levetiracetam=1000-2000, 
 
Table 5-11 shows the rate of intolerable adverse reactions at the different dosage 
levels (low, moderate, and high dose). Acute neurotoxicity symptoms resulted in 
22% of treatment failures at low dose, 57% at moderate dose, and 21% at high 
dose. The majority (67%) of skin rash reactions caused treatment withdrawal at 
low drug dose while the remaining (33%) were on moderate dose. The Majority of 
chronic reactions were reported at moderate dose level (70%), and a further 23% 
at high dose. Psychiatric and behavioural disorders appeared frequently (63%) with 
the moderate dose, while 21% appeared at low dose and 16% at high dose. Similar 
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patterns were seen with GI side effects, headaches, and insomnia: around half of 
the cases were on a moderate dosage, and one quarter were on a low dose and 
one quarter were on a high dose. 
Table 5-11. Adverse effects causing treatment discontinuation at different dose levels  
n Low 
dose 
Moderate 
dose 
High 
dose 
Acute neurotoxic symptoms (tiredness, 
poor coordination, tremor) 
151 33 (22) 86 (57) 32 (21) 
Skin rash 69 46 (67) 24 (33) 
 
Chronic reactions (weight gain, sexual 
dysfunction, hair loss, hyponatremia, 
muscle pain) 
44 3 (7) 31 (70) 10 (23) 
Psychiatric and behavioural side effects 
(aggression, mood change, irritability, 
psychosis, cognitive dysfunction) 
43 9 (21) 27 (63) 7 (16) 
Gastrointestinal side effects  42 11 (26) 27 (64) 4 (10) 
headache 27 7 (26) 15 (56) 5 (18) 
insomnia 14 2 (14) 10 (72) 2 (14) 
Data are presented in case number (%), Low, moderate and high doses were <, =, and > than 
Interquartile range, respectively. IQR in mg/day for lamotrigine=150-350, valproate=1000-1700, 
carbamazepine=400-800, and levetiracetam=1000-2000. 
 
 
5.3.8 Adverse effects causing treatment discontinuation at 
specific time periods 
Table 5-12 presents the intolerable side effects reported at specific time periods. 
Within two weeks of treatment initiation, early appearing problems such as a skin 
rash and gastrointestinal problems were common. They remained common after 
two months, at which time acute neurotoxicity symptoms such as tiredness, poor 
coordination and insomnia were also reported commonly. Between two and six 
months of treatment, chronic effects such as weight gain, hair loss, sexual 
dysfunction and hyponatremia began to emerge, as well as frequent reports of 
side effects such as tremor, headaches, aggression and mood changes. In the time 
period between six months and two years of therapy, weight gain was a common 
compliant, along with tremor and tiredness. Between two and five years, 
frequently reported side effects were psychiatric and behavioural disorders, 
cognitive impairment, and sexual dysfunction. In long-term treatment (more than 
five years), tremor, poor coordination, and tiredness were reported frequently, 
along with cases of sexual dysfunction.  
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Table 5-12. Adverse effects causing treatment failure at specific time periods  
  LTG 
(n=109) 
VPA 
(n=143) 
CBZ 
(n=106) 
LEV 
(n=61) 
<2 weeks rash (15) GI side effect (3) rash (9) aggression (2) 
GI side effect 
(2) 
tiredness (2) headache  headache 
poor 
coordination 
rash poor 
coordination  
mood change 
irritability tremor GI side effect tiredness 
headache   tiredness    
2 weeks- 
2 months 
rash (14) GI side effect (4) rash (18)  tiredness (3) 
tiredness (5) weight gain (2) GI side effect 
(4) 
aggression (2) 
 
Irritability (2) tremor (2) tiredness (4) insomnia (2) 
insomnia (2) mood change headache (3) GI side effect 
aggression poor coordination aggression mood change 
headache tiredness mood change irritability 
poor 
coordination 
  poor 
coordination  
poor 
coordination 
muscle pain   sexual 
dysfunction  
  
2-6 
months 
 
 
 
 
 
 
 
 
 
 
 
 
skin rash (5) weight gain (14) 
 
poor 
coordination 
(4) 
Aggression (3) 
GI side effect 
(3)  
tremor (14) 
 
 tiredness (3) irritability (3) 
insomnia (2) 
 
tiredness (10) 
 
skin rash (2) 
 
mood change 
(2) 
psychosis GI side effect (9) 
 
sexual 
dysfunction (2) 
insomnia (2)  
headache hair loss (3) hyponatremia poor 
coordination 
poor 
coordination 
headache (2) GI side effect  tiredness 
tiredness poor 
coordination  
headache  skin rash 
aggression aggression  paraesthesia 
muscle pain      
irritability      
mood change      
6 months 
-2 years 
 
 
 
 
 
 
 
 
 
headache (8) weight gain (9) tiredness (12) 
 
mood change 
(5) 
poor 
coordination 
(5) 
tiredness (7) 
 
skin rash (4) 
 
headache (4) 
insomnia (2) tremor (6) poor 
coordination 
(2) 
tiredness (4) 
tiredness (2) GI side effect (4) 
 
headache (2) GI side effect 
(3) 
sweaty  hair loss (2) GI side effect aggression (3) 
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Table 5-12. Adverse effects causing treatment failure at specific time periods  
  LTG 
(n=109) 
VPA 
(n=143) 
CBZ 
(n=106) 
LEV 
(n=61) 
 
 
 
6 months 
-2 years 
 
tremor insomnia tremor  insomnia (2) 
aggression headache     
GI side effect irritability     
psychosis gynaecomastia     
 teratogenicity     
  thrombocytopenia     
  poor coordination     
2-5 years GI side effect 
(2) 
tiredness (4) 
 
tiredness (3) mood change 
(2) 
tiredness (2) weight gain (2) poor 
coordination 
(3) 
aggression 
tremor (2) mood change sexual 
dysfunction (2) 
tiredness 
skin rash   tremor poor 
coordination 
insomnia   GI side effect   
cognitive 
dysfunction 
  cognitive 
dysfunction 
  
Poor 
coordination 
      
>5 years poor 
coordination 
tremor (10) tiredness (7) headache 
tiredness GI side effect (2) poor 
coordination 
  
 
tiredness     
  poor coordination     
  sexual 
dysfunction 
    
Data are presented in case number. Key: LTG: lamotrigine, VPA: valproate, CBZ: carbamazepine, 
LEV: levetiracetam. GI: gastrointestinal. Other less common side effects are not shown on this 
table. 
 
5.4 Discussion 
Retention on treatment is often used as a surrogate for effectiveness as it shows 
time to discontinuation of treatment for any reason. Therefore, it provides useful 
and practical knowledge for optimising treatment selection. While regulatory 
clinical trials provide evidence-based information for selecting AEDs, identifying 
the retention rates of treatments in real-world practice could provide a 
comprehensive insight into long-term effectiveness, efficacy, and tolerability 
(Chung et al., 2007). This large and long-term cohort study provides valuable 
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information on the outcomes of four common standard and new AEDs in a daily 
clinical setting. 
This research investigated the long-term retention rates of LTG, VPA, CBZ, and 
LEV used as monotherapies in adult patients with new-onset seizures. Patients 
were treated and followed up for up to 32 years in the Glasgow Epilepsy Unit.  
The primary finding of the study is that LTG showed a higher retention rate (at 
and after six months of treatment initiation) than VPA, CBZ and LEV, and there 
was no significant difference in the retention rates of other investigated AEDs. In 
earlier clinical trials, LTG exhibited a higher retention rate than CBZ. In a 48-week 
trial, 65% of patients treated with LTG (n=131) completed the study, compared to 
51% of CBZ patients (n=129), and this difference was significant (p:0.018, HR:1.57, 
95% CI: 1.07, 2.31) (Brodie et al., 1995). Steinhoff et al. (2005) found that the 
retention rate of LTG (92%, n=88) was higher than CBZ (81%, n=88) in patients with 
focal seizures, although the difference was not significant. Furthermore, a 
comprehensive review of five randomised control trials which compared LTG and 
CBZ determined that LTG was significantly better than CBZ regarding time to 
treatment discontinuation (HR 0.55, 95% CI 0.35, 0.84) (Gamble et al., 2006). 
Moreover, LTG demonstrated significantly superior outcome times to treatment 
failure than CBZ (HR 0.78, 95% CI 0.63-0.97) in the treatment of focal epilepsy 
(Marson et al., 2007a).  
LTG also achieved higher retention rates than LEV. In a 26-week comparative 
study, the retention of LTG and LEV were 71.4, and 63.1% respectively, although 
this difference did not reach statistical significance (p: 0.07, HR 1.34, 95% CI 0.95, 
1.88) (Rosenow et al., 2012). The authors of the study proposed that lack of 
retention in the LEV group was due to poor tolerability rather than poor efficacy, 
and adverse events leading to discontinuation were more frequent in the LEV arm 
(74.5%) than LTG (70.6%), yet once again the difference was not significant. These 
findings from CBZ and LEV trials are in line with the observations of the current 
investigation.  
However, the results of the present study contrast with existing VPA trials, in 
which LTG has demonstrated a non-significantly lower retention in patients with 
generalised epilepsy. In a 24-week comparative study, Steinhoff et al. (2005) 
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found that the retention rate of LTG (88%, n=33) was lower than VPA (97%, n=30). 
However, during the early stages of LTG therapy, seizure-related discontinuation 
(first seizure under-treatment) caused by compulsory slow dose titration led to 
the low retention rate in the LTG group, which was acknowledged by the authors. 
Indeed, in the current study, LTG had a lower short-term retention rate (before 
six months of treatment initiation) to VPA. In another clinical trial with a longer 
follow-up (seven years), VPA achieved slightly and non-significantly better 
retention than LTG (HR 1.25, 95% CI 0.94, 1.68) (Marson et al., 2007b). However, 
the two preceding trials mentioned here were limited to patients with generalised 
epilepsy, whereas the cohort for this study was more heterogeneous, which may 
have contributed to inconsistent outcomes for the time to treatment failure in 
patients treated with VPA.  
The subsequent observational studies with longer follow-up have confirmed that 
LTG has superior retention. Zeng et al. (2015) compared the long-term 
effectiveness of five monotherapies (CBZ, VPA, LTG, TPM, and OXC) in adult focal 
epilepsy patients. They demonstrated that LTG had the highest retention rate, 
significantly higher than VPA (HR 0.53, 95% CI 0.37, 0.74) and CBZ (HR 0.80, 95% 
CI 0.67, 0.96), and there was no significant difference in the retention rates of 
CBZ and VPA. Furthermore, Chung et al. (2007) observed the retention rates of 
five new medications (LEV, LTG, OXC, TPM, and ZNS) and showed that the 
retention rate was highest with LTG, which was significantly different from LEV 
(P<0.0001). Both these studies were relatively short-term, with three and two-
year follow-ups, respectively. A ten-year follow-up, observational study 
performed by Hu et al. (2011) did not identify a significant difference in the 
retention rates of CBZ and VPA used as the initial monotherapies in patients with 
newly diagnosed focal seizures. These findings are consistent with the findings of 
the present study. However, a study conducted in China showed that CBZ 
exhibited the highest retention rate, followed by LEV, LTG, and then VPA. CBZ 
was significantly different from VPA (p=0.008) and LTG (p=0.041), and LEV 
significantly different from VPA (p=0.021) (Zhu et al., 2015). However, the authors 
of the former study explained the possible reasons for the poor outcomes with 
LTG. Firstly, the slow titration of the LTG dosage caused poor drug adherence, as 
some patients did not increase their drug dosage according to their clinicians’ 
recommendations. Furthermore, the rash rate with LTG was high in their 
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institution (17.31%), therefore, they assumed that Chinese people exposed to LTG 
are more prone to rash and will more readily withdraw medications due to the 
appearance of a rash. However, the authors highlighted that this assumption needs 
further validation.  
In the current analysis, there was high discontinuation of CBZ and LTG within six 
months of therapy start. The notable high initial discontinuation of CBZ and LTG 
may be due to skin rash, which led to 49% (n=34/69) and 37% (n=29/78) of 
discontinuation within six months for CBZ and LTG therapies, respectively. 
Moreover, in order to diminish the risk of rash, LTG was started at a low dose with 
a slow titration schedule. Consequently, due to the time taken to reach 
therapeutic maintenance dose, it may be difficult to control seizures during early 
stages of LTG therapy. This may indicate that the tolerability of CBZ and LTG 
should be carefully assessed in the first six months after commencement of 
therapy. Indeed, this investigation also concludes that after the hurdle initial six 
months of LTG therapy, the continuation rate was markedly high. However, the 
discontinuation rate of CBZ remained high for the first two years of therapy in this 
study. The primary reason for CBZ discontinuation was poor tolerability, while in 
all other AEDs ineffectiveness was the main reason for discontinuation, Poor 
tolerability resulted in early discontinuation compared to other reasons, which 
may explain the high withdrawal rate of CBZ compared to all other AEDs at most 
evaluation points during first two years of therapy. With VPA and LEV therapies, 
the nature of the most frequent adverse effects may explain the relatively high 
short-term retention rate. Tremor and weight gain were the most common 
intolerable adverse effects reported with VPA, while psychiatric and behavioural 
difficulties were most common with LEV therapy. These adverse effects were 
frequently reported during the periods of two-six months and six months-two 
years, and continued to appear after two years of therapy. 
It is important to emphasise that a high retention rate does not necessarily 
indicate better efficacy, this assumption is in common with existing studies that 
evaluated retention rates of treatments (Zeng et al., 2015, Zhu et al., 2015). Many 
patients in this research continued treatment despite the lack of optimal efficacy, 
as shown in Chapter 3: 24-30% of patients continued with LTG, VPA, CBZ, and LEV 
although they were not completely effective.  
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To the best of our knowledge, this is the largest and longest observational cohort 
study of newly diagnosed epilepsy patients. The large number of patients included 
in this research and the long-term follow-up period has increased the possibility 
of finding clinically important differences between medications. Moreover, few 
studies have investigated the retention rates of standard and new AEDs, and these 
were limited to the Chinese population (Zeng et al., 2015, Zhu et al., 2015). 
Therefore, the current research may present novel findings in terms of population 
as well. 
It may raise concern that prior exposure to AEDs would influence the retention 
rate. In fact, the efficacy of AEDs declines substantially after failure of the second 
AED regimen, and patients develop drug resistant epilepsy (Kwan and Brodie, 
2000, Brodie et al., 2013). Therefore, the probability of treatment continuation 
might be lower with a drug tried after two prior medication trials compared to 
one tried as a first or second regimen (Chung et al., 2007). However, this potential 
bias is unlikely to affect the reported retention rate results in this study. Firstly, 
the regression analysis in this study revealed that a history of prior AED use did 
not influence the treatment continuation significantly (p>0.05). Moreover, there 
was no significant difference in number of prior AEDs between different treatment 
groups. The majority (92%) of the AEDs were used as a first or second regimen 
because these four AEDs (LTG, VPA, CBZ, and LEV) are the most common first-line 
and second-line monotherapies for epilepsy (Gamble et al., 2006, Hu et al., 2011, 
Glauser et al., 2013, Brodie, 2017b).  
However, there was a significant (P<0.05) difference in gender and epilepsy type 
between treatment groups. More females tried LTG and LEV than CBZ and VPA; 
perhaps due to teratogenicity concerns. Studies showed that LTG and LEV safer in 
pregnancy than VPA and similar to CBZ (Perucca and Gilliam, 2012). Indeed, VPA 
should be avoided in childbearing women (Tomson et al., 2015). In this study, 
more patients with focal epilepsies tried LTG than VPA, because LTG was found 
to be less officious than VPA in generalised epilepsies (Marson et al., 2007b). This 
unavoidable selection bias may affect the reported retention rates in this study as 
discussed in Chapter 6.  
Besides the comparison of retention rates, this study identified several further 
noteworthy findings. Overall, lack of efficacy was the primary reason for 
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treatment failure in the analysis, which accounted for 42% (n=309/728) of total 
treatment discontinuation. This was also the case with several other studies 
(Chung et al., 2007, Zhu et al., 2015). Similarly, lack of efficacy was the main 
cause of treatment discontinuation with individual AEDs in this investigation, 
except for CBZ. 
Poor tolerability was the primary reason for treatment discontinuation with CBZ 
therapy. This may indicate inferior tolerability of CBZ compared to LTG, VPA and 
LEV. In fact, CBZ has demonstrated lower tolerability than LTG, VPA and LEV in 
several studies. Brodie et al. (1995) found that more patients on CBZ (27%, n=129) 
than LTG (15%, n=131) withdrew due to adverse events. Likewise, unacceptable 
adverse events occurred more frequently with CBZ (74%, n=88) compared to LTG 
(43%, n=88) in another study (Steinhoff et al., 2005). Moreover, the SANAD study 
indicated that adverse events leading to discontinuation were more frequent with 
CBZ (13%, n=50/378) than LTG (8%, n=30/378), and compared with CBZ, LTG 
achieved 10–11% less treatment withdrawal for adverse events and was 
statistically different at all time points between one and six years (Marson et al., 
2007a). In addition, Mohanraj and Brodie (2005) demonstrated that adverse 
effects leading to withdrawal were significantly higher with CBZ (16%, n=45/268) 
than VPA (7%, n=17/198) or LTG (7%, n=15/198). Furthermore, Zeng et al. (2015) 
showed that adverse effects leading to treatment failure were more common with 
CBZ (25.5%, n=32/125) than VPA (23.8%, n=36/151) and LTG (11.1%, n=15/135). 
Brodie et al. (2007) found that more CBZ treated patients discontinued treatment 
because of adverse effects (19.2%, n=56/291) than LEV (14.4%, n=41/285), 
although this difference was not significant. Finally, Zhu et al. (2015) 
demonstrated that CBZ and LTG were most frequently associated with treatment 
failure as a result of unacceptable adverse effects (23.7 and 23.3%, respectively), 
while LEV (9.1%) was the least likely to result in treatment failure; although none 
of the differences between the AEDs with regard to treatment failure were 
statistically significant. These observations are keeping with the findings of the 
current study. However, in another study conducted by Hu et al. (2011), patients 
were less likely to discontinue treatment of CBZ than VPA. Yet this difference only 
occurred during the time period from the first six months to two years of 
treatment initiation, and the overall discontinuation due to adverse effects in the 
two groups were comparable. 
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Cutaneous reactions were the most frequent adverse effect reported for CBZ and 
LTG in the cohort for the present study. However, the incidence was higher with 
CBZ (9.4%, n=33/350) than LTG (6.2%, n=35/562), although the difference was not 
statistically significant (p=0.086). This result is consistent with the findings from 
studies conducted in the UK. Brodie et al. (1995) showed that 9% of patients 
treated with LTG developed rash necessitating drug withdrawal compared with 
13% receiving CBZ. Marson et al. (2007a) demonstrated that CBZ (7%, n=378) 
exhibited a higher rash rate than LTG (3%, n=378). In contrast, Wang et al. (2012) 
from China found that more patients experienced rash following LTG treatment 
(11.1%, n=139) than CBZ therapy (3.8%, n=1172). Similarly, LTG (8.7%, n=115) was 
associated with a higher rate of skin reactions than CBZ (4.1%, n=193) in another 
Chinese study (Zhu et al., 2015). Genetic factors play a role in the development 
of AED-induced cutaneous reactions (Zaccara et al., 2007, Franciotta et al., 2009). 
This may explain the discrepancy in findings from different populations, in 
addition to the differences in dosing guidelines for treatment commencement and 
titration that affect rash appearance, particularly for LTG.  
In VPA monotherapy, tremor and weight gain were the most frequent adverse 
effects that led to treatment discontinuation in this research. The incident rate 
of intolerable tremor was 6.5% (n=36/555) of VPA patients. VPA-induced essential 
tremor has been observed in 6-45% of patients in different studies (Perucca, 2002, 
Hamed and Abdellah, 2017). A potential reason for this wide range may be the use 
varied VPA dosage, as well as the use of different methods to assess tremor across 
studies. Furthermore, different VPA formulations have been found to influence 
the rate of tremor. Controlled-release VPA may have less tremorigenic activity 
compared to conventional VPA, as the latter exhibits higher peak-trough variation 
(Rinnerthaler et al., 2005). The appearance of tremor is dose-dependent, but the 
mechanism is not known. In general, VPA enhances γ-amino butyric acid (GABA) 
and inhibits N-methyl-D-aspartate (NMDA) in a dose-related manner. VPA also 
affects several other central neurotransmitters such as dopamine, epinephrine, 
and norepinephrine. These effects involved in the mechanism of VPA as 
anticonvulsant and the latter effect may be related to a number of CNS adverse 
effects of VPA including tremor (Hamed and Abdellah, 2017). 
Weight gain has been identified as another common adverse effect of VPA therapy 
in several studies (Corman et al., 1997, Jallon and Picard, 2001, Biton, 2003, Ben-
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Menachem, 2007). In the current study, the rate of unacceptable weight gain was 
5% (n=29/555) in VPA recipients. This is keeping with other published data. In 
SANAD trial, the weight gain was observed in 4% of patients randomised to VPA 
(n=238) (Marson et al., 2007b). However, the rate in the present study was slightly 
lower than the rate reported in one observational study in which weight gain that 
led to discontinuation of therapy was observed in 9% (n=5/55) of patients treated 
with VPA (Corman et al., 1997). In fact, the rate of weight gain reported as an 
adverse event with VPA used in clinical trials not designed to assess the incident 
of this adverse effect was relatively low (3%), but the figure was far higher in 
studies intended to evaluate weight gain (up to 70%) (Biton, 2003). The mechanism 
of VPA-associated bodyweight gain is not yet clear. One possible mechanism is 
involvement of eating stimulation and increasing hunger through an effect on the 
hypothalamus as a result of decreased blood glucose levels (Jallon and Picard, 
2001). Weight gain can pose a health hazard (possible increase in the risk of 
diabetes mellitus and/or heart disease) and lead to poor adherence with therapies 
(Biton, 2003, Ben-Menachem, 2007). The risk factors for VPA-associated 
bodyweight gain are not entirely clear (Jallon and Picard, 2001, Biton, 2003). 
With the LEV monotherapy tried in this study, psychiatric disorders including mood 
changes, aggression and irritability were the most common reported adverse 
effects (11%). Other studies showed similar figures. A prospective study of 517 
adult patients treated with LEV found that 10% of the patients developed a 
psychiatric adverse effect, and aggression (3.5%) was the most frequently 
presented psychiatric condition (Mula et al., 2003b). Furthermore, a retrospective 
observational study that compared the psychiatric and behavioural side effects of 
nine new AEDs in 1394 adults found that LEV exhibited the highest rate of 
psychiatric and behavioural adverse effects, which contributed to 8.8% (n=521) of 
the treatment failures for that therapy (Weintraub et al., 2007). Another study 
demonstrated a higher rate, in which 20% (n=38/196) of patients reported 
behavioural problems or irritability with LEV, but it did not review the patients’ 
past psychiatric history, and it was not clear whether this could have contributed 
to the results (Chung et al., 2007). In the present study, in which patients were 
treated in the Glasgow Epilepsy Unit, LEV therapy was avoided for patients with 
current or previous psychiatric conditions whenever possible. The effect of 
psychiatric coexistence was examined and is shown in Table 5-13. In general, past 
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psychiatric history has been regarded as the most important determinant for the 
probability of a patient experiencing psychiatric effects with AED use, including 
LEV therapy (Mula et al., 2003b, Weintraub et al., 2007). Furthermore, psychiatric 
adverse effects occurred similarly in AEDs (including LEV) used as monotherapies 
and as polytherapies (Weintraub et al., 2007), and LTG co-medication was 
protective (Mula et al., 2003b). It should be highlighted that the data used in this 
study on psychiatric conditions were not collected systematically using a validated 
tool. In addition, other comorbidities (other than epilepsy and psychiatric 
conditions) and co-prescribed medications (other than AEDs) were not taken into 
account, which may have influenced LEV-associated psychiatric adverse effects. 
Nevertheless, the rate of psychiatric adverse effects in the LEV monotherapy was 
similar in patients with and without psychiatric comorbidities Table 5-13, which 
suggests that the differences were most likely due to LEV use and not due to other 
variables. 
Table 5-13. Levetiracetam-related psychiatric and behavioural adverse effects in 
patients with and without pre-treatment psychiatric history  
Pre-treatment 
psychiatric comorbidities 
Psychiatric and 
behavioural adverse effect   
P-value (95% CI) of 
2-Proportion test 
No (n=186) 17 (9) 0.142  
(-0.026, 0.182) Yes (n=59) 10 (17) 
Data are presented in case number (%).  
 
It is important to note that, in the current study, treatment discontinuation due 
to intolerable adverse effects was commonly limited to the early period after 
treatment initiation, while the time of therapy discontinuation due to poor seizure 
control with or without intolerable adverse effects was later. The median number 
of months to failure for intolerable adverse effects was two, and for poor seizure 
control with or without intolerable adverse effects was nine and eighteen 
respectively. Moreover, the majority (70%) of treatment failures caused by 
unacceptable side effects appeared within six months of therapy commencement. 
Zhu et al. (2015) found that the most frequent time to discontinuation was within 
one month of treatment introduction, and the main cause of discontinuation 
during this early period was the adverse effects associated with the medication. 
This was followed by inadequate seizure control during the next few months. The 
average number of months to discontinuation for unacceptable adverse effects 
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was 1.89, and was 15.4 for inadequate seizure control. Similarly, in SANAD studies, 
the median number of months to treatment failure due to unacceptable adverse 
events was three, and was eight for inadequate seizure control (Marson et al., 
2007a, Marson et al., 2007b). These findings are consistent with the observations 
of the present analysis. These characterisations of treatment stages may indicate 
that adverse effect should be thoroughly assessed soon after the introduction of 
an AED.  
The types of adverse effects were also varied between the different treatments 
stages. In the earliest phase, within two months of treatment commencement, 
skin rash, gastrointestinal disorders and acute neurotoxicity symptoms (such as 
sedation, poor balance and sleep difficulties) were predominate. In the later 
phase, six months and onwards, chronic reactions such as weight gain, hair loss 
and hyponatremia started to appear, in addition to psychiatric and cognitive 
disorders. In the latter stage, early appearing problems such as sedation and 
tremor where also reported, which may have been caused by dose elevation.  
AED dosage had a substantial effect on treatment outcomes during the three 
treatment characterisations in this research. The dosage at which the treatment 
was discontinued was the lowest for poor tolerability, intermediate for both 
ineffectiveness and intolerance, and highest for poor seizure control. This is in 
line with other studies (Marson et al., 2007a, Marson et al., 2007b). Treatment 
failure due to poor tolerability alone frequently occurred early and at low dose 
(in some cases the doses were sub-therapeutic) in the current study, although it 
could also be caused by high starting dose and/or rapid titration. The intermediate 
stage, in which treatment failure was frequently due to both inadequate seizure 
control and unacceptable side effects, was also associated with intermediate 
dosage. This stage is interesting because treatment failure may have been caused 
by drug toxicity in some patients, as the dose was increased aggressively in an 
attempt to achieve seizure freedom; in other patients, it may have been caused 
by drug intolerance that prevented the usage of a fully effective dosage. 
Therefore, it is important to differentiate between dose-response drug tolerability 
and drug-toxicity to avoid poisoning the patients with inadequate seizure control. 
In fact, at low dose, the majority (94%) of treatment failure was due to 
unacceptable side effects with or without poor seizure control, and this may 
represent true drug intolerance. This dose-response drug intolerance may be 
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unavoidable in most cases, although a low starting dose and slow titration 
schedule can minimise it. At high dose, one quarter of treatment discontinuation 
was due to intolerable adverse effects with or without inadequate seizure control, 
and this may represent drug toxicity as the patients initially tolerated the low and 
moderate dosages. 
In this study, the median dose of continued therapy was 200 mg/day for LTG, 
600mg/day for CBZ, and 1000mg/day for VPA and LEV. These doses can be 
considered as moderate dosages. Few studies have investigated the doses of 
successful and unsuccessful AEDs, which may be an additional novelty of this 
research. Mohanraj and Brodie (2005) showed that the majority of patients with 
new-onset seizures respond to moderate doses of AEDs, but the doses of 
unsuccessful AEDs were not evaluated. In the present analysis, continued therapy 
does not necessarily mean successful treatment (i.e. seizure-free achievement). 
Moreover, the results show that the continued dosage was lower than the 
discontinued dosage for each AED. Furthermore, the interquartile range doses 
(mg/day) were wider for discontinued therapies than continued therapies for each 
drug, especially LEV, which was 1000-1500 for the continued group while 1000-
2500 for the discontinued. However,  Chung et al. (2007) demonstrated that the 
dosages of the continuing groups were higher and with a wider range than those 
of the discontinued groups for new AEDs (LEV, LTG, OXC, TPM, and ZNS), which 
contradicts the observations of this study. However, the preceding research (Zeng 
et al., 2015) differed to the current study in several aspects: their clinic had a 
larger refractory epilepsy population, and AEDs were frequently prescribed as the 
third, fourth and fifth treatment approach. Whereas the cohort for the present 
study was newly diagnosed epilepsy patients, and the AEDs were generally used 
as a first or second choice. In addition to this variation in the intractability of 
study populations, the number of concurrent AEDs used was also different. The 
current analysis focused on monotherapy, while their patients were taking AEDs 
as monotherapy or as adjunct therapy. Consequently, the doses of AEDs drugs 
were different. 
In conclusion, evaluating retention rates of the most commonly used established 
and modern AEDs can provide valuable insight into their long-term effectiveness 
in routine clinical setting. This study found highest retention rate with LTG after 
six months of treatment initiation, which was significantly higher than VPA, CBZ, 
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and LEV. Beside ineffectiveness, other main reasons for discontinuation were rash 
with LTG and CBZ, tremor and weight gain with VPA, and psychiatric and 
behavioural adverse effects with LEV.   
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6.1 Overview of study presented 
The present study provides a comprehensive evaluation of clinical effectiveness 
of different standard new AEDs.  The treatment efficacy (1-year seizure –free), 
poor tolerability (adverse effects leading to treatment failure), and retention rate 
(time to discontinuation) were measured in a real-world practice and therefore 
can largely present the clinical effectiveness (Figure 6-1). 
 
 
Figure 6-1. Measuring different treatment outcomes of antiepileptic drugs [modified from 
(Lee, 2014)] 
Clinical effectiveness evaluation should include comprehensive measures of efficacy, tolerability 
and quality of life in a setting relevant to real-life, and retention rate is very similar to this concept. 
This study assessed the efficacy (1-year seizure-free) and intolerable adverse effects of 17 
antiepileptic drugs. As well as the retention rates of the most common four monotherapies was 
compared and therefore can largely present the clinical effectiveness 
 
This study provides some novel and strong aspects. This study included a large 
number of patients (n=1,528) with newly diagnosed epilepsy who were followed-
up for up to 32 years. During this period, 14 new AEDs has been introduced to 
Retention rate 
(time to discontinuation)
Efficacy
(response rate, 
percent seizure 
reduction, seizure 
free rate)
Tolerability
Quality of life
50% response rate
Clinical effectiveness
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clinical use some with novel mechanism of actions. Additionally, a number of 
previous analyses were performed on same expanding cohort at different points 
during this period. Therefore, this study provides a strong evidence that treatment 
outcomes in epilepsy have not improved despite the availability of increasing 
number of AEDs. This study has extensively evaluated the clinical and 
pharmacological predictors for poor tolerability. This may present novel findings 
as few observational studies have evaluated the predictors for poor tolerability 
particularly non-AEDs variables. This study compared the long-term retention 
rates of the most widely used AEDs in a large number of patients from everyday 
clinical practice. Moreover, few observational studies have investigated the 
retention rates of standard and new AEDs, and these were limited to the Chinese 
population (Zeng et al., 2015, Zhu et al., 2015). Therefore, the current research 
may present novel findings in terms of population as well.  
This research concluded that treatment failure could be categorised into three 
distinct types based on time to discontinuation, reasons of discontinuation, and 
dosage at which AEDs were discontinued. As shown in Table 6-1, early treatment 
failure at which treatments were largely failed within 2 months, mainly due to 
intolerable adverse effect, and at low dose (< IQR). Cutaneous adverse reactions 
were frequent in that phase. This type of adverse effects may represent the drug 
intolerability and may be difficult to avoid, although low starting dose and slow 
titration can minimise it.  Late treatment failure (median time to discontinuation 
18 months) was mainly due to poor seizure control and at high dose (>IQR). The 
intermediate stage was an overlap between two previous phases. This stage is 
interesting because treatment failure may have been caused by drug toxicity in 
some patients, as the dose was increased aggressively in an attempt to achieve 
seizure freedom; in other patients, it may have been caused by drug intolerance 
that prevented the usage of a fully effective dosage. Therefore, it is important to 
differentiate between dose-response drug tolerability and drug-toxicity to avoid 
poisoning the patients with inadequate seizure control. More strengths of this 
study are discussed in the next section. 
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Table 6-1. Three distinct types of treatment failure of antiepileptic drugs concluded from the 
current study 
Predominant 
reasons for 
discontinuation 
 Intolerable 
adverse effects 
 Both   Poor seizure 
control 
Type of treatment 
failure 
 Early   Intermediate   Late  
Time to 
discontinuation 
(median) 
 2 months  9 months  18 months 
Percentage of 
treatment failure 
 28%  28%  44% 
Predominant 
dosage  
 Low dose (<IQR)  Moderate (within 
IQR) 
 High (>IQR) 
Predominant 
adverse effects 
 Rash  Neurotoxicity/ 
chronic adverse 
effects 
 Neurotoxicity/ 
chronic adverse 
effects 
Type of adverse 
effects 
 Tolerability  Both   Drug toxicity 
Management   Mainly 
unavoidable 
 Low start dose/ 
slow titration 
 Important to 
differentiate 
between dose-
response adverse 
effect and drug 
toxicity 
 Avoid pushing 
dose aggressively 
in uncontrolled 
patients 
  Minimise number 
of concomitant 
drugs 
IQR: interquartile range 
 
6.2 Study strengths  
To the best of my knowledge, this is the largest and longest observational study 
of newly diagnosed epilepsy patients. The large number of patients included in 
this study and the long-term follow-up period have increased the possibility of   
finding clinically important differences between medications. This as well allow 
assessment of rare and late appearing side effects of drugs. 
More recent, longer duration, larger sample size, and higher rate new drug use 
represent the advantages of the current analysis over the previous analyses on the 
same expanding cohort. Extra new agents were included in the current study as 
several new AEDs have been approved since the previous research conducted in 
2005 and some new agents have become more popular. This particular analysis 
has allowed the evaluation of changes in treatment outcome of epilepsy over the 
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last three decades as a result of availability of an increasing number of AEDs by 
comparing the results of the current analysis to previous analyses.  
Furthermore, this analysis has provided a comprehensive assessment of 
tolerability aspect of AED treatments. The tolerability of 17 standard and new 
AEDs was studied and this covers almost all AEDs used in UK for adult epilepsy 
patients. The examination of the adverse effects in all regimens used during 
follow-up represent a uniqueness as this enabled investigation of poor tolerability 
in initial AED monotherapies, as well as successive AED regimens. Therefore, the 
tolerability of newer agents used as adjunct therapy was well evaluated. This 
method also allowed investigation of poor tolerability in polytherapies. 
Furthermore, the study assessed treatment failure due to drug intolerance alone 
and in combination with poor drug efficacy; the latter is a common occurrence in 
epilepsy patients. 
6.3 Study Limitations 
Although this is the largest observational study of newly diagnosed epilepsy 
patients, there were small sample sizes in some subgroup analyses. The following 
part explain other caveats of the current study. 
6.3.1 Generalisability 
It should be acknowledged that this study has its restrictions such as the tertiary 
care character of the Epilepsy Unit, as well as being on a single centre. Thus, the 
results may not be generalisable to the entire population but may reflect 
treatment outcomes in the institutions with similar patient demographics.  
Although excluding patients with persistent poor drug adherence may provide 
accurate evaluation of AEDs efficacy, the employment of intention-to-treat 
principle was impossible. Patients younger than 18 years were excluding as well, 
as their seizure types/ syndromes along with treatment response may be different 
from adults. Therefore, findings of this study may not reflect complete scenario 
sufficiently. 
The findings of this study can be therefore generalised to epilepsy centres for 
adult patients with newly diagnosed epilepsy including both focal and generalised 
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epilepsies in the UK. Different health care systems are used outside the UK which 
can affect the treatment outcomes. This study included a tertiary care clinic from 
specialists, their patients may have more severe epilepsy than primary clinics. On 
the other hand, this is an out-patient clinic and these patients may be less 
intractable than patients admitted to hospital or emergency for severe seizures 
like status epilepticus. Additionally, this study included patients from one clinic 
in West of Glasgow which had been managed by few neurologists, this may limit 
the generalisability. 
6.3.2 Assessment of seizure outcomes 
There are a number of caveats in regards with evaluation of efficacy of AEDs in 
this study. First, the efficacy evaluation based on seizure outcomes at last clinic 
visit but many patients particularly seizure-free were discharged from the Epilepsy 
Clinic to primary care. Nevertheless, patients usually re-refer in case of relapse, 
poor tolerability, or for a pregnancy consultation, etc. General practitioners and 
all patients are aware of this arrangement; they also could phone the Epilepsy 
Unit if necessary. Therefore, it was assumed that the patients remained seizure-
free if they were not referred back to the Epilepsy Clinic. This limitation is 
difficult to overcome but a potential statistical analysis, i.e. sensitivity analysis, 
could be performed to test the robustness of the results. Generally, sensitivity 
analysis is a process of recalculating outcomes under alternative assumptions that 
differ from those used in the primary analysis to test the robustness of the results 
of a study in the presence of uncertainty. Sensitivity analysis can be performed 
for different reasons, including Good Clinical Practice (GCP) violations, protocol 
violations, ambiguous/missing data. This analysis has not performed in the current 
analysis to test the result of the assumption that the discharged controlled 
patients remained seizure-free if they do not come back to the Epilepsy Unit. The 
sensitivity analysis could be performed under alternative assumption, for 
example, the discharged patients did not remain controlled. Then the results of 
this sensitivity analysis could be compared to results of primary analysis to check 
robustness. 
Further issue is that a complete seizure control (i.e. seizure-free for at least 12 
months) was the only outcome measure for AEDs efficacy in the current study. A 
reduction in seizure frequency / severity and an improvement in post-ictal 
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recovery have not been measured. Although these improvement may increase 
seizure acceptance by some patients, several studies have indicated that 
complete seizure freedom is a major determinant of quality of life, independent 
from seizure severity or frequency, due to the psychological impact of the 
unpredictability of seizures (Kwan et al., 2010).  
Seizures were counted based on patients’ seizure diaries in each clinic visit, 
however, studies have shown that seizure diaries are unreliable. Scalp electrodes 
and electronic devices are recommended instead to detect and count seizures 
prospectively (Jory et al., 2016). 
6.3.3 Assessment of adverse drug reactions 
Generally, there are several challenges regarding assessment of adverse drug 
reactions of AEDs. The following section will discuss these difficulties and how 
they have been overcome in the current study.  Attribution of causality of adverse 
drug reactions can be challenging particularly when managing individual patients 
(Edwards and Aronson, 2000). It is important to distinction between the terms 
adverse effect and adverse event. An adverse effect is an unpleasant reaction that 
can be attributed to the medication. An adverse event is an unpleasant reaction 
appearing during treatment but not necessary caused by the medication (Perucca 
and Gilliam, 2012). In RCTs or case-control studies, the causality of suspected 
adverse drug reactions can be estimated by comparison with a control group; but 
this is impossible for the observational studies of patients from routine clinical 
practice. Therefore, in this study, several criteria were considered to establish a 
certain causality of adverse effects, whenever possible. First, reasonable time 
relation between the use of AEDs (introduction or does elevation) and the 
incidence of adverse effect. Furthermore, concomitant disease or drugs cannot 
explain the adverse effect. Additionally, the pattern of the adverse effect may fit 
the known pharmacology or sensitivity pattern of AEDs. Moreover, reversibility of 
adverse effects after drug discontinuation.  Finally, the background frequency of 
the event and how often it is associated with drugs were considered. For instance, 
headache is relatively common, so its association with a medicine may be by 
chance. In contrast, rash has a low background incidence and is often associated 
with particular AED, therefore it is more likely to be an adverse drug reaction. 
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Further common issue associated with the tolerability evaluation is the 
methodology used to detect and quantify adverse effect as the rate of side effects 
tends to be underestimated or overestimated by relying on spontaneous reporting 
or checklists, respectively (Perucca and Gilliam, 2012). In the current study, 
however, the tolerability was assessed prospectively in each clinic visit by 
structured interview focused on common concerns of each particular AEDs. 
Moreover, only intolerable adverse effects were evaluated using a definitive 
outcome measure i.e. withdrawal of a drug (or failure of therapy). Nevertheless, 
it should be pointed out that drug withdraw due to side effect is often based on 
clinical benefit-risk judgment (Edwards and Aronson, 2000), considering the 
severity of reaction and the efficacy of drug (i.e. seizure control). Therefore, 
adverse effect that caused dosage reduction and addition of AED was regarded as 
intolerable adverse effect in this study.   
Side effects of AEDs were recorded based on patient complaints and clinical 
judgments by epilepsy specialists. Most of these symptoms were not standardised 
or validated. This is most likely due to the fact that no universally-recognised 
method of capturing these patient-reported outcomes, and that the difficulties 
inherent in capturing and analysing indices of quality of life and more subjective 
adverse effects has been discussed in the literature (Gilliam, 2002). Furthermore, 
there is no need for routine screening for adverse effects with blood and urine 
tests, or AEDs blood level, etc., in clinical practice. Camfield and Camfield (2006) 
showed that these tests have little value in preventing, detecting, or reducing side 
effects. Moreover, this is a pragmatic study and recorded those problems which 
the patients felt were important to them. Setting thresholds would be 
complicated and might arguably detract from the value of the information (for 
example, a 5kg weight gain would be more of a problem to a 60 kg teenager than 
to a 100 kg adult). Studies have shown that patient concerns about adverse effects 
of AEDs, whether actual or perceived, has negative impacts on adherence to 
medication and quality of life (Eatock and Baker, 2007). 
To make the analysis clear and straightforward, a single side effect of a single 
offender AED was assigned for each intolerable adverse effect case in this study. 
However, this ideal situation is not always the case in real world in which more 
than one intolerable of one or more AED(s), in polytherapy, could cause treatment 
failure. For example, in an instance of tremor with a VPA/LTG combination that 
188 
Chapter 6. Conclusion and future direction 
 
results from the pharmacodynamics and pharmacokinetic interaction, both AEDs 
contribute to this side effect. However, in this study, only the discontinued AED 
was indicated as a culprit one. 
6.3.4 Potential confounding factors 
There is an unavoidable selection bias in observational studies of patients from 
everyday clinical practice because of absence of randomisation. The selection of 
AED for each patient is based on seizure type and patients’ characteristics such as 
age, gender and comorbidities (French et al., 2004). For an instance, VPA is a 
potent teratogenic agent and therefore is recommended to be avoided in girls and 
young women (Tomson et al., 2015). On the other hand, LTG and LEV are 
associated with low risk of teratogenicity (Tomson and Battino, 2012). Likewise, 
LTG has showed less efficacious than VPA in generalised and unclassifiable 
epilepsy (Marson et al., 2007b). Consequently, in the current study, female 
patients used LTG and LEV significantly higher than VPA and CBZ; and patients 
with focal epilepsies used LTG significantly higher than VPA. Other potential 
confounders were number of concurrent AEDs and previous unsuccessful AED 
schedules. Therefore, dissimilar seizure severity between patient groups of AEDs 
used as first line monotherapy and AEDs used as adjunct therapy for intractable 
seizure. 
Several attempts have been made to minimise the risk of bias or confounding in 
this study. First, restricted patient selection was applied so all groups had the 
same value for the confounder. For instances, restricting this study to adult 
patients with newly diagnosed epilepsy, comparison of efficacy and tolerability of 
AEDs monotherapy was separated than AEDs polytherapy, and the comparative 
retention rates analysis was restricted to four AEDs (LTG, VPA, CBZ, and LEV) 
monotherapy that frequently used as first-line therapy. In addition, to show the 
extent of the balance between treatment groups for the confounder, the baseline 
characteristics were compared for different treatment groups. Moreover, the 
effect of the confounder was quantified and adjusted, whenever possible, in 
regression statistical analyses. 
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6.4 Clinical implications 
This study identified some characteristics of patients likely to be 
pharmacoresistant. Failure to response to two or more AEDs was the strongest 
predictor for intractable seizures which lends further support to the ILAE 
definition of pharmacoresistant epilepsy, which recommends that a specialist 
should review these patients for confirmation of diagnosis of seizure/ syndrome 
and consideration of epilepsy surgery. 
This study also identified the patients at high risk of adverse drug effects. It is 
important to recognise these patients in order to avoid specific AEDs, counsel 
them and their families about the possible adverse effects, to use a careful 
titration scheme, and to make sure that the patients are seen frequently. When 
recognised at an early stage, adverse effects are mild and reversible in most cases. 
This research showed that there were distinct tolerability profiles for each AED 
which may affect each patient on different way depending on several of factors 
such as age, gender, lifestyle, type of occupation and comorbidity. Tolerability, 
also, related to patients’ susceptibility. Therefore, patients more likely to 
experience specific adverse effect based on their intolerability history or 
comorbidity should rationally avoid AEDs with potential risk of that particular 
adverse effect. For instance, AEDs with potential risk of rash such as LTG and CBZ 
should be avoided in patients who have a history of cutaneous adverse drug 
reactions. LEV and GBP have a lower risk of hypersensitivity. Similarly, AEDs that 
known to cause or worse psychiatric disorders such as LEV, PER and TPM should be 
avoided in patients with psychiatric comorbidity. VPA should be avoided in women 
with childbearing potential due to its teratogenicity, and LTG and LEV seems safer 
alternatives. Finally, LEV, GBP, and LTG appear to have better tolerability and 
have lower potential of drug interactions than CBZ in the elderly with concomitant 
medications. In short, tolerability offers the opportunity for patients-tailored 
AEDs to optimise efficacy, minimise adverse effects, and eventually improve 
patients’ quality of life. 
Intolerable adverse effects were mainly appeared early after treatment initiation 
that may indicate that tolerability should be thoroughly assessed soon after the 
introduction of an AED. Especially for LTG in which continuation rate after the 
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hurdle initial six months was markedly high. The strategy of “start low and go 
slow” may be helpful. Although most of the observed intolerability occurred at 
low dose, some intolerable adverse effects cases were on moderate or high dose. 
It is important, thus, to differentiate between dose-response tolerability and drug 
toxicity to avoid poison uncontrolled patients, avoid pushing dose aggressively and 
minimise number of concurrent AEDs. 
Psychiatric comorbidity seems to be a predictor for poor seizure control and poor 
tolerability. Therefore, assessment and management of psychiatric disorder may 
help in management of epilepsy and enhance quality of life. As expected, poor 
adherence was associated with poor seizure control. Assessment and management 
of poor drug adherence may be required before alteration of AEDs schedule/ dose. 
As forgetfulness was the most common reason for that behaviour, a simple 
intervention like a reminder (e.g. phone alarm) or pill organiser may be helpful. 
Furthermore, particular groups of patients have been shown to be more likely to 
be poorly drug adherent (such as patients with psychiatric comorbidity and alcohol 
or drug abuse). Thus, prescribing measurable AEDs in blood may be suitable for 
those patients in order to assess adherence regularly. 
6.5 Future directions of research 
The results of the present study provide further evidence that current AEDs are 
seizure suppress but not anti-epileptogenic thus, researchers should focus on 
novel treatments that can modify the development or progression of the epilepsy. 
The following section outline the directions of future research in epilepsy. 
6.5.1 Anti-epileptogenesis 
Epileptogenesis is the gradual processes that lead to development of chronic 
epilepsy after a brain injury.  As shown in Figure 6-2, novel approaches may 
produce anti-epileptogenic effect (prevent epilepsy development after an 
epileptogenic insult), disease-modifying effect (reduce seizure frequency / 
severity, or alter disease natural history), neurodegeneration inhibition, or 
prevent behavioural and cognitive alterations associated with epilepsy. Results 
from studies on neuroprotective, anti-inflammatory and neuro-modulatory agents 
suggest that these approaches are realistic. However, many other pathological 
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changes occur simultaneously during the epileptogenic process, therefore, 
targeting only single process probably impossible to prevent epileptogenesis. 
Instead, combinations of agents that target various epileptogenic processes should 
be taken after brain injuries (Loscher, 2012). 
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Figure 6-2. Strategies for antiepileptigenesis [modified from (Loscher, 2012)] 
Novel approaches may produce anti-epileptogenic effect (prevent epilepsy development after an epileptogenic insult), disease-modifying effect (alter disease natural 
history, or reduce seizure frequency / severity), neurodegeneration inhibition, or prevent behavioural and cognitive alterations associated with epilepsy. 
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6.5.2 Gene and cell therapy for epilepsy 
Gene therapy is a technique used to introduce a functional copy of a gene in place 
of defective copy in order to restore normal function (Riban et al., 2009).  
Epilepsy is the most challenging and may be not the most suitable target for 
development of gene therapy for several reasons. First, only minority of epilepsy 
syndromes are pure monogenic forms, the majority of epilepsy disorders are 
complex conditions involving several genetic and environmental factors. 
Additionally, it is difficult to identify the link between the gene mutation and the 
hyper-excitability phenotype (specific seizure) as a result of the compensatory 
mechanisms that occur in the brain. Finally, because of the technical limitations, 
it is difficult to achieve widespread gene transfer for a disease like epilepsy that 
often involves a large area of the brain (Riban et al., 2009).  
Nevertheless, this approach may represent an alternative therapy for 
pharmacoresistant patients, and focal epilepsies with epileptogenic lesion seem 
to be the best candidate epilepsy forms for gene therapy (Simonato, 2014).  
Gene therapy has been used to provide anti-epileptogenic, anti-seizure, and 
disease-modifying effects (Figure 6-2). Results from animal studies have shown 
that several candidate genes such as brain-derived neurotrophic factor (BDNF) and 
fibroblast growth factor 2 (FGF-2) produced anti-epileptogenic effects. While 
galanin or neuropeptide Y provided anti-seizure effects (Simonato, 2014). 
Viral and non-viral (cell transplantation) approaches can be used to delivery of 
gene to the brain. Recombinant adeno-associated viral (rAAV) vectors, which are 
safe and stable persistence in neurons, have shown a promise for gene therapy of 
neurological disorders in clinical trials (Riban et al., 2009).  
Before starting studies in human, more research are required to evaluate the 
safety and therapeutic benefit of gene therapy in chronic models of 
epileptogenesis (Riban et al., 2009, Simonato, 2014). 
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6.5.3 Pharmacogenomics and precision medicine in epilepsy 
Genetic factors contribute to the high variability in the response to AED treatment 
across patients (Franco and Perucca, 2015). Many genetic markers have been 
studied to identify predictors of efficacy and adverse effects of AED therapy. 
Variation in ABCB1 gene was associated with refractory epilepsy in some studies, 
this gene encoding drug transporter protein that extrudes AEDs from the seizure 
focus. Furthermore, there is an established evidence that variation in CYP2C9 
gene is associated with PHT-induced neurotoxicity. Moreover, there is a strong 
association between HLA-B*15:02 allele and CBZ-induced Stevens-Johnson 
syndrome in patients from Han Chinese origin (Balestrini and Sisodiya, 2017), and 
genetic testing is recommended for those patients (Franco and Perucca, 2015).  
However, the value of genetic testing in guiding AED treatment in other situations 
remains limited. As most genetic markers identified to date have limited 
sensitivity and specificity (Franco and Perucca, 2015). Furthermore, 
responsiveness to AED therapy is a complex outcome that based on an interaction 
of several genetic and environmental factors (Mohanraj and Brodie, 2013). 
Moreover, the biology of almost all epilepsy syndromes is largely unknown 
(Balestrini and Sisodiya, 2017). But in future, the use of genetic testing to guide 
epilepsy treatment is likely to increase because of greater understanding of the 
function of epilepsy genes, this  will also allow the application of precision 
medicine (Franco and Perucca, 2015). 
Precision medicine treatments represent a growing area of interest, focussing on 
reversing the pathophysiological effects of specific gene mutations.  A current 
established example of the application of the precision medicine concept in 
epilepsy is in the management of GLUT-1 deficiency syndrome, a genetic 
metabolic encephalopathy due to mutations in the SLC2A1 gene, which encodes 
the glucose type I transporter (GLUT-1), resulting in impaired transport of glucose 
across the blood-brain barrier. The gold standard treatment is the ketogenic diet 
for treating the symptoms of neuroglycopenia. A second example, with less robust 
evidence, is the use of quinidine in KCNT1-related epilepsies, (Balestrini and 
Sisodiya, 2017). 
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6.5.4 Detecting seizures 
The unpredictability of epileptic seizures is disabling for patients. If a seizure can 
be reliably detected then the patient or carer could be alerted, and therefore, 
injury and death could be prevented. Seizure detection theories based on 
detecting physiological changes that occur before and during a seizure such as 
changes of movements and heart rate. Electronic devices, scalp electrodes, and 
alert dogs are studied to detect and count seizures. A new example of using 
electronic devices for seizure detection is EpiWatch, an app designed for use on 
an Apple Watch with its paired iPhone. The development of seizure detection 
devices can offer a practical benefit for the management of epilepsy, however, 
these devices are at a relatively early stage of development (Jory et al., 2016). 
6.5.5 Biomarkers for pharmacoresistant epilepsy 
Early identification of patients likely to be drug resistant allows earlier specialist 
intervention. To date, early prediction of pahrmacoresistant patients is mainly 
based on clinical characteristics such as the numbers of pre-treatment seizures 
and the early response to antiepileptic drugs (Mohanraj and Brodie, 2013). 
However, these manifestations are subjective and poorly defined. Therefore, 
objective and definite biomarkers are in need. Several studies have showed that 
microRNAs were differentially expressed in epilepsy; microRNAs may be involved 
in epilepsy by regulating inflammatory response, neuronal apoptosis and 
transcription factors involved in differentiation. In a preliminary study, several 
circulating microRNAs showed a diagnostic value in drug resistant epilepsy as they 
were deferentially expressed between drug resistant patients and drug responsive 
patients (Wang et al., 2015). 
6.6 Conclusion 
Despite the availability of many AEDs, this research concluded that seizure control 
rates have not improved over the last three decades. Probably because the current 
AEDs are anti-seizure and not anti-epilepsy. Future research should therefore 
focus on novel treatments that can interfere or reverse the development and 
progression of epilepsy, such as anti-epileptogenic agents and gene therapy. 
Although the new generation of AEDs has failed to provide more efficacious 
treatment options, the findings of this study indicated that their use has 
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increased, most likely due to their enhanced tolerability.  Indeed, some new AEDs 
such as LTG showed high tolerability rate in this study, however, the results did 
not demonstrate a unidirectional better tolerability with new agents over 
established AEDs.  Nevertheless, each AED has shown a distinct adverse effects 
profile that may influence each individual patient differently. Therefore, 
tolerability of AEDs provides the opportunity of tailoring AED selection more 
effectively to optimise efficacy and minimise adverse effects in the individual 
patients and eventually resulting in enhanced quality of life. This research also 
has identified the patients more likely to experience poor seizure control and poor 
drug tolerability; psychiatric comorbidity and previous unsuccessful AEDs 
schedules were associated with poor treatment outcomes. Early identification of 
these patients allowing interventions by specialists such as early referral of 
intractable patients for epilepsy surgery and carful use of pharmacotherapy in 
patients at high risk of adverse drug reactions. This study also concluded that LTG 
demonstrated better outcomes in terms of retention rate and therefore clinical 
effectiveness, most probably due to its superior tolerability which may explain 
why it was the most frequent prescribed AED in this cohort.
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